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Genome Engineering Technology and Its Application in Mammalian Cells 
Abstract 
 
The advancement of high-throughput, large-scale biochemical, biophysical, and 
genetic technologies has enabled the generation of massive amounts of biological data 
and allowed us to synthesize various types of biomaterial for engineering purposes. This 
enabled improved observational methodologies for us to navigate and locate, with 
unprecedented resolution, the potential factors and connections that may contribute to 
biological and biomedical processes. Nonetheless, it leaves us with the increasing 
demand to validate these observations to elucidate the actual causal mechanisms in 
biology and medicine. Due to the lack of powerful and precise tools to manipulate 
biological systems in mammalian cells, these efforts have not been able to progress at an 
adequate pace.  
This work aims to bridge the gap between data generation and experimental 
verification by developing molecular-resolution genome engineering technologies that 
can effect cell-specific genetic and epigenetic perturbation in mammalian cells. The 
development of these novel tools starts from harnessing aspects of two prominent 
families of microbial systems, the Transcription Activator-like Effectors (TALEs) and the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas systems. The 
development of these technologies was executed through several lines of engineering 
efforts. When applied in higher eukaryotes, these tools provide researchers with new 
   
 
iv 
reverse engineering instruments to directly probe relevant biological molecules and 
pathways that are observed from analysis of biological data. In combination with 
sensitive and accurate readout methods in mammalian systems, these technologies could 
together establish transformative means for modeling the causal relationships between 
genetic or epigenetic variances and human disease, while also serving as the first step 
towards the development of rational molecular therapies for complex human disorders 
and of synthetic biology applications for the research community. 
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1. General Introduction 
The emergence of high-throughput biology has generated tremendous amount of data, which in 
combination with enhancement of observational tools exemplified by super-high resolution 
microscopy, has greatly improved our observation of biological details related to human 
diseases. Almost every field of study from the classic genetics to relatively recent stem cell 
biology is going through an explosion of new hypotheses for various biological processes from 
molecular level to organismic level.  
 
Ensuing efforts to systematically validate these hypotheses and quantitatively verify and apply 
these models require new powerful tools for these genome-scale investigations. New 
technologies centered around the specific perturbation of genome properties opened up the 
possibility for accurate and efficient genome-scale engineering, such as designer zinc-finger 
protein (ZFP), multiplex genome engineering and accelerated evolution (MAGE), complete 
whole-genome synthesis, among others (1-8). However, despite this advancement in biological 
manipulation techniques, our ability to perform this type of research is still limited by the lack of 
genome engineering tools that are precise, easy to design, quick to implement, low-cost and 
readily deliverable into mammalian cells (1, 2, 5).  
 
With respect to earlier work in the field, zinc-finger nucleases have been synthesized by fusing 
the zinc finger DNA recognition module to a catalytic domain from nucleases such as FokI. This 
kind of chimeric nuclease have been shown to be functional to promote homologous 
recombination at target site, although off-target effects and toxicity are major issues that need to 
be addressed (9, 10). Over the years, several reports have confirmed the feasibility of designing a 
 2 
customized zinc-finger protein using various approaches and demonstrated their functionality (3, 
4, 11-16). Nonetheless, it is very difficult to apply this technology generally due to the 
unreliability of the zinc-finger binding domain in terms of its DNA-binding affinity and 
specificity, and the difficulty in scaling up the system in mammalian cells. To date, the most 
well-established method to build a customized zinc finger protein is to utilize randomized library 
screening with phage display technique, yeast two-hybrid library, or bacterial screening library 
(10, 12, 14, 17-22). All these issues have been underlying obstacles for the generalization and 
application of zinc-finger based technology, and the monopoly of a few commercial companies 
has prevented the wide application of this system in the broad scientific community.  
 
Recent reports demonstrated the modularity of DNA-binding domain from Transcription 
Activator Like Effectors (TALEs), a group of microbial effector proteins from a diversity of 
plant bacteria (23-26). My thesis work focuses on two different projects to harness this system to 
address the challenges for developing genome engineering technologies in mammalian cells. The 
first part of my work describes my effort to engineer programmable genome targeting tools 
based on TALEs to activate gene expression and introduce genome modifications (27, 28). The 
second part of my work focuses on the optimization and development of TALE technology to 
improve its targeting accuracy and expand additional functions, in particular, the ability to 
repress transcription at endogenous loci in mammalian systems (29).  
 
Similarly, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system 
in prokaryotes has been studied by several groups to elucidate their organizations and functions 
in bacteria cells (30-32). We decided to try to engineer this new family of biological system for 
mammalian genome engineering purposes. This third part of my research employs CRISPR/Cas 
 3 
systems from prokaryotic cells to develop a multiplexable genome engineering system that is 
simple, efficient, fast to deploy, and cost-effective (33).  
 
The contents of these three parts of work have been published in peer-reviewed research journals 
as cited above and in each chapter. Together the efforts of my research constitute a series of 
mammalian genome engineering technologies that have been designed and developed to address 
the lack of powerful, precise, affordable tools to meet a critical need for biological and 
biomedical research. 
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2. Efficient Construction of Sequence-specific TAL Effectors for Modulating Mammalian 
Transcription 
This work is done with Dr. Feng Zhang as equal contributors, and this entire chapter has been 
published as Zhang F*1, Cong L*, et al. Nature Biotechnology. 2011 (27).  
 
2.1 Existing genome engineering tools and basic properties of TAL effectors 
Systematic interrogation and engineering of biological systems in normal and pathological states 
depend on the ability to manipulate the genome of target cells with efficiency and precision(1, 
34). Some naturally occurring DNA binding proteins have been engineered to enable sequence-
specific DNA perturbation, including designer polydactyl zinc finger (ZFs)(14, 17, 35) and 
meganuclease(36, 37) proteins. In particular, designer ZFs can be attached to a wide variety of 
effector domains such as nucleases, transcription effectors, and epigenetic modifying enzymes to 
carry out site-specific modifications near their DNA binding site. However, due to the lack of a 
simple correspondence between amino acid sequence and DNA recognition, design and 
development of sequence-specific DNA binding proteins based on designer ZFs and 
meganucleases remain difficult and expensive, often involving elaborate screening procedures 
and long development time on the order of several weeks. Here we developed an alternative 
DNA targeting platform based on the naturally occurring transcription activator-like effectors 
(TALEs) from Xanthomonas sp.(23-26) 
 
                                                
1 * indicates equal contribution. 
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TALEs are natural effector proteins secreted by numerous species of Xanthomonas to modulate 
host gene expression and facilitate bacterial colonization and survival(24, 26). Recent studies of 
TALEs have revealed an elegant code linking the repetitive region of TALEs with its target 
DNA binding site(23, 25). Common among the entire family of TALEs is a highly conserved 
and repetitive region within the middle of the protein, consisting of tandem repeats of mostly 33 
or 34 amino acid segments (Fig. 2.1a). Repeat monomers differ from each other mainly in amino 
acid positions 12 and 13 (variable diresidues), and recent computational and functional 
analysis(24, 26) have revealed a strong correlation between unique pairs of amino acids at 
positions 12 and 13 and the corresponding nucleotide in the TALE binding site (e.g. NI to A, HD 
to C, NG to T, and NN to G or A; Fig. 2.1a). The existence of this strong association suggests a 
potentially designable protein with sequence-specific DNA binding capabilities, and the 
possibility of applying designer TALEs to specify DNA binding in mammalian cells. However, 
our ability to test the modularity of the TALE DNA binding code remains limited due to the 
difficulty in constructing custom TALEs with specific tandem repeat monomers. Early studies 
have tested the DNA binding properties of TALEs(23, 38-42), including two studies that tested 
artificial TALEs with customized repeat regions(39, 40). 
 
2.2 Efficient method for synthesis of the modular, repetitive, sequence-specific DNA 
binding domain of TAL effectors 
A prerequisite for exploring the modularity TALE repeat monomers is the ability to synthesize 
designer TALEs with tailored repetitive DNA binding domains. While this has been recently 
shown to be possible(38-40), the repetitive nature of the TALE DNA binding domains renders 
routine construction of novel TALEs difficult when using PCR-based gene assembly or serial 
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DNA ligation, and may not be amenable to high-throughput TALE synthesis. Furthermore, even 
though commercial services can be employed for the synthesis of novel TALE binding 
domains(40), they present a cost-prohibitive option for large scale TALE construction and 
testing. Hence a more robust protocol to construct large numbers of designer TALEs would 
enable ready perturbation of any genome target in many organisms. 
 
To enable high-throughput construction of designer TALEs, we developed a reliable hierarchical 
ligation-based strategy to overcome the difficulty of constructing TALE tandem repeat domains 
(Fig. 2.1b and Supplementary Methods). To reduce the repetitiveness of designer TALEs and to 
facilitate amplification using PCR, we first optimized the DNA sequence of the four repeat 
monomers (NI, HD, NN, NG) to minimize repetitiveness while preserving the amino acid 
sequence. In order to assemble the individual monomers in a specific order, we altered the DNA 
sequence at the junction between each pair of monomers, similar to the Golden Gate cloning 
strategy for multi-piece DNA ligation(43, 44). Using different codons to represent the junction 
between each pair of monomers (Gly-Leu), we designed unique 4 base pair sticky-end ligation 
adapters for each junction (Supplementary Methods). Using this strategy, 4 monomers can be 
ligated simultaneously to form 4-mer tandem repeats. Three 4-mer repeats can be simultaneously 
ligated to form the desired 12-mer tandem repeat and subsequently ligated into a backbone 
vector containing a 0.5 length repeat monomer specifying the 13th nucleotide of the binding site 
at the C-terminus of the repeat domain, as well as the N- and C-terminal non-repetitive regions 
from the Xanthomonas campestris pv. armoraciae TALE hax3 (Fig. 2.1b). Using this method, 
we attempted to construct 17 artificial TALEs with specific combinations of 12.5-mer repeats to 
target 14 base pair DNA binding sites – TALEs require the first letter of the binding site to be a 
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T, and the 12.5-mer repeat targets a 13 bp binding site. We analyzed 2 clones for each of the 17 
dTALEs via sequencing and found that all dTALEs were accurately assembled. Furthermore, we 
were able to construct 16 dTALEs in parallel in 3 days, a time substantially shorter than what is 
required for constructing a similar number of dTALEs via commercial DNA synthesis, and at a 
fraction of the cost. 
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Figure 2.1 Design and construction of customized artificial transcription activator like 
effectors (dTALEs) for use in mammalian cells. a, Schematic representation of the native TALE 
hax3 from Xanthomonas campestris pv. armoraciae depicting the tandem repeat domain and the 
two variable repeat diresidues (red) within each repeat monomer that specify the base 
recognition specificity. The four most common naturally occurring diresidues that were used for 
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(Figure 2.1, continued) the construction of customized artificial TAL effectors are listed together 
with their proposed major base specificity. b, Schematic of the hierarchical ligation assembly 
method for the construction of customized dTALEs. 12 individual PCRs are performed for each 
of the 4 types of repeat monomers (NI, HD, NG, and NN) to generate a set of 48 monomers to 
serve as assembly starting material. Each of the 12 individual PCR products for a given 
monomer type (i.e. NI) has a unique linker specifying its programmed position in the assembly 
(color-coded digestion and ligation adapters). After enzymatic digestion with a Type IIs cutter 
(e.g. BsaI), unique overhangs (generated by leveraging the alternate codons for each amino acid 
in the junction) are generated. The unique overhangs facilitate the positioning of each monomer 
in the ligation product. The ligation product was PCR amplified subsequently to yield the full-
length repeat regions, which were then cloned into a backbone plasmid containing the N- and C-
termini of the wild type TALE hax3. c, Schematic representation of the fluorescence reporter 
system for testing dTALE-DNA recognition. The diagram illustrates the composition of the 
tandem repeat for a dTALE and its corresponding 14bp DNA binding target in the fluorescent 
reporter plasmid. NLS, nuclear localization signal; AD, activation domain of the native TAL 
effector; VP64, synthetic transcription activation domain; 2A, self-cleavage peptide. d, 293FT 
cells co-transfected with a dTALE plasmid and its corresponding reporter plasmid exhibited 
significant level of mCherry expression compared to the reporter-only control. Scale bar, 200µm. 
 
2.3 Designer TALEs (dTALEs) effiiently targets desired DNA sequences 
The DNA binding code of TALEs was identified based on analysis of TALE binding sites in 
plant genomes(23, 25) and the binding specificity of TALEs have been analyzed using various in 
vitro and in vivo methods(23, 38, 40-42, 45-47). In order to determine whether this code can be 
used to target DNA in mammalian cells, we designed a fluorescence-based reporter system 
(Supplementary Fig. 1) by placing the DNA binding site for each dTALE upstream of a minimal 
CMV promoter driving the fluorescence reporter gene mCherry (Fig. 2.1c). To generate dTALE 
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transcription factors, we replaced the endogenous nuclear localization signal (NLS) and acidic 
transcription activation domain (AD) of wild type hax3 with a mammalian NLS derived from the 
simian virus 40 large T-antigen and the synthetic transcription activation domain VP64 (Fig. 
2.1c). To allow quantitative comparison of the dTALE activity, we also fused a self-cleaving 
green fluorescent protein (GFP) to the C-terminus of each dTALE, so that we could quantify the 
relative level of dTALE expression using GFP fluorescence measurements. 
 
Co-transfection of a dTALE (dTALE1) and its corresponding reporter plasmid in the human 
embryonic kidney cell line 293FT led to robust mCherry fluorescence (Fig. 2.1d). In contrast, 
transfection of 293FT cells with the reporter construct alone did not yield appreciable levels of 
fluorescence (Fig. 2.1d). Therefore, dTALEs are capable of recognizing their target DNA 
sequences, as predicted by the TALE DNA binding code, in mammalian cells. We quantified the 
level of reporter induction by measuring the ratio of total mCherry fluorescence intensity 
between cells co-transfected with dTALE and its corresponding reporter plasmid, and cells 
transfected with the reporter plasmid alone. To account for differences in dTALE expression 
level, we use the total GFP fluorescence from each dTALE transfection as a normalization factor 
to assess the fold of reporter induction fold. 
 
Next we asked whether the DNA recognition code is sufficiently modular so that dTALEs could 
be customized to target any DNA sequence of interest. We first synthesized 13 distinct dTALEs 
targeting a range of DNA binding sites with diverse DNA sequence compositions (Fig. 2.2a) and 
found that 10 out of 13 dTALEs (77%) drove robust mCherry expression (> 10 folds) from their 
corresponding reporters. Three dTALEs exhibited more than 50 folds reporter induction 
 11 
(dTALE1, dTALE4 and dTALE8), and only one out of 13 dTALEs (dTALE11) generated less 
than 5 fold induction of mCherry reporter expression (Fig. 2.2a). As a positive control, we 
constructed an artificial zinc finger-VP64 (ZF-VP64) fusion, where the ZF has previously been 
shown to activate transcription from a binding site in the human erbB-2 promoter(48). This 
artificial ZF-VP64 protein was tested using the same mCherry reporter assay and demonstrated 
approximately 16-fold mCherry reporter activation (Fig. 2.2a). 
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Figure 2.2 Functional characterization of the robustness of dTALE-DNA recognition in 
mammalian cells and truncation analysis of TALE N- and C-termini. a, 13 dTALEs were tested 
with their corresponding reporter constructs. Customized repeat regions and binding site   
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(Figure 2.2, continued) sequences are shown on the left. The activities of the dTALE to activate 
target gene expression are shown on the right as the fold induction of the mCherry reporter gene 
in a log scale. b, The N- and C-terminal amino acid sequence of wild type TAL effector hax3 
showing the positions of all N- and C-terminal truncation constructs tested in 293FT cells. N0 to 
N8 designates N-terminal truncation positions (N0 retains the full-length N-terminus), and C0 to 
C7 designate C-terminal truncations. The amino acids representing the nuclear localization signal 
and the activation domain in the native HAX3 protein were underlined. c, Sequential truncation 
at the N-terminus of dTALE1 led to decreasing levels of reporter activity. Each truncation 
constructs is designated by its corresponding N-terminal and C-terminal truncation positions as 
indicated in panel b. Cartoon representations of all truncation constructs are shown on the left; 
the relative activity of each dTALE truncation construct compared to the dTALE(N0-C0) is 
demonstrated on the right. This relative activity is calculated from the fold induction of the 
reporter gene. d, Sequential truncation at the C-terminus of dTALE1 was used to characterize the 
optimal length of the C-terminus. Truncation position is designated in panel b. The relative 
activity of each truncation design compared to dTALE(N1,C0) is shown on the right. All error 
bars indicate s.e.m.; n=3. The fold induction was determined via flow cytometry analysis of 
mCherry expression in transfected 293FT cells, and calculated as the ratio of the total mCherry 
fluorescence intensity of cells transfected with and without the specified dTALE, normalized by 
the GFP fluorescence to control for transfection efficiency differences, as detailed in the Online 
Methods. 
 
These data indicate that sequence-specific dTALEs can be designed and synthesized to target a 
wide spectrum of DNA binding sites at a similar or greater level as artificial ZF-VP64 
transcription factors. While most dTALEs exhibited robust transcription activation in our 
reporter assay, the large range of observed activity suggests that other effects might contribute to 
dTALE DNA-targeting efficacy. Possible causes might include differences in DNA-interacting 
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capabilities such as binding strength of individual repeat types, context-dependence of monomer 
binding strength, or complexities of mammalian transcription processes(47). 
 
To further characterize the robustness of dTALEs activities and their DNA binding specificity, 
we altered the target nucleotides in the binding sites of dTALE1 and dTALE13 to test the impact 
of mismatch position and number on dTALE activity. In general, we found that dTALE activity 
is inversely correlated with the number of mismatches (Supplementary Figs. 2 and 3). However, 
the specific dTALE recognition rules most likely depend on a combination of positional and 
contextual effects as well as the number of mismatchs, and need to be further characterized in 
greater detail. 
 
2.4 Optimization of dTALE architecture through serial truncation testing 
Each fully assembled dTALE has more than 800 amino acids. Therefore we sought to identify 
the minimal N- and C-terminal capping region necessary for DNA binding activity. We used 
Protean (LASERGENE) to predict the secondary structure of the TALE N- and C-termini and 
truncations were made at predicted loop regions. We first generated a series of N-terminal 
dTALE1 truncation mutants and found that transcriptional activity is inversely correlated with 
the N-terminus length (Fig. 2.2b,c). Deletion of 48 amino acids from the N-terminus (truncation 
mutant N1-C0, Fig. 2.2c) retained the same level of transcription activity as the full length N-
term dTALE1, while deletion of 141 amino acids from the N-term (truncation mutant N2-C0, 
Fig. 2.2c) retained approximately 80% of transcription activity. Therefore given its full 
transcriptional activity, we chose to use truncation position N1 for all subsequent studies. 
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Similar truncation analysis in the C-terminus revealed that a critical element for DNA binding 
resides within the first 68 amino acids (Fig. 2.2b,d). Truncation mutant N1-C3 retained the same 
level of transcriptional activity as the full C-terminus, whereas truncation mutant N1-C4 reduces 
dTALE1 activity by more than 50% (Fig. 2.2d). Therefore in order to preserve the highest level 
of dTALE activity, approximately 68 amino acids of the C-terminus of hax3 should be 
preserved. 
 
2.5 Designer TALEs is capacle of modulating endogenous gene transcription in 
mammalian cells 
The modularity of the TALE code is ideal for designing artificial transcription factors for 
transcriptional manipulation from the mammalian genome. In order to test whether dTALE could 
be used to modulate transcription of endogenous genes, we designed 4 additional dTALEs to 
directly activate transcription of SOX2, KLF4 in human genome, and c-Myc, Oct4 in mouse 
genome. dTALE binding sites were selected from the proximal 200bp promoter region of each 
gene (Fig. 2.3a). To assay the DNA binding activity of the 4 new dTALEs, we used the mCherry 
reporter assay as in previous experiments. three out of four dTALEs (SOX2-dTALE, KLF4-
dTALE, and cMyc-dTALE) exhibited greater than 20-fold of mCherry reporter activation (Fig. 
2.3a,b).  
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Figure 2.3 Activation of endogenous pluripotency factors from the human genome by 
designer TALEs. a, dTALEs designed to target the pluripotency factors, SOX2, KLF4 in human 
geonme and c-Myc, Oct4 in mouse genome, facilitate activation of mCherry reporter in 293FT 
cells. The target sites are selected from the 200bp proximal promoter region. The fold induction 
was determined via flow cytometry analysis using the same methodology as stated in Fig. 2.2 
and detailed in Supplementary Methods. b, Images of dTALE induced mCherry reporter 
expression in 293FT cells. Scale bar, 200µm. c, mRNA levels of SOX2 and KLF4 in 293FT cells 
transfected with mock, dTALE1, SOX2-dTALE and KLF4-dTALE. Bars represent the levels of 
SOX2 or KLF4 mRNA in the transfected cell as determined via quantitative RT-PCR. Mock 
consists of cells receiving the transfection vehicle and dTALE1 is used as a negative control. The 
quantitation of the endogenous gene activation by dTALEs targeting the mouse genome is 
presented in Supplementary Information. All error bars indicate s.e.m.; n=3. *** p < 0.005. 
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To test the activity of dTALEs on endogenous genes, we transfected each dTALE targeting 
human or mouse genome into 293FT or Neuro2A cells respectively and quantified mRNA levels 
of each target gene using qRT-PCR. dTALE-SOX2 and dTALE-KLF4 were able to upregulate 
their respective target genes by 5.5 ± 0.1 and 2.2 ± 0.1 folds (Fig. 2.3c), providing a 
demonstration that dTALE can be used to modulate transcription from the genome. To control 
for specificity of activation, we transfected 293FT cells in parallel with dTALE1, which was not 
designed to target either SOX2 or KLF4, and found no change in the level of Sox2 or Klf4 
expression relative to the mock control. Interestingly, we observed a statistically significant 
decrease in the level of KLF4 mRNA in 293FT cells transfected with SOX2-dTALE 
(approximately a 2-fold reduction). This is potentially due to secondary cross-regulation among 
reprogramming factors(49, 50). Similar activation of endognous gene expression is also observed 
in mouse Neuro2A cell lines with cMyc-dTALE and Oct4-dTALE (Supplementary Fig. 4). 
Finally, the degree of activation varies depending on the specific dTALE targets. This is not 
surprising as different genetic loci may not be equally accessible for activation, possibly due to 
epigenetic repression. Together, the data demonstrated that dTALE can be designed to bind and 
specifically activate transcription from the promoters of endogenous mammalian genes. 
 
2.6 Implication and significance of TAL effector technology 
The modular nature of the TALE DNA recognition code provides a novel and attractive solution 
for achieving sequence-specific DNA interaction in mammalian cells. For the first time, 
sequence-specific DNA binding proteins with predictable binding specificity can be generated in 
a matter of days, economically using molecular biology methods accessible to most. Future 
studies exploring the molecular basis of TALE-DNA interaction will likely extend the modular 
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nature of the TALE code for increased precision, specificity, and robustness. Given the ability of 
dTALEs to efficiently anchor transcription effector modules to endogenous genomic targets, 
other functional modules, including nucleases(8), recombinases(51), and epigenetic modifying 
enzymes(34), can be similarly targeted to specific binding sites. The designer TALE toolbox will 
empower researchers, clinicians, and technologists alike with a new repertoire of programmable 
precision genome engineering technologies. 
 
2.7 Material and methods 
2.7.1 Design and construction of designer TALEs and reporters 
To simplify construction of designer TALEs, a dTALE backbone containing the N-term, a single 
0.5 repeat regions carrying the variable diresidue NI, and C-term of hax3 was synthesized 
(DNA2.0) and cloned into a lentiviral expression vector containing the mammalian ubiquitous 
EF-1α promoter (pLECYT)(52). To allow for insertion of customized repeat domains, a linker 
containing two Type IIs BsmBI sites are inserted between the N-term and the 0.5 repeat region. 
A DNA fragment containing a mammalian NLS, transcription activation domain VP64, and 2A-
GFP was assembled via PCR assembly and fused to the C-term of the synthesized dTALE 
backbone (pLenti-EF1a-dTALE(0.5 NI)-WPRE).  HD, NG, and NN versions of the backbone 
were generated via site directed PCR mutagenesis using QuikChange II XL (Stratagene). The 
full nucleotide sequences for the four backbone vectors are available in Supplementary 
Information. Customized dTALE repeat domains were synthesized via hierarchical ligation of 
individual repeat monomers (Supplementary Methods). To minimize repetitiveness of the final 
assembled tandem repeat domain, the DNA sequence for each type of repeat monomer (HD, NG, 
NI, or NN) has been optimized by altering the amino acid codons. The sequences for the 
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optimized monomers are listed in Supplementary Table 1, and the assembly primers are listed in 
Supplementary Table 2. mCherry reporter plasmids carrying dTALE binding site were generated 
by inserting sequences containing the binding site upstream of the minimal CMV promoter 
(Supplementary Fig.  1.) 
 
2.7.2 Cell culture and reporter activation assay 
The human embryonic kidney cell line 293 FT (Invitrogen) was maintained under 37ºC, 5% CO2 
using Dulbecco’s modified Eagle’s Medium supplemented with 10% fetal bovine serum, 2mM 
GlutaMAX (Invitrogen), 100U/mL Penicillin, and 100µg/mL Streptomycin. mCherry reporter 
activation was tested by co-transfecting 293FT cells with plasmids carrying dTALEs and 
mCherry reporters. 293FT cells were seeded into 24- or 96-well plates the day prior to 
transfection at densities of 2x105 cells/well or 0.8x104 cells/well respectively. Approximately 
24h after initial seeding, cells were transfected using Lipofectamine 2000 (Invitrogen). For 24-
well plates we used 500ng of dTALE and 30ng of reporter plasmids per well. For 96-well plates 
we used 100ng of dTALE and 7ng of reporter plasmids per well. All transfection experiments 
were performed according to manufacturer's recommended protocol. 
 
2.7.3 Flow cytometry 
mCherry reporter activation was assayed via flow cytometry using a LSRFortessa cell analyzer 
(BD Biosciences). Cells were trypsinized from their culturing plates approximately 18 hours 
after transfection and resuspended in 200ul of media for flow cytometry analysis. The flow 
cytometry data was analyzed using BD FACSDiva (BD Biosciences). At least 25,000 events 
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were analyzed for each transfection sample. The fold induction of mCherry reporter gene by 
dTALEs was determined via flow cytometry analysis of mCherry expression in transfected 
293FT cells, and calculated as the ratio of the total mCherry fluorescence intensity of cells from 
transfections with and without the specified dTALE. All fold induction values were normalized 
to the expression level of dTALE as determined by the total GFP fluorescence for each 
transfection. 
 
2.7.4 Endogenous gene activation assay 
293FT cells were seeded in 6 well plates. 4ug of dTALE plasmid was transfected using 
Lipofectamine 2000 (Invitrogen). Transfected cells were cultured at 37oC for 48 hours, sorted for 
GFP positive population using BD FACSAria (BD Biosciences) to obtain cells that were 
successfully transfected and expressing dTALE. At least 1,000,000 cells were harvested and 
subsequently processed for total RNA extraction using the RNAeasy Mini Kit (Qiagen). cDNA 
was generated using the iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's 
recommended protocol. SOX2 and KLF4 mRNA were detected using TaqMan Gene Expression 
Assays (Applied Biosystems: Sox2 - Hs00602736_s1, Klf4 - Hs01034973_g1). 
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3. Methods and Protocols of A Transcription Activator-Like Effector Toolbox for 
Genome Engineering 
The optimization and development of the methods and protocols are done with Drs. Neville 
Sanjana and Yang Zhou as equal contributors, and the work described in this chapter has been 
published as Sanjana NE*, Cong L*, Zhou Y*, et al. Nature Protocols. 2012 (28). 
 
3.1 Introduction 
Systematic reverse engineering of the functional architecture of the mammalian genome requires 
the ability to perform precise perturbations on gene sequences and transcription levels. Tools 
capable of facilitating targeted genome editing and transcription modulation are essential for 
elucidating the genetic and epigenetic basis of diverse biological functions and diseases. Recent 
discovery of the transcription activator-like effector (TALE) code(23, 25) has enabled the 
generation of custom TALE DNA binding domains with programmable specificity(27, 39, 53-
60). When coupled to effector domains, customized TALEs provide a promising platform for 
achieving a wide variety of targeted genome manipulations(27, 53, 54, 57, 60-62). Previously, 
we reported efficient construction of TALEs with customized DNA binding domains for 
activating endogenous genes in the mammalian genome(27). Here we describe an improved 
protocol for rapid construction of customized TALEs and methods to apply these TALEs to 
achieve endogenous transcriptional activation(27, 53, 54, 57) and site-specific genome 
editing(39, 53, 56, 58, 60-63). Investigators should be able to use this protocol to construct 
TALEs for targets of their choice in less than one week. 
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3.1.1 Transcription Activator-Like Effectors.  
TALEs are natural bacterial effector proteins used by Xanthomonas sp. to modulate gene 
transcription in host plants to facilitate bacterial colonization(64, 65). The central region of the 
protein contains tandem repeats of 34 amino acids sequences (termed monomers) that are 
required for DNA recognition and binding(45, 46, 66, 67) (Fig. 3.1a). Naturally occurring 
TALEs have been found to have a variable number of monomers, ranging from 1.5 to 33.5 (ref. 
16). Although the sequence of each monomer is highly conserved, they differ primarily in two 
positions termed the repeat variable diresidues (RVDs, 12th and 13th positions). Recent reports 
have found that the identity of these two residues determines the nucleotide binding specificity of 
each TALE repeat and a simple cipher specifies the target base of each RVD (NI = A, HD = C, 
NG = T, NN = G or A)(23, 25). Thus, each monomer targets one nucleotide and the linear 
sequence of monomers in a TALE specifies the target DNA sequence in the 5` to 3` orientation. 
The natural TALE binding sites within plant genomes always begin with a thymine(23, 25), 
which is presumably specified by a cryptic signal within the non-repetitive N-terminus of 
TALEs. The tandem repeat DNA binding domain always ends with a half length repeat (0.5 
repeat, Fig. 3.1a). Therefore, the length of DNA sequence being targeted is equal to the number 
of full repeat monomers plus two.  
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Figure 3.1 A TALE toolbox for genome engineering. (a) Natural structure of TALEs derived 
from Xanthomonas sp. Each DNA binding module consists of 34 amino acids, where the repeat 
variable diresidues (RVDs) in the 12th and 13th amino acid positions of each repeat specify the 
DNA base being targeted according to the cipher NG = T, HD = C, NI = A, and NN = G or A. 
The DNA binding modules are flanked by non-repetitive amino and carboxyl termini, which 
carry the translocation, nuclear localization (NLS), and transcription activation (AD) domains. A 
cryptic signal within the amino terminus specifies a thymine as the first base of the target site. 
(b) The TALE toolbox allows rapid and inexpensive construction of custom TALE-TFs and 
TALENs. The kit consists of 12 plasmids in total: 4 monomer plasmids to be used as templates 
for PCR amplification, 4 TALE-TF and 4 TALEN cloning backbones corresponding to 4 
different bases targeted by the 0.5 repeat. CMV: cytomegalovirus promoter; N-term: non  
a
Figure 1
NH2 COOH
NLS AD34aa repeat modules
LTPEQVVAIASNGGGKQALETVQRLLPVLCQAHG
RVD
Translocation
NG
HD
NI
NN
=
=
=
=
T
C
A
G or A
b
CMV
NLS
VP64
2A
EGFP
polyA
signal
N-term C-term
ccdB+CmR
BsaI BsaI
TALE-TF cloning backbone 
0.5 repeat
(NI, HD, NG, NN)
CMV
BsaI BsaI
NLS
polyA
signal
N-term C-term
ccdB+CmR FokI
TALEN cloning backbone 
0.5 repeat
(NI, HD, NG, NN)
TALE monomer
templates
NI
HD
NG
NN
T T A T T C C C T G A CT C
VP64
Transcription
complex
Activate transcriptionPromoter region
gene of interest
FokI
FokI
Nucleolytic target site
 Generate double strand break
c
d
5’
3’
3’
5’
5’
3’
3’
5’
14 to 20 bp
Left TALEN Right TALEN
TALE-TF
 24 
(Figure 3.1, continued) repetitive amino terminus from the Hax3 TALE; C-term: non-repetitive 
carboxyl terminus from the Hax3 TALE; BsaI: type IIs restriction sites used for the insertion of 
custom TALE DNA binding domains; ccdB+CmR: negative selection cassette containing the 
ccdB negative selection gene and chloramphenicol resistance gene; NLS: nuclear localization 
signal; VP64: synthetic transcriptional activator derived from VP16 protein of herpes simplex 
virus; 2A: 2A self-cleavage linker; EGFP: enhanced green fluorescent protein; polyA signal: 
polyadenylation signal; FokI: catalytic domain from the FokI endonuclease. (c) TALEs can be 
used to generate custom transcription factors (TALE-TFs) and modulate the transcription of 
endogenous genes from the genome. This schematic shows a TALE-TF designed to target the 
SOX2 locus in the human genome. The SOX2 TALE-TF recognizes the sense strand of the SOX2 
proximal promoter, and the recognition site begins with T. The TALE DNA-binding domain is 
fused to the synthetic VP64 transcriptional activator, which recruits RNA polymerase and other 
factors needed to initiate transcription. (d) TALE nucleases (TALENs) can be used to generate 
site-specific double strand breaks to facilitate genome editing through non-homologous repair or 
homology-directed repair. This schematic shows a pair of TALENs designed to target the 
AAVS1 locus in the human genome. Two TALENs target a pair of binding sites flanking a 16bp 
spacer. The left and right TALENs recognize the top and bottom strands of the target sites 
respectively. Each TALE DNA-binding domain is fused to the catalytic domain of FokI 
endonuclease; when FokI dimerizes, it cuts the DNA in the region between the left and right 
TALEN binding sites. 
 
 
3.1.2 Comparison to other genome manipulation methods.  
For targeted gene insertion and knockout, there are several techniques that have been used 
widely in the past, such as homologous gene targeting(68-70), transposases(71, 72), site-specific 
recombinases(73), meganucleases(74), and integrating viral vectors(75, 76). However most of 
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these tools target a preferred DNA sequence and cannot be easily engineered to function at non-
canonical DNA target sites. The most promising, programmable DNA-binding domain has been 
the artificial zinc finger (ZF) technology, which enables arrays of ZF modules to be assembled 
into a tandem array and target novel DNA binding sites in the genome. Each finger module in a 
ZF array targets three DNA bases(77, 78). In comparison, TALE DNA binding monomers target 
single nucleotides and are much more modular than ZF modules. For instance, when two 
independent ZF modules are assembled into a new array, the resulting target site cannot be easily 
predicted based on the known binding sites for the individual finger modules. Perhaps the 
biggest caveat of ZFs is that most of the intellectual property surrounding the ZF technology 
platform is proprietary and expensive (>$10k per target site). A public effort for ZF technology 
development also exists through the Zinc Finger Consortium but the publicly available ZF 
modules can only target a subset of the 64 possible trinucleotide combinations(27, 79, 80). 
TALEs theoretically can target any sequence and have already been deployed in many organisms 
with impressive success (see Table 3.1). Although TALEs seem superior in many ways, zinc 
fingers have a much longer track record in DNA-targeting applications(78), including their use in 
human clinical trials(81).  Despite their relatively recent development, early results with TALEs 
have been promising and it seems that they can be applied in the same way as zinc fingers for 
many DNA-targeting applications (e.g. transcriptional modulator(27, 53, 54, 57), nuclease(39, 
53, 56, 58, 60-63), recombinase(82-84), transposase(85, 86)).  
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Table 3.1 Applications of custom TALEs on endogenous genome targets 
 Species Genomic Loci References 
TALE-TF A. thaliana EGL3 (54) 
  KNAT1  
    
 H. sapiens KLF4 (27) 
  SOX2  
  NTF3 (53) 
  
PUMA 
IFNα1 
IFNβ1 
(57) 
    
TALEN S. cerevisiae URA3 (58) 
  LYS2  
  ADE2  
    
 H. sapiens CCR5 (53) 
  NTF3  
  PPP1R12C (AAVS1) (61) 
  OCT4 (POU5F1)  
  PITX3  
    
 C. elegans BEN-1 (60) 
    
 D. rerio HEY2 (87, 88) 
  
GRIA3A 
TNIKB 
 
 R. norvegicus IGM (89) 
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3.1.3 Constructing customized TALE-TFs and TALENs.  
Due to the repetitive nature of TALEs, construction of the DNA-binding monomers can be 
difficult. Previously, we and other groups have used a hierarchical ligation strategy to overcome 
the difficulty of assembling the monomers into ordered multimer arrays, taking advantage of 
degeneracy in codons surrounding the monomer junction and Type IIs restriction enzymes(27, 
55-59). In this protocol, we employ the same basic strategy that we previously used(27) to 
construct TALE-TFs to modulate transcription of endogenous human genes. We have further 
improved the TALE assembly system with a few optimizations, including maximizing the 
dissimilarity of ligation adaptors to minimize misligations and combining separate digest and 
ligation steps into single Golden Gate(43, 44, 90) reactions. Briefly, we first amplify each 
nucleotide-specific monomer sequence with ligation adaptors that uniquely specify the monomer 
position within the TALE tandem repeats. Once this monomer library is produced, it can 
conveniently be re-used for the assembly of many TALEs. For each TALE desired, the 
appropriate monomers are first ligated into hexamers, which are then amplified via PCR. Then, a 
second Golden Gate digestion-ligation with the appropriate TALE cloning backbone (Fig. 3.1b) 
yields a fully-assembled, sequence-specific TALE. The backbone contains a ccdB negative 
selection cassette flanked by the TALE N- and C-termini, which is replaced by the tandem repeat 
DNA-binding domain when the TALE has been successfully constructed. ccdB selects against 
cells transformed with an empty backbone, therefore yielding clones with tandem repeats 
inserted(56). 
 
Assemblies of monomeric DNA binding domains can be inserted into the appropriate TALE 
transcription factor (TALE-TF) or TALE nuclease (TALEN) cloning backbones to construct 
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customized TALE-TFs and TALENs. TALE-TFs are constructed by replacing the natural 
activation domain within the TALE C-term with the synthetic transcription activation domain 
VP64 (ref. 3) (Fig. 3.1c). By targeting a binding site upstream of the transcription start site, 
TALE-TFs recruit the transcription complex in a site-specific manner and initiate gene 
transcription. TALENs are constructed by fusing a C-term truncation (+63aa) of the TALE DNA 
binding domain(53) with the non-specific FokI endonuclease catalytic domain (Fig. 3.1d). The 
+63aa C-term truncation has also been shown to function as the minimal C-term sufficient for 
transcriptional modulation(27). TALENs form dimers through binding to two target sequences 
separated by ~17 bases. Between the pair of binding sites, the FokI catalytic domains dimerize 
and function as molecular scissors by introducing double-strand breaks (DSBs) (Fig. 3.1d). 
Normally, DSBs are repaired by the non-homologous end-joining(91) (NHEJ) pathway, resulting 
in small deletions and functional gene knock-out.  Alternatively, TALEN-mediated DSBs can 
stimulate homologous recombination, enabling site-specific insertion of an exogenous donor 
DNA template(53, 61). 
 
We also present a short procedure for verifying correct TALE assembly: using colony PCR to 
verify the correct insert length followed by DNA sequencing. With our cloning procedure, we 
routinely achieve high efficiency (correct length) and high accuracy (correct sequence). The 
cloning procedure is modular in several ways: We can construct TALEs to target DNA 
sequences of different lengths and the protocol is the same for producing either TALE-TFs or 
TALENs. The backbone vectors can be modified with different promoters to achieve cell-type 
specific expression. 
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Our protocol includes functional assays for evaluating TALE-TF and TALEN activity in human 
cells. This step is important because we have observed some variability in TALE activity on the 
endogenous genome, possibly due to epigenetic repression and/or inaccessible chromatin at 
certain loci. For TALE-TFs, we perform quantitative reverse-transcription polymerase chain 
reaction (qRT-PCR) to quantify changes in gene expression. For TALENs, we use the Surveyor 
mutation detection assay (i.e. the base-mismatch cleaving endonuclease Cel2) to quantify NHEJ. 
Although these assays are standard and have already been described elsewhere(92, 93), we feel 
that the functional characterization is integral to TALE production and therefore have presented 
it here with the assembly procedure. Other functional assays such as plasmid-based reporter 
constructs(27, 56), restriction sites destroyed by NHEJ(94), or other enzymes that detect DNA 
mismatch(95) may also be used to validate TALE activity. 
 
Our protocol (Fig. 3.2) begins with the generation of a monomer library, which takes one day 
and can be re-used for building many TALEs. Using the monomer library, several TALEs can be 
constructed in a single day with an additional two days for transformation and sequence 
verification. To assess TALE function on the endogenous genome, we take ~3 days to go from 
mammalian cell transfection to qRT-PCR or Surveyor results.  
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Figure 3.2 Timeline for the construction of TALE-TFs and TALENs. Steps for the 
construction and functional testing of TALE-TFs and TALENs are outlined. TALEs can be 
constructed and sequence verified in 5 days following a series of ligation and amplification steps. 
During the construction phase, samples can be stored at -20oC at the end of each step and 
continued at a later date. After TALE construction, functional validation via qRT-PCR (for 
TALE-TFs) and Surveyor nuclease assay (for TALENs) can be completed in 2-3 days.  
 
3.1.4 Comparison with other TALE assembly procedures. 
A number of TALE assembly procedures have described the use of Golden-Gate cloning to 
construct customized TALE DNA binding domains(27, 55-59). These methods rely on the use of 
a large collection of plasmids (typically over 50 plasmids) encoding repeat monomers and 
intermediate cloning vectors. Our PCR-based approach requires significantly less initial plasmid 
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preparation, as our monomer library can be amplified on one 96-well PCR plate, and facilitates 
more rapid construction of custom TALEs. Plasmid-based amplification has a much lower 
mutation/error rate but, in our experience, the combination of a high-fidelity polymerase and the 
short length of the monomer template (~100 nt) results in accurate assembly. For building 
similar length TALEs to those presented in this protocol, the plasmid-based approaches also 
require an additional transformation and colony selection that extends the time needed to build 
TALEs. Thus, these alternative assembly protocols require a greater time investment both 
upfront (for monomer library preparation) and on a recurring basis (for each new TALE). For 
laboratories seeking to produce TALEs quickly, our protocol requires only a few hours to 
prepare a complete monomer library and less than a day to proceed from monomers to the final 
transformation into bacteria. 
 
3.1.5 Targeting limitations. 
There are a few important limitations with the TALE technology. Although the RVD cipher is 
known, it is still not well understood why different TALEs designed according to the same 
cipher act on their target sites in the native genome with different levels of activity. It is possible 
that there are yet unknown sequence dependencies for efficient binding or site-specific 
constraints (e.g. chromatin state) that are responsible for differences in functional activity. 
Therefore we suggest constructing at least 2 or 3 TALE-TFs or TALEN pairs for each target 
locus. Also, it is possible that engineered TALEs can have off-target effects – binding 
unintended genomic loci – which can be difficult to detect without additional functional assays at 
these loci. Given the relatively early state of TALE technology development, these issues remain 
to be addressed in a conclusive manner. 
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3.1.6 Experimental design. 
TALE-TF target site selection. The programmable nature of TALEs allows for a virtually 
arbitrary selection of target DNA binding sites. As previously reported, the N-terminus of the 
TALE requires that the target site begin with a thymine nucleotide. For TALE-TFs, we have 
been successful targeting 14 to 20 bp sequences within 200bp of the transcription start site (Fig. 
3.1c). It can be advantageous to select a longer sequence to reduce off-target activation, as it is 
known from reporter activation assays that TALEs interact less efficiently with targets contain 
more than one mismatching base. In our assembly protocol, we describe ligation of 18 monomers 
into a backbone containing a nucleotide-specific final 0.5 monomer; combined with the initial 
thymine requirement, this yields a total sequence specificity of 20 nucleotides. Specifically, the 
TALE-TF binding site takes the form 5`-TN19-3`. When selecting TALE-TF targeting sites for 
modulating endogenous gene transcription, we recommend selecting multiple target sites within 
the proximal promoter region (can target either the sense or antisense strand), as epigenetic and 
local chromatin dynamics might impede TALE binding. Larger TALEs might be beneficial for 
TALE-TFs targeting genes with less unique regions upstream of their transcription start site. 
 
TALEN target site selection. Since TALENs function as dimers, a pair of TALENs, referred to as 
the left and right TALENs, need to be designed to target a given site in the genome. The left and 
right TALENs target sequences on opposite strands of DNA (Fig. 3.1d). As with TALE-TF, we 
design each TALEN to target a 20 base pair sequence. TALENs are engineered as a fusion of the 
TALE DNA-binding domain and a monomeric FokI catalytic domain. To facilitate FokI 
dimerization, the left and right TALEN target sites are chosen with a spacing of ~14-20 bases. 
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Therefore, for a pair of TALENs, each targeting 20 base pair sequences, the complete target site 
should have the form 5`-TN19N14-20N19A-3`, where the left TALEN targets 5`-TN19-3` and the 
right TALEN targets the antisense strand of 5`-N19A-3` (N = A, G, T, or C). TALENs should 
have fewer off-target effects due to the dimerization requirement for the FokI nuclease, although 
no significant off-target effects have been observed in limited sequencing verifications(61). 
Because DSB formation only occurs if the spacer between the left and right TALEN binding 
sites (Fig. 3.1d) is ~14-20 bases, nuclease activity is restricted to genomic sites with both the 
specific sequences of the left TALEN and the right TALEN with this small range of spacing 
distances between those sites. These constraints should greatly reduce potential off-target effects. 
 
TALE monomer design. To ensure that all synthesized TALEs are transcribed at a similar level, 
all of the monomers have been optimized to share identical DNA sequences except in the 
variable di-residues – and are codon-optimized for expression in human cells (see Supplementary 
Data 3.1). This should minimize any difference in translation due to codon availability.  
 
Construction strategy. Synthesis of monomeric TALE DNA binding domains in a precise order 
is challenging due to their highly repetitive nature. Previously(27), we took advantage of codon 
redundancy at the junctions between neighboring monomers and devised a hierarchical ligation 
strategy to construct ordered assemblies of multiple monomers. In this protocol, we describe a 
similar strategy but with several important improvements that make the procedure easier, more 
flexible, and more reliable (Fig. 3.3). 
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Figure 3.3 Construction of TALE DNA binding domains using hierarchical ligation 
assembly. Schematic of the construction process for a custom TALE containing a 18-mer tandem 
repeat DNA binding domain. Stage 1: specific primers are used to amplify each monomer and 
add the appropriate ligation adapters (Procedure Steps 1-9). Stage 2: hexameric tandem repeats 
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(Figure 3.3, continued) (1—6, 7—12, and 13—18) are assembled first using Golden Gate 
digestion-ligation. The 5` ends of monomers 1, 7, and 13 and the 3` ends of monomers 6, 12, and 
18 are designed so that each tandem hexamer assembles into an intact circle (Procedure Steps 
10-15).  Stage 3: the Golden Gate reaction is treated with an exonuclease to remove all linear 
DNA, leaving only the properly assembled tandem hexamer (Procedure Steps 16-17). Stage 4: 
each tandem hexamer is amplified individually using PCR and purified (Procedure Steps 18-25). 
Stage 5: tandem hexamers corresponding to 1—6, 7—12, and 13—18 are ligated into the 
appropriate TALE-TF or TALEN cloning backbone using Golden Gate cut-ligation (Procedure 
Steps 26-28). Stage 6: The assembled TALE-TF or TALEN is transformed into competent cells 
and successful clones are isolated and sequence verified (Procedure Steps 29-38). 
 
In our initial protocol(27), the digestion and ligation steps were carried out separately with an 
intervening DNA purification step. This improved protocol adopts the powerful Golden Gate 
cloning technique(43, 44, 90), requiring less hands-on time and resulting in a more efficient 
reaction. The Golden Gate procedure involves combining the restriction enzyme and ligase 
together in a single reaction with a mutually compatible buffer. The reaction is cycled between 
optimal temperatures for digestion and ligation. Golden Gate digestion-ligation capitalizes on 
Type IIs restriction enzymes, for which the recognition sequence is spatially separated from 
where the cut is made. During a Golden Gate reaction, the correctly ligated products no longer 
contain restriction enzyme recognition sites and cannot be further digested. In this manner, 
Golden Gate drives the reaction toward the correct ligation product as the number of cycles of 
digestion and ligation increases.  
 
For the hierarchical ligation steps, we have optimized our previous cloning strategy for faster 
TALE production. The improved design takes advantage of a circularization step that allows 
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only properly assembled hexameric intermediates to be preserved (Fig. 3.3). Correctly ligated 
hexamers consist of six monomers ligated together in a closed circle, and incomplete ligation 
products are left as linear DNA. After this ligation step, an exonuclease degrades all non-circular 
DNA, leaving intact only the complete circular hexamers. Without circularization and 
exonuclease treatment, the correct ligation product would need to be gel purified before 
proceeding. The combination of Golden Gate digestion-ligation and circularization reduces the 
overall hands-on time required for TALE assembly.  
 
Primer design for monomer library preparation. Each monomer in the tandem repeat must have 
its position uniquely specified. The monomer primers are designed to add ligation adaptors that 
enforce this positioning. Our protocol uses a hierarchical ligation strategy: For the 18mer tandem 
repeat, we first ligate monomers into hexamers. Then, we ligate three hexamers together to form 
the 18mer. By breaking down the assembly into two steps, we do not need unique ligation 
junctions for each monomer in the 18mer. Instead the same set of ligation junctions internal to 
each hexamer are re-used in all three hexamers (first ligation step), whereas unique (external) 
ligation junctions are used to flank each hexamer (second ligation step). As shown in Fig. 3.4, 
the internal primers used to amplify the monomers within each hexamer are the same, but the 
external primers differ between the hexamers. By re-using the same internal primers between 
different hexamers, our protocol minimizes the number of primers necessary for monomer 
amplification. 
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Figure 3.4 PCR plate setup used to generate a plate of monomers for constructing custom 18-
mer TALE DNA binding domains. One 96-well plate can be used to carry out 72 reactions (18 
for each monomer template). The position of each monomer and the primers used for the 
position is indicated in the well. Color coding in the well indicates the monomer used as the PCR 
template. Typically, 2-4 plates of 100 ul PCR reactions are pooled together and purified to 
generate a monomer library of sufficient quantity for production of many TALEs. During TALE 
construction, the corresponding monomer for each DNA base in the 18 bp target sequence can be 
easily picked from the plate. 
 
Controls. As a negative control for Golden Gate assembly, we recommend performing a separate 
reaction with only the TALE-TF or TALEN backbone. Transformation of this negative control 
should result in few or no colonies due to the omission of the tandem repeats and resulting re-
ligation of the toxic ccdB insert. After completing the TALE cloning, we use colony PCR or 
restriction digests to screen for correct length clones. For the final verification of proper 
assembly, we sequence the entire length of the tandem repeats. Due to limits in Sanger 
sequencing read length, other TALE assembly protocols have difficulty sequencing the entire 
tandem repeat region(56, 58, 59). The similarity of the monomers within the region makes 
primer annealing to specific monomers impossible. We have overcome this problem by slightly 
modifying the codon usage at the 5` end of monomer 7 to create a unique annealing site so that a 
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TALE with a 18mer DNA binding array can be verified through a combination of three 
staggered sequencing reads. Specifically, during the monomer amplification, the codons for the 
first 5 amino acids in monomer 7 are mutated via PCR to use different but synonymous codons, 
creating a unique priming site without changing the encoded TALE protein. This modification 
allows each hexamer in the 18mer to be sequenced with a separate sequencing read and requires 
only a standard read length of ~700 bp for complete sequence verification. For TALEs 
containing more than 18 full monomer repeats, we introduced a third unique priming site for 
sequencing at the 3` end of the 18th monomer using a similar approach. For construction of 
TALEs containing up to 24 full monomers with the entire tandem repeat region easily 
sequenced, see Box 3.1. 
 
Design of functional validation assays. For TALE-TFs, qRT-PCR quantitatively measures the 
increase in transcription driven by the TALE-TF.  For TALENs, the Surveyor assay provides a 
functional validation of TALEN cutting and quantifies the cutting efficiency of a particular pair 
of TALENs. These assays should be performed in the same cell type as intended for the TALE 
application, as TALE efficacy can vary between cell types, presumably due to differences in 
chromatin state or epigenetic modifications.  
 
For qRT-PCR, we use commercially-available probes to measure increased transcription of the 
TALE-TF-targeted gene. For most genes in the human or mouse genomes, specific probes can be 
purchased (e.g. TaqMan Gene Expression Probes from Applied Biosystems). There are a wide 
variety of qRT-PCR protocols and, although we describe one of them here, others can be 
substituted. For example, a more economical option is to design custom, transcript-specific 
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primers (e.g. with NCBI Primer-BLAST) and use a standard fluorescent dye to detect amplified 
dsDNA (e.g. SYBR Green).  
 
For Surveyor, we follow the recommendations given by the assay manufacturer when designing 
specific primers for genomic PCR. We typically design primers that are ~30 nucleotides long 
and with melting temperatures of ~65 °C. The primers should flank the TALEN target site and 
generate an amplicon of ~300-800 bp with the TALEN target site near the middle. During the 
design, we also check to make sure the primers are specific over the intended genome using 
NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Before using the 
primers for Surveyor, the primers and specific PCR cycling parameters should be tested to 
ensure that amplification results in a single clean band. In difficult cases where a single band 
product cannot be achieved, it is acceptable to gel extract the correct length band before 
proceeding with heteroduplex re-annealing and Surveyor nuclease digest. 
 
3.2 Materials 
3.2.1 Reagents 
TALE construction 
• TALE monomer template plasmids:  
pNI_v2 
pNG_v2 
pNN_v2 
pHD_v2 
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• TALE transcriptional activator (TALE-TF) plasmids: 
pTALE-TF_v2 (NI)  
pTALE-TF_v2 (NG) 
pTALE-TF_v2 (NN) 
pTALE-TF_v2 (HD) 
• TALE nuclease (TALEN) backbone plasmids: 
pTALEN_v2 (NI) 
pTALEN_v2 (NG) 
pTALEN_v2 (NN) 
pTALEN_v2 (HD) 
These plasmids can be obtained individually or bundled together as a single kit from the 
Zhang Lab plasmid collection at Addgene (http://www.addgene.org/TALE_Toolbox). 
See Supplementary Data 1 for plasmid sequences. 
• PCR primers for TALE construction (Table 3.3, Integrated DNA Technologies, custom 
DNA oligonucleotides) 
• Herculase II Fusion polymerase (Agilent Technologies, cat. no. 600679) 
CRITICAL Standard Taq polymerase, which lacks 3’-5’ exonuclease proofreading activity, 
has lower fidelity and can lead to errors in the final assembled TALE. Herculase II is a high-
fidelity polymerase (equivalent fidelity to Pfu) that produces high yields of PCR product with 
minimal optimization. Other high-fidelity polymerases may be substituted. 
• 5x Herculase II reaction buffer (Agilent Technologies, included with polymerase) 
• Taq-B polymerase (Enzymatics, cat. no. P725L) 
• 10x Taq-B buffer (Enzymatics, included with polymerase) 
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• 25mM (each) dNTP solution mix (Enzymatics, cat. no. N205L) 
• MinElute Gel Extraction Kit (Qiagen, cat. no. 28606) 
CRITICAL MinElute columns should be stored at 4°C until use. 
• QIAprep Spin Miniprep Kit (Qiagen, cat. no. 27106) 
• QIAquick 96 PCR Purification (Qiagen, cat. no. 28181) 
• UltraPure DNase⁄RNase-Free Distilled Water (Invitrogen, cat. no. 10977-023) 
• UltraPure 10X TBE Buffer (Invitrogen, cat. no. 15581-028) 
• SeaKem LE agarose (Lonza, cat. no. 50004) 
• 10,000x SYBR Safe DNA stain (Invitrogen, cat. no. S33102) 
• Low DNA Mass Ladder (Invitrogen, cat. no. 10068-013) 
• 1 kb Plus DNA Ladder (Invitrogen, cat. no. 10787-018) 
• TrackIt™ Cyan⁄Orange Loading Buffer (Invitrogen, cat. no. 10482-028) 
• Restriction enzymes:  
o BsmBI (Esp3I) (Fermentas/ThermoScientific cat. no. ER0451)  
o BsaI-HF (New England Biolabs, cat. no. R3535L) 
o AfeI (New England Biolabs, cat. no. R0652S) 
• Fermentas Tango Buffer and 10x NEBuffer 4 (included with enzymes) 
• 100x Bovine Serum Albumin (New England Biolabs, included with BsaI-HF) 
• DL-Dithiothreitol (DTT) (Fermentas/ThermoScientific cat. no. R0862) 
• T7 DNA ligase, 3,000 U/ul (Enzymatics, cat. no. L602L) 
CRITICAL Do not substitute the more commonly-used T4 ligase. T7 ligase has 1000-fold 
higher activity on sticky ends than blunt ends and higher overall activity than commercially 
available concentrated T4 ligases. 
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• 10 mM Adenosine 5’-Triphosphate (New England Biolabs, cat. no. P0756S) 
• Plasmid-Safe™ ATP-Dependent DNase (Epicentre, cat. no. E3101K) 
• One Shot® Stbl3™ Chemically Competent E. coli (Invitrogen, cat. no. C7373-03) 
• SOC medium (New England Biolabs, cat. no. B9020S) 
• LB medium (Sigma, cat. no. L3022) 
• LB agar medium (Sigma, cat. no. L2897) 
• 100 mg/ml ampicillin, sterile-filtered (Sigma, cat. no. A5354) 
 
TALEN and TALE-TF functional validation in mammalian cells 
• HEK293FT cells (Invitrogen, cat. no. R700-07) 
• Dulbecco’s Minimum Eagle Medium (DMEM) (1X), high glucose (Invitrogen, cat. no. 
10313-039) 
• Dulbecco’s Phosphate Buffered Saline (DPBS) (1X) (Invitrogen, cat. no. 14190-250) 
• Fetal bovine serum, qualified and heat inactivated (Invitrogen, cat. no. 10438-034) 
• Opti-MEM® I reduced-serum medium (Invitrogen, cat. no. 11058-021) 
• GlutaMAX™-I (100X) (Invitrogen, cat. no. 35050079) 
• Penicillin-streptomycin (100X) (Invitrogen, cat. no. 15140-163) 
• Trypsin, 0.05% (1X) with EDTA•4Na (Invitrogen, cat. no. 25300-062) 
• Lipofectamine 2000 TM transfection reagent (Invitrogen, cat. no. 11668027) 
• QuickExtract TM  DNA extraction solution (Epicentre, cat. no. QE09050) 
• Herculase II Fusion polymerase (Agilent Technologies, cat. no. 600679) 
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 CRITICAL Since Surveyor assay is sensitive to single-base mismatches, it is important to 
use only a high-fidelity polymerase. Other high-fidelity polymerases can be substituted; refer 
to the Surveyor manual for PCR buffer compatibility details. 
• 5x Herculase II reaction buffer (Agilent Technologies, included with polymerase) 
• Surveyor Mutation Detection Kit for Standard Gel Electrophoresis (Transgenomic, cat. 
no. 706025) 
CRITICAL The Surveyor assay includes the Cel2 base-mismatch nuclease. Alternatives 
include the Cel1, T7, mung bean, and S1 nucleases(96, 97). Of these, Cel1 has been applied 
extensively for mutation detection(98-100) and established protocols are available for its 
purification(98, 100). 
• Primers for Surveyor assay of TALEN cutting efficiency (see Experimental design for 
further information on Primer design, , Integrated DNA Technologies, custom DNA 
oligonucleotides) 
• RNeasy Mini Kit (Qiagen, cat. no. 74104) 
• QIAshredder (Qiagen, cat. no. 79654) 
• 2-mercaptoethanol (Sigma, cat. no. 63689) 
! CAUTION Wear appropriate personal protective equipment and work in a fume hood 
when handling 2-mercaptoethanol, which is acutely toxic and corrosive. 
• RNAseZAP (Applied Biosystems, cat. no. AM9780) 
• iScript cDNA synthesis kit (BioRad, cat. no. 170-8890) 
• TaqMan® Universal Master Mix (Applied Biosystems, cat. no. 4364341) 
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• TaqMan® Gene Expression Assay Probes for the TALE-TF-targeted gene (Applied 
Biosystems, http://bioinfo.appliedbiosystems.com/genomic-products/gene-
expression.html) 
 
3.2.2 Equipment 
• 96-well thermocycler with programmable temperature stepping functionality (Applied 
Biosystems Veriti, cat no. 4375786) 
CRITICAL Programmable temperature stepping is needed for the TALEN (Surveyor) functional 
assay. Other steps only require a PCR-capable thermocycler. 
• 96-well qPCR system (Applied Biosystems StepOnePlus™ Real-Time PCR System, Cat. 
No. 4376600) 
• 96-well optical plates (Applied Biosystems MicroAmp, cat. no. N801-0560) 
• 96-well PCR plates (Axygen, cat. no. PCR-96-FS-C) 
• 8-well strip PCR tubes (Applied Biosystems, cat. no. N801-0580) 
• QIAvac 96 vacuum manifold (Qiagen, cat. no. 19504) 
• Gel electrophoresis system (BioRad PowerPac Basic Power Supply, cat no. 164-5050, 
and BioRad Sub-Cell GT System gel tray, cat. no. 170-4401).  
• Digital gel imaging system (BioRad GelDoc EZ, cat. no. 170-8270, and BioRad Blue 
Sample Tray, cat. no. 170-8273) 
• Blue light transilluminator and orange filter goggles (Invitrogen SafeImager 2.0, cat. no. 
G6600) 
• Sterile 20 ul pipette tips for colony picking 
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• Gel quantification software (BioRad ImageLab, included with GelDoc EZ, or open-
source NIH ImageJ, available at http://rsbweb.nih.gov/ij/) 
• TALE online sequence verification software (Zhang Lab: http://taleffectors.com/tools/) 
• 60 mm x 15 mm petri dishes (BD Biosciences, cat. no. 351007) 
• Incubator for bacteria plates (Quincy Lab Inc, cat. no. 12-140E) 
• Shaking incubator for bacteria suspension culture (Infors HT Ecotron) 
• 6-well, cell culture-treated polystyrene plates (Corning, cat. no. 3506) 
• UV spectrophotometer (ThermoScientific, cat. no. NanoDrop 2000c) 
 
3.2.3 Reagent setup 
Tris-borate EDTA (TBE) electrophoresis solution. Dilute in distilled water to 1x working 
solution for casting agarose gels and as a buffer for gel electrophoresis. Buffer can be stored at 
room temperature indefinitely. 
10X BSA. Dilute 100x bovine serum albumin (BSA, supplied with BsaI-HF) to 10x 
concentration and store at -20 oC for at least 1 year in 20 ul aliquots.  
10mM ATP. Divide 10mM ATP into 50ul aliquots and store at -20 oC for up to 1 year; avoid 
repeated freeze-thaw cycles.  
10 mM DTT. Prepare 10 mM DTT solution in distilled water and store 20ul aliquots at -70 oC 
for up to 2 years; for each reaction, use a new aliquot since DTT is easily oxidized. 
D10 culture medium. For culture of HEK293FT cells, prepare D10 culture medium by 
supplementing DMEM with 1X GlutaMAX and 10% fetal bovine serum. As indicated in the 
protocol, this medium can also be supplemented with 1X penicillin-streptomycin. D10 medium 
can be made in advance and stored at 4 oC for up to 1 month. 
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3.3 Procedure 
3.3.1 Amplification and normalization of monomer library with ligation adaptors for 
18mer TALE DNA binding domain construction 
TIMING 6 hr 
1| Prepare diluted forward and reverse monomer primer mixes. In a 96-well PCR plate, 
prepare primer mixes for amplifying a TALE monomer library (Figure 3.3, stage 1). Mix 
forward and reverse primers for each of the 18 positions according to the first two rows 
(A and B) of Figure 3.4 and achieve a final concentration of 10uM for each primer. If 
using multi-channel pipettes, arrange the oligonucleotide primers in the order indicated in 
Figure 3.4 to allow for easy pipetting. Typically, prepare 50ul mixes for each primer pair 
(40ul ddH2O, 5ul 100uM forward primer, 5ul 100uM reverse primer). 
 
2| Set up two 96-well monomer library plates following the organization shown in Figure 
3.4; each plate will contain a total of 72 PCR reactions (18 positions for each monomer × 
4 types of monomers). Although it is acceptable to have smaller volume PCR reactions, 
we typically make the monomer set in larger quantities since one monomer library plate 
can be used repeatedly for the construction of many TALEs. Each PCR reaction should 
be made up as follows to a total volume of 200ul, and then split between the two 96-well 
plates so that each well contains a 100ul PCR reaction:  
Component Amount Final 
concentration 
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Monomer template plasmid (5 ng/ul) 2 ul 50 pg/ul 
100mM dNTP (25mM each) 2 ul 1 mM 
5X Herculase II PCR buffer 40 ul 1x 
20uM primer mix (10 uM forward primer and 10 
uM reverse primers from Step 1)  
4 ul 200 nM 
Herculase II Fusion polymerase 2 ul  
Distilled water 150 ul  
Total 200 ul (for 
2 reactions) 
 
 
3| Perform PCR on the reactions from Step 2 using the following cycling conditions: 
Cycle number Denature Anneal Extend 
1 95°C, 2 
min 
  
2-31 95°C, 20 s 60°C, 20 s 72°C, 10 s 
32   72°C, 3 min 
 
4| After the reaction has completed, use gel electrophoresis to verify that monomer 
amplification was successful. Cast a 2% agarose gel in 1x TBE electrophoresis buffer 
with 1x SYBR Safe dye. The gel should have enough lanes to run out 2 ul of each PCR 
product from Step 3. Run the gel at 15 V/cm for 20 minutes. It is not necessary to check 
all 72 reactions at this step; it is sufficient to check all 18 reactions for one type of 
monomer template. Successful amplification should show a ~100 bp product. Monomers 
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positioned at the ends of each hexamer (monomers 1, 6, 7, 12, 13 and 18) should be 
slightly longer than the other monomers due to the length difference of the longer 
external primers. 
? TROUBLESHOOTING 
 
5| Pool both of the 100 ul PCR plates into a single deep-well plate. Purify the combined 
reactions using the QIAquick 96 PCR Purification kit following the manufacturer’s 
directions. Elute the DNA from each well using 100 ul of Buffer EB (included with kit) 
pre-warmed to 55°C. Alternatively, PCR products can also be purified using individual 
columns found in standard PCR cleanup kits. 
w CRITICAL STEP Before eluting the DNA, let the 96-well column plate air dry, preferably at 
37°C, for 30 minutes on a clean Kimwipe so that all residual ethanol has enough time to 
evaporate. 
  
6| Normalization of monomer concentration. Cast a 2% agarose gel. The gel should have 
enough lanes to run out 2 ul of each purified PCR product from Step 5. Include in one 
lane 10 ul of the quantitative DNA ladder. Run the gel at 20 V/cm for 20 minutes. 
 
7| Image the gel using a quantitative gel imaging system. Monomers 1, 6, 7, 12, 13, and 18 
are ~170 bp in size, whereas the other monomers are ~150 bp size (Fig. 3.5a, lanes 1-6). 
Make sure the exposure is short enough so that none of the bands are saturated. 
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8| Quantify the integrated intensity of each PCR product band using ImageJ or other gel 
quantification software. Use the quantitative ladder with known concentrations (5, 10, 20, 
40, 100 ng) to generate a linear fit and quantify the concentration of each purified PCR 
product. 
? TROUBLESHOOTING 
 
 
Figure 3.5 Example gel results from the TALE construction procedure. (a) Lanes 1—6: 
products from the monomer PCR reaction (Stage 1 in Figure 3) after purification and gel 
normalization (Procedure Steps 8-9). The molar concentrations of samples shown on this gel 
have been normalized so that equal moles of monomers are mixed for downstream steps. 
Monomers 1 and 6 are slightly longer than monomers 2, 3, 4, and 5 due to the addition of 
sequences used for circularization. Lane 7: result of the hexamer Golden Gate cut-ligation 
(Procedure Step 15). A series of bands with size ~700 bp and lower can be seen. Successful 
hexamer Golden Gate assembly should show a band ~700 bp (as indicated by arrow). Lane 8: 
hexamer assembly after PlasmidSafe exonuclease treatment (Procedure Step 17). Typically the 
amount of circular DNA remaining is difficult to visualize by gel. Lane 9: result of hexamer 
amplification (Procedure Step 20). A ~700 bp band should be clearly visible. The hexamer gel 
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(Figure 3.5, continued) band should be gel-purified to remove shorter DNA fragments. (b) 
Properly assembled TALE-TFs and TALENs can be verified using bacterial colony PCR (2175 
bp band, lane 1) (Procedure Step 35) and restriction digest with AfeI (2118 bp band for correctly 
assembled 18-mer in either backbone; other bands for TALE-TF are 165 bp, 3435 bp, 3544 bp; 
other bands for TALEN are 165 bp, 2803 bp, 3236 bp; digest shown is for TALE-TF backbone 
vector, lane 2) (Procedure Step 35). 
 
9| Adjust the plate of purified PCR products by adding Buffer EB so that each monomer has 
the same molar concentration. Since monomers 1, 6, 7, 12, 13, and 18 are longer than the 
other monomers, it is necessary to adjust them to a slightly higher concentration. For 
example, we adjust monomers 1, 6, 7, 12, 13, and 18 to 18 ng/ul and the other monomers 
to 15 ng/ul.  
w CRITICAL STEP For subsequent digestion and ligation reactions, it is important that all 
monomers are at equimolar concentrations. 
PAUSE POINT Amplified monomers can be stored at -20 oC for several months and can be re-
used for assembling additional TALEs. 
 
3.3.2 Construction of custom 20bp-targeting TALEs 
TIMING 1.5 days (5 hr hands-on time) 
10| Select target sequence(s). Typical TALE recognition sequences are identified in the 5’ to 
3’ direction and begin with a 5’ thymine. The procedure below describes the construction 
of TALEs that bind a 20 bp target sequence (5`-
T0N1N2N3N4N5N6N7N8N9N10N11N12N13N14N15N16N17N18N19-3`, where N = A, G, T, or C), 
where the first base (typically a thymine) and the last base are specified by sequences 
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within the TALE backbone vector. The middle 18 bp are specified by the RVDs within 
the middle tandem repeat of 18 monomers according to the cipher NI = A, HD = C, NG = 
T, and NN = G or A. For targeting shorter or longer sequences, see Box 1. 
 
11| Divide target sequences into hexamers. Divide N1-N18 into sub-sequences of length 6 
(N1N2N3N4N5N6, N7N8N9N10N11N12, and N13N14N15N16N17N18). For example, a TALE 
targeting 5`-TGAAGCACTTACTTTAGAAA-3` can be divided into hexamers as (T) 
GAAGCA CTTACT TTAGAA (A), where the initial thymine and final adenine (in 
parenthesis) are encoded by the appropriate backbone. In this example, the three 
hexamers will be: hexamer 1 = NN-NI-NI-NN-HD-NI, hexamer 2 = HD-NG-NG-NI-HD-
NG, hexamer 3= NG-NG-NI-NN-NI-NI. Due to the adenine in the final position, we will 
use one of the NI backbones: pTALE-TF_v2(NI) or pTALEN_v2(NI). 
 
12| Assembling hexamers using Golden Gate digestion-ligation (Fig. 3.3, stage 2). Prepare 
one reaction tube for each hexamer. Using the monomer plate schematic (Fig. 3.4), 
pipette 1ul of each normalized monomer into the corresponding hexamer reaction tube. 
Repeat this for all hexamers. For example, for the target from Step 10, set up tube 1 (1ul 
from each of G1, A2, A3, G4, E5, and A6), tube 2 (1 ul from each of E7, C8, C9, A10, 
E11, C12), and tube 3 (1 ul from each of D1, D2, B3, H4, B5, B6). To construct a TALE 
with 18 full repeats, 3 separate hexamer tubes are used. 
w CRITICAL STEP Pay close attention when pipetting the monomers; it is very easy to 
accidentally pipette from the wrong well during this step.  
 
 52 
13| To perform a simultaneous digestion-ligation (Golden Gate) reaction to assemble each 
hexamer (Fig. 3.3, stage 2) add the following reagents to each hexamer tube: 
Component Amount Final 
concentration 
Esp3I (BsmBI) 5 U/ul 0.75 ul 0.375 U/ul 
Tango Buffer 10X 1 ul 1x 
Dithiothreitol (DTT) 10mM 1ul 1 mM 
T7 Ligase 3000 U/ul 0.25 ul 75 U/ul 
ATP 10mM  1 ul 1 mM 
 4 ul   
6 monomers 6 x 1 ul  
Total 10 ul  
w CRITICAL STEP Dithiothreitol (DTT) is easily oxidized in air. It should be freshly made or 
thawed from aliquots stored at -70 oC and used immediately. 
 
14| Place each hexamer tube in a thermocycler to carry out the Golden Gate reactions using 
the following cycling conditions for ~ 3 hours:  
Cycle number Digest Ligate 
1-15 
Hold at 4°C. 
37°C, 5 
min 
20°C, 5 
min 
 
PAUSE POINT This reaction can be left to run overnight. 
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15| Run out the ligation product on a gel to check for ~700 bp bands corresponding to the 
hexamer products (Fig. 3.5a, lane 7). Cast a 2% agarose gel in 1x TBE electrophoresis 
buffer with 2x SYBR Safe dye. The additional dye helps to visualize faint bands. The gel 
should have enough lanes to run out each Golden Gate reaction from Step 14; load 3 ul of 
each ligation product in separate lanes. Include in one lane 1 ug of the 1kb Plus DNA 
ladder. Run the gel at 15 V/cm until there is separation of the 650 bp ladder band from 
neighboring bands. 
? TROUBLESHOOTING 
 
16| Exonuclease treatment to degrade non-circular ligation products (Fig. 3.3, stage 3). 
During the Golden Gate reaction, only fully-ligated hexamers should be able to 
circularize. PlasmidSafe exonuclease selectively degrades non-circular (incomplete) 
ligation products. Add the following reagents to each hexamer reaction tube: 
Component Amount Final 
concentration 
PlasmidSafe DNAse 10U/ul 1 ul 0.66 U/ul 
Plasmid-Safe 10X Reaction Buffer 1 ul 1x 
ATP 10mM 1 ul 1 mM 
 3 ul  
Golden gate reaction from Step 14 7 ul  
Total 10 ul  
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17| Incubate each hexamer reaction tube with PlasmidSafe at 37°C for 30 minutes followed 
by inactivation at 70°C for 30 minutes. 
PAUSE POINT After completion, the reaction can be frozen and continued later. The circular 
DNA should be stable for at least a week.   
 
18| Hexamer PCR (Fig. 3.3, stage 4). Amplify each PlasmidSafe-treated hexamer in a 50 ul 
PCR reaction using high-fidelity Herculase II polymerase and the hexamer forward and 
reverse primers (Hex-F and Hex-R; Table 3.3). Add the following reagents to each PCR 
reaction: 
Component Amount Final 
concentration 
100mM dNTP (25mM each) 0.5 ul 1 mM 
5X Herculase II reaction buffer 10 ul 1x 
10uM each Hex-F and Hex-R primers 1 ul 200 nM 
Herculase II Fusion DNA polymerase 0.5 ul 1x 
Distilled water 37 ul  
 49ul  
PlasmidSafe-treated hexamer from Step 17 1 ul  
Total 50 ul  
 
19| Perform PCR on the reactions in Step 18 using the following cycling conditions: 
Cycle number Denature Anneal Extend 
1 95°C, 2   
 55 
min 
2-36 95°C, 20 s 60°C, 20 s 72°C, 30 s 
37   72°C, 3 min 
 
20| Gel purification of amplified hexamers. Due to the highly repetitive template, it is 
necessary to purify the amplified hexamer product from the other amplicons. Cast a 2% 
agarose gel in 1x TBE electrophoresis buffer with 1x SYBR Safe dye. The gel should 
have enough lanes to run out each PCR product from Step 19 and the comb size should 
be big enough to load 40-50ul of PCR product. Include in one lane 1 ug of the 1kb Plus 
DNA ladder. Run the gel at 15 V/cm until there is separation of the 650 bp ladder band 
from neighboring bands. Using a clean razor blade, excise each hexamer band, which 
should be nearly aligned with the 650bp band from the ladder (Fig. 3.5, lane 9). 
w CRITICAL STEP Avoid any cross-contamination by ethanol sterilization of work surfaces, 
razor blades, etc. during the gel extraction and between each individual band excision. 
! CAUTION Wear appropriate personal protective equipment, including a facemask, when 
performing gel stabs to minimize risks associated with prolonged light or mutagenic DNA dye 
exposure. 
? TROUBLESHOOTING 
  
21| Purify the hexamer gel bands from Step 20 using the MinElute Gel Extraction kit 
following the manufacturer’s directions. Elute the DNA from each reaction using 20 ul of 
Buffer EB prewarmed to 55°C. 
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22| Gel normalization of purified hexamer concentrations. Cast a 2% agarose gel in 1x TBE 
electrophoresis buffer with 1x SYBR Safe dye. The gel should have enough lanes to run 
out 2 ul of each purified hexamer from Step 21. Include in one lane 10 ul of the 
quantitative DNA ladder. Run the gel at 15V/cm until all lanes of the quantitative ladder 
are clearly separated. Each hexamer lane should contain only a single (purified) band.  
  
23| Image the gel using a quantitative gel imaging system. Each lane should have only the 
~700 bp hexamer product. Make sure the exposure is short enough so that none of the 
bands are saturated. 
 
24| Quantify the integrated intensity of each hexamer band using ImageJ or other gel 
quantification software. Use the quantitative ladder with known concentrations (5, 10, 20, 
40, 100 ng) to generate a linear fit and quantify the concentration of each purified 
hexamer. 
? TROUBLESHOOTING 
 
25| Adjust the concentration of each hexamer to 20 ng/ul by adding Buffer EB. 
 
26| Golden Gate assembly of hexamers into TALE backbone (Fig. 3.3, stage 5). Combine the 
hexamers and the appropriate TALE backbone vector (transcription factor or nuclease) in 
a Golden Gate digestion-ligation. For example, we will use a TALE backbone with NI as 
the 0.5 repeat for the target sequence in Step 10 since N19=A. For this ligation, a 1:1 
molar ratio of insert:vector works well. Set up one reaction tube for each TALE. Also, 
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prepare a negative control ligation by including the TALE backbone vector without any 
hexamers. 
Component TALE Negative 
control 
Final 
concentration 
TALE backbone vector (100ng/ul) 1 ul 1 ul 10 ng/ul 
BsaI-HF (20 U/ul) 0.75 ul 0.75 ul 1.5 U/ul 
10x NEBuffer 4 1 ul 1 ul 1x 
10x Bovine serum albumin 1 ul 1 ul 1x 
ATP 10mM 1 ul 1 ul 1 mM 
T7 Ligase (3000 U/ul) 0.25 ul 0.25 ul 75 U/ul 
 5 ul 5 ul  
3 purified hexamers (20 ng/ul) 3 ul (1 ul 
each) 
 2 ng/ul each 
Distilled water 2 ul 5 ul  
Total 10 ul 10 ul  
w CRITICAL STEP As a negative control, set up a separate reaction omitting the purified 
hexamers (i.e. including only the TALEN or TALE-TF backbone). 
 
27| Place the tubes from Step 26 in a thermocycler to carry out the Golden Gate reactions 
using the following cycling conditions for ~4 hours:  
Cycle number Digest Ligate Inactivate 
1-20 37°C, 5 min 20°C, 5 min  
21   80°C, 20 min 
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PAUSE POINT Ligation products can be frozen at -20 °C and stored at least one month for 
transformation into bacteria at a later time. 
 
28| Although it is not necessary, it is possible to run out the ligation product on a gel to check for 
~1.8 kbp band corresponding to the properly assembled 18mer tandem repeat. To check the 
ligation product, cast a 2% agarose gel in 1x TBE electrophoresis buffer with 2x SYBR Safe dye. 
The additional dye helps to visualize faint bands. Load 5ul of the ligation product from Step 27. 
Include in one lane 1 ug of the 1kb Plus DNA ladder. Run the gel at 15 V/cm until there is clear 
separation of the 1650 bp and 2000 bp ladder bands. Alternatively, proceed directly to 
transformation (Step 29) without running a gel; transformation is very sensitive and, even when a 
clear band cannot be visualized on the gel, there is often enough plasmid for transformation of 
high competency cells. 
? TROUBLESHOOTING 
 
3.3.3 Verifying correct TALE repeat assembly 
TIMING 3 days (4 hr hands-on time)    
29| Transformation. Transform the ligation products from Step 27 into a competent E. coli; in 
our lab, we use Stbl3 for routine transformation. Transformation can be done following 
the protocol supplied with the cells. Briefly, add 5 ul of the ligation product to 50 ul of 
ice-cold chemically competent Stbl3 cells, incubate on ice for 5 min, incubate at 42°C for 
45 sec, return immediately to ice for 5 min, add 250 ul of SOC medium, incubate at 37°C 
for 1 hr on a shaking incubator (250 rpm), plate 100 ul of transformation on a LB plate 
containing 100 ug ml-1 ampicillin and incubate overnight at 37°C. 
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30| Inspect all plates from Step 29 for bacterial colony growth. Typically, we see few 
colonies on the negative control plates (only backbone in the Golden Gate digestion-
ligation) and tens to hundreds of colonies on the complete TALE ligation plates. 
? TROUBLESHOOTING 
  
31| For each TALE plate, pick 8 colonies to check the assembly fidelity. Using a sterile 20 ul 
pipette tip, touch the tip to a single colony, streak onto a single square on a pre-warmed, 
new gridded LB-ampicillin plate to save the colony, and then swirl the tip in 100ul of 
distilled water to dissolve the colony for colony PCR. Repeat this procedure for all 
colonies to be checked, streaking each new colony into a separate square on the gridded 
LB-ampicillin plate. After finishing, incubate the gridded plate at 37°C for at least 4 
hours to grow up the colony streaks. 
 
32| Colony PCR. Using the colonies selected in Step 31 as templates, set up colony PCR to 
verify that the correctly assembled tandem 18mer repeat has been ligated into the TALE 
backbone. We have found that the colony PCR reaction is sensitive to excessive template 
concentration; therefore we typically use 1 ul of the 100 ul colony suspension from Step 
31. For colony PCR, use primers TALE-Seq-F1 and TALE-Seq-R1 for amplification 
(Table 2). Set up the following colony PCR reaction: 
Component Amount Final 
concentration 
Colony suspension from Step 31 1 ul  
 60 
100mM dNTP (25mM each) 0.25 ul 1 mM 
10x Taq-B polymerase buffer 2.5 ul 1x 
10uM each TALE-Seq-F1 and TALE-Seq-R1 
primers 
0.25 ul 100 nM 
Taq-B polymerase (5 U/ul) 0.1 ul 0.02 U/ul 
Distilled water 20.9 ul  
Total 25 ul  
 
33| Perform colony PCR on the reactions in Step 32 using the following cycling conditions: 
Cycle number Denature Anneal Extend 
1 94°C, 3 
min 
  
2-31 94°C, 30 s 60°C, 30 s 68°C, 2 min 
32   68°C, 5 min 
 
34| To check the colony PCR result, cast a 1% agarose gel in 1x TBE electrophoresis buffer 
with 1x SYBR Safe dye. The gel should have enough lanes to run out 10 ul of each PCR 
product from Step 33. Include in one lane 1 ug of the 1 kb Plus DNA Ladder.  Run the gel 
at 15 V/cm until there is clear separation of the 1650 bp and 2000 bp ladder bands. 
 
35| Image the gel and identify which colonies have the correct insert size. For an insert of 18 
monomers (3 hexamers ligated into the TALE backbone vector), the product should be a 
single band of size 2175 bp (Fig. 3.5b, lane 1). Incorrect ligation products will show 
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bands of different sizes. In place of colony PCR, plasmid DNA from prepared clones can 
be digested with AfeI. In both backbones (TALE-TF and TALEN), AfeI cuts 4 times. For 
both backbones, one fragment contains the entire tandem repeat region and should be of 
size 2118 bp for a correctly assembled 18mer. For the TALE-TF backbone, the correct 
clone will produce 4 bands with sizes: 165bp, 2118bp, 3435bp and 3544bp (Fig. 3.5b, 
lane 2). The 3435bp and 3544bp bands are difficult to separate on a 1% agarose gel and 
therefore a correct clone will show three bands with the middle 2118bp band indicating 
an intact tandem 18mer repeat (Fig. 3.5b, lane 2).  For the TALEN backbone, the correct 
clone will produce 4 bands with sizes: 165 bp, 2118 bp, 2803 bp, 3236 bp. 
? TROUBLESHOOTING 
  
36| Miniprep and sequencing. For each clone with the correct band size, inoculate a colony 
from the gridded plate into 3 ml of LB media with 100 ug ml-1 ampicillin and incubate at 
37°C in a shaking incubator overnight. 
 
37| Isolate plasmid DNA from overnight cultures using a QIAprep Spin Miniprep Kit 
following the manufacturer’s instructions. 
 
38| Verify the sequence of each clone by sequencing the tandem repeat region using 
sequencing primers (see Table 3.3) TALE-Seq-F1 (forward primer annealing just before 
the first monomer), TALE-Seq-F2 (forward primer annealing at the beginning of the 
seventh monomer) and TALE-Seq-R1 (reverse primer annealing after the final 0.5 
monomer). For most TALEs, reads from all 3 primers are necessary to unambiguously 
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verify the entire sequence. Verify the sequencing result using our online, freely-available 
TALE software (http://taleffectors.com/tools/) or using standard sequence alignment 
methods (e.g. ClustalW). After entering the target site sequence, our software generates a 
TALE-TF or TALEN reference sequence in either FASTA format or as an annotated 
GenBank vector map (*.gb file) that can be viewed using standard plasmid editor 
software (e.g. everyVECTOR, VectorNTI, or LaserGene SeqBuilder). The software also 
aligns sequencing reads (entered in FASTA format) to the generated reference sequence 
to allow for easy clone verification. Detailed instructions can be found on our website. 
? TROUBLESHOOTING 
 
3.3.4 Transfection of TALE-TF and TALEN into HEK293FT cells 
TIMING 2 days (1 hour hands-on time) 
39| Plate HEK293FT cells onto 6-well plates in D10 culture medium without antibiotics 
approximately 24h prior to transfection at a seeding density of around 1×106 cells per 
well and a seeding volume of 2mL. Scale up and down the culture according to the 
manufacturer’s manual provided with the 293FT cells if needed. 
 
40| Prepare DNA for transfection. Quantify the DNA concentration of the TALE plasmids 
used for transfection using reliable methods (such as UV spectrophotometry or gel 
quantification). 
w CRITICAL STEP: The DNA concentration of the TALE plasmids should be quantified to 
guarantee that an accurate amount of TALE DNA will be used during the transfection. 
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41| Prepare the DNA-Opti-MEM mix as follows using option A if testing transcriptional 
modulation, or option B if testing nuclease activity: 
 A.  DNA-Opti-MEM mix for testing transcriptional modulation. 
i) Mix 4 µg of TALE-TF plasmid DNA with 250 µl of Opti-MEM medium. Include controls 
(e.g. RFP plasmid or mock transfection) to monitor transfection efficiency and cell health 
respectively. 
 B.  DNA-Opti-MEM mix for testing nuclease activity. 
i) Mix 2 µg of the Left and 2 µg of the Right TALEN (Figure 3.1d) plasmid DNA with 250 µl 
of Opti-MEM medium. Control transfections should be done by omitting one or both of the 
TALENs. Also include controls (e.g. an RFP plasmid or mock transfection) to monitor 
transfection efficiency and cell health respectively. For all transfections, make sure the total 
amount of DNA transfected is the same across conditions – when omitting one or both TALENs, 
supplement with empty vector DNA to maintain the same total DNA amount. 
 
42| Prepare the Lipofectamine-Opti-MEM solution by diluting 10 µl of Lipofectamine 2000 
with 250 µl of Opti-MEM. Mix the solution thoroughly by tapping the tube and 
incubating for 5 minutes at room temperature. 
 
43| Add the Lipofectamine-Opti-MEM solution to the DNA-Opti-MEM solution to form the 
DNA-Lipofectamine complex. Mix well by gently pipetting up and down. Incubate for 20 
minutes at room temperature. 
w CRITICAL STEP Make sure the complex is thoroughly mixed. Insufficient mixing results in 
lower transfection efficiency. 
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w PAUSE POINT The transfection complex will remain stable for 6 hours at room temperature.  
 
44| Add 500 µl of the DNA-Lipofectamine complex to each well of the 6-well plate from 
Step 39 directly. Mix gently by rocking the plates back and forth. 
 
45| Incubate cells at 37°C with 5% CO2 for 24 hours. At this point, determine the transfection 
efficiency by estimating the fraction of fluorescent cells in the positive control 
transfection (e.g. RFP plasmid) using a fluorescence microscope.  
CRITICAL STEP If incubation beyond 48 hours is needed, change the culture medium with 
fresh D10 supplemented with antibiotics on a daily basis. This will not affect the transfection 
efficiency.  
? TROUBLESHOOTING 
 
3.3.5 TALE functional characterization  
46| To measure TALEN cutting efficiency using Surveyor nuclease follow option A, or to 
measure TALE-TF transcriptional activation using qRT-PCR follow option B: 
 
A. Measuring TALEN cutting efficiency using Surveyor nuclease 
TIMING 6 hr (3 hr hands-on time) 
 
i) Remove culture medium from each well from Step 45 and add 100 µl of QuickExtract DNA 
Extraction Solution to each well and pipette thoroughly to lyse cells. Transfer the lysate to a 
PCR tube. 
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ii) Extract DNA from the lysate from Step 46Ai using the following cycling conditions: 
Cycle number Condition 
1 68°C, 15 min 
2 95°C, 8 min 
 
iii) PCR amplification of region surrounding TALEN target site. Prepare the following PCR 
reaction using the genomic DNA from Step 46Aii: 
Component Amount Final 
concentration 
gDNA from Step 46Aii 0.5 ul  
100mM dNTP (25mM each) 0.5 ul 1 mM 
5X Herculase II reaction buffer 10 ul 1x 
10uM each of target-specific Surveyor forward 
and reverse primers (see Experimental Design) 
1 ul 200 nM 
Herculase II Fusion DNA polymerase 0.5 ul 1x 
Distilled water 37.5 ul  
Total 50 ul  
w CRITICAL STEP Surveyor procedure (Steps 46Aiii-xv) is carried out according to the 
manufacturer’s protocol and is described in greater detail in the Surveyor manual. We provide 
brief details here since mutation detection by mismatch endonuclease is not a common procedure 
for most laboratories. 
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w CRITICAL STEP When performing the Surveyor assay for the first time, we suggest carrying 
out the positive control reaction included with the Surveyor nuclease kit. 
 
iv) Perform PCR using the following cycling conditions: 
Cycle number Denature Anneal Extend 
1 95°C, 3 
min 
  
2-36 95°C, 30 s 55°C, 15 s 72°C, 30s 
37   72°C, 5 min 
 
v) Check the PCR result by running 5 ul of PCR product on a 2% agarose gel in 1x TBE 
electrophoresis buffer with 1x SYBR Safe dye. Include in one lane 10 ul of the quantitative 
DNA ladder. Run the gel at 15 V/cm until all bands are clearly separated. For all templates, it 
is important to make sure that there is only a single band corresponding to the intended 
product for the primer pair. The size of this band should be the same as calculated from the 
distance between the two primer annealing sites in the genome.   
w CRITICAL STEP If multiple amplicons are generated from the PCR reaction, re-design 
primers and re-optimize the PCR conditions to avoid off-target amplification.  
? TROUBLESHOOTING 
  
vi) Image the gel using a quantitative gel imaging system. Make sure the exposure is short 
enough so that none of the bands are saturated. Quantify the integrated intensity of each PCR 
product using ImageJ or other gel quantification software. Use the quantitative ladder with 
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known concentrations (5, 10, 20, 40, 100 ng) to generate a linear fit. Adjust the DNA 
concentration of the PCR product by diluting with 1x Herculase II reaction buffer so that it is 
in the range of 25 - 80 ng/µl.  
 
vii) DNA heteroduplex formation. At this point, the amplified PCR product includes a mixture 
of both modified and unmodified genomic DNA (TALEN-modified DNA will have a few 
bases of sequence deletion near the TALEN cut site due to exonuclease activity during NHEJ). 
For Surveyor mismatch detection, this mixture of products must first be melted and re-
annealed such that heteroduplexes are formed. DNA heteroduplexes contain strands of DNA 
that are slightly different but annealed (imperfectly) together. Given the presence of both 
unmodified and modified DNA in a sample, a heteroduplex may include one strand of 
unmodified DNA and one strand of TALEN-modified DNA. Heteroduplexes can also be 
formed from re-annealing of two different TALEN-modified products as NHEJ exonuclease 
activity can produce different mutations. To cross-hybridize wild type and TALEN-modified 
PCR products into hetero- and homoduplexes, all strands are melted and then slowly re-
annealed (Figure 3.6a). Place 300 ng of the PCR product from Step 46Avi in a thermocycler 
tube and bring to a total volume of 20 µl with 1x Herculase II reaction buffer.  
 
viii) Perform cross-hybridization on the diluted PCR amplicon from Step 46Avii using the 
following cycling conditions: 
Cycle number Condition 
1 95°C, 10 min 
2 95°C to 85°C, -2°C/s 
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3 85°C, 1 min 
4 85°C to 75°C, -0.3°C/s 
5 75°C, 1 min 
6 75°C to 65°C, -0.3°C/s 
7 65°C, 1 min 
8 65°C to 55°C, -0.3°C/s 
9 55°C, 1 min 
10 55°C to 45°C, -0.3°C/s 
11 45°C, 1 min 
12 45°C to 35°C, -0.3°C/s 
13 35°C, 1 min 
14 35°C to 25°C, -0.3°C/s 
15 25°C, 1 min 
 
ix) Surveyor Nuclease S digestion. To treat the cross-hybridized homo- and hetero-duplexes 
using Surveyor Nuclease S to determine TALEN cleavage efficiency (Figure 3.6a), add the 
following components together on ice and mix by pipetting gently: 
Component Amount Final 
concentration 
0.15 M MgCl2 solution 2 ul 15 mM 
Surveyor Nuclease S 1 ul 1x 
Surveyor Enhancer S 1 ul 1x 
 4 ul  
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Re-annealed duplexes from Step 46Aviii 16 ul  
Total 20 ul  
 
x) Incubate the reaction from Step 46Aix at 42°C for 1 hour. 
 
xi) Add 2 ul of the Stop Solution from the Surveyor kit. 
w PAUSE POINT: The digestion product can be stored at -20°C for analysis at a later time.  
 
xii) Cast a 2% agarose gel in 1x TBE electrophoresis buffer with 1x SYBR Safe dye. When 
casting the gel, it is preferable to use a thin comb size (<1 mm) for the sharpest possible 
bands. The gel should have enough lanes to run out 20 ul of each digestion product band from 
Step 46Axi. Include in one lane 1 ug of the 1kb Plus DNA ladder. Run the gel at 5 V/cm until 
the Orange G loading dye has migrated 2/3rds of the way down the gel.  
 
xiii) Image the gel using a quantitative gel imaging system. Make sure the exposure is short 
enough so that none of the bands are saturated. Each lane from samples transfected with both 
left and right TALENs should have a larger band corresponding to the uncut genomic 
amplicon (the same size as in Step46Av) and smaller bands corresponding to the DNA 
fragments resulting from the cleavage of the genomic amplicon by Surveyor nuclease. 
Controls (no transfection, control plasmid transfection, or transfection omitting one of the 
TALENs) should only have the larger band corresponding to the uncut genomic amplicon. 
? TROUBLESHOOTING 
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xiv) Quantify the integrated intensity of each band using ImageJ or other gel quantification 
software. For each lane, calculate the fraction of the PCR product cleaved (fcut) using the 
following formula: fcut = a / (a+b), where a = the integrated intensity of both of the cleavage 
product bands, and b = the integrated intensity of uncleaved PCR product band. A sample 
Surveyor gel for TALENs targeting human AAVS1 is shown in Figure 3.6b. 
 
xv) Estimate the percentage of TALEN-mediated gene modification using the following 
formula(93): 
100 x (1-(1- fcut)1/2 ) 
This calculation can be derived from the binomial probability distribution given a few conditions: 
that strand reassortment during the duplex formation is random, that there is a negligible 
probability of the identical mutations reannealing during duplex formation, and that the Surveyor 
nuclease digestion is complete. 
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Figure 3.6 Examples of TALE-TF and TALEN activity in 293FT cells. (a) Schematic of the 
Surveyor nuclease assay used to determine TALEN cleavage efficiency. First, genomic PCR is 
used to amplify the TALEN target region from a heterogeneous population of TALEN-modified 
and unmodified cells, and the gPCR products are re-annealed slowly to generate heteroduplexes. 
The re-annealed heteroduplexes are cleaved by Surveyor nuclease while homoduplexes are left 
intact. TALEN cleavage efficiency is calculated based on the fraction of cleaved DNA. (b) Gel 
showing the Surveyor nuclease result from the AAVS1 TALEN pair (from Fig. 3.1d). Lanes 1—
4: controls from un-transfected (N.T.) cells and cells transfected with a plasmid carrying GFP 
(Mock), AAVS1 left TALEN only (L), and AAVS1 right TALEN only (R). Lanes 5—7: cells 
transfected with AAVS1 Left and Right TALENs (L+R) for 24, 48, and 72 hours. The two lower 
bands indicated by the arrows are Surveyor-cleaved DNA products. (c) 293FT cells transfected 
with the SOX2 TALE-TF (from Fig. 3.1c) exhibited a 5 fold increase in the amount of SOX2 
mRNA compared with mock transfected cells. Error bars indicate s.e.m.; n = 3. *** indicates P < 
0.005. Panel c was modified with permission from Nature Biotechnology (27) (Nature 
Biotechnology (c) 2011, Macmillian Publishers Ltd.). 
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B. Measuring TALE-TF transcriptional activation using qRT-PCR 
TIMING 5 hr (3 hr hands-on time) 
 
i) RNA extraction. Aspirate the medium in each well of the 6-well plates from Step 45 at 72 
hours after transfection. 
w CRITICAL STEP Use proper RNA handling techniques to prevent RNA degradation, 
including cleaning bench surfaces and pipettes with RNAseZAP. Use RNAse-free consumables 
and reagents. 
 
ii) Wash the cells in each well twice with 1 ml of DPBS.  
 
iii) Harvest ~1×106 cells for subsequent total RNA extraction by trypsinizing the cells with 
500 µl trypsin with EDTA. Incubate for 1-2 minutes to let the cells detach from the bottom of 
the wells. 
w CRITICAL STEP Do not leave the cells in trypsin for longer than a few minutes. 
 
iv) Neutralize the trypsin by adding 2ml of D10 medium. 
 
v) In a 15ml centrifuge tube, centrifuge the cell suspension at 300×g for 5 min. Carefully 
aspirate all of the supernatant. 
w CRITICAL STEP Incomplete removal of the supernatant can result in inhibition of cell lysis. 
PAUSE POINT: Cells can be frozen at -80°C for 24 hours. 
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vi) Extract and purify RNA from the cells in Step 46Bv using the RNeasy Mini Kit and 
QIAshredder following the manufacturer’s directions. Elute the RNA from each column using 
30 ul of nuclease-free water. 
 
vii) Measure the RNA concentration using a UV spectrophotometer. 
 
viii) cDNA reverse-transcription. Generate cDNA using the iScript cDNA Synthesis Kit 
following the manufacturer’s directions. For matched negative controls, perform the reverse 
transcription without the reverse-transcriptase enzyme. 
 
ix) Quantitative PCR. Thaw on ice the appropriate TaqMan probe for the target gene and for 
an endogenous control gene.  
w CRITICAL STEP Protect the probes from light and do not allow the thawed probes to stay on 
ice for an extended time. 
 
x) Following the TaqMan Universal PCR Master Mix manufacturer’s directions, prepare 4 
technical replicate qPCR reactions for each sample in optical thermocycler strip tubes or 96-
well plates. Set up negative controls for non-specific amplification as indicated in the 
directions: namely, RNA template processed without reverse transcriptase (“no RT”) and a 
no-template control. 
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xi) Briefly centrifuge the samples to remove any bubbles and amplify them in a TaqMan-
compatible qRT-PCR machine with the following cycling parameters. 
 
Cycle number Denature Anneal and Extend 
1 95°C, 20 s  
2-41 95°C, 1 s 60°C, 20 s 
 
xii) Analyze data and calculate the level of gene activation using the ΔΔ CT method(92, 101). 
TALE-TF results from qRT-PCR assay of SOX2 activation in HEK293 cells are shown in 
Figure 3.6c. 
w CRITICAL STEP The ΔΔ CT method assumes that amplification efficiency is 100% (ie. 
number of amplicons doubles after each cycle). For new probes (such as custom TaqMan 
probes), amplification from a template dilution series (spanning at least 5 orders of magnitude) 
should be performed to characterize amplification efficiency. For standard TaqMan Gene 
Expression Assay probes, this is not necessary as they are designed to have 100±10% 
amplification efficiency. 
? TROUBLESHOOTING 
 
 TIMING 
Steps 1-9, Monomer library amplification and normalization: 6 hr 
Steps 10-28, TALE hierarchical ligation assembly: 1.5 days (5 hr hands-on time) 
Steps 29-38, TALE transformation and sequence verification: 3 days (4 hr hands-on time) 
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Steps 39-45, Transfection of TALE-TF and TALEN into HEK293FT cells: 2 days (1 hr hands-on 
time) 
Steps 46A and B, TALE functional characterization with RT-qPCR or Surveyor: 6 hr (3 hr 
hands-on time) 
 
3.4 Troubleshooting 
Troubleshooting advice can be found in Table 3.2.  
 
Table 3.2 Troubleshooting 
Step Problem Possible reason Solution 
4 Uneven 
amplification 
across monomers 
Not using Herculase 2 
Fusion polymerase 
Optimize annealing temperature and 
Mg2+ and DMSO concentrations 
8 Low DNA 
concentration after 
elution 
Residual ethanol on 
purification column 
Air dry columns before elution at 
37°C for a longer period of time 
  Incorrect vacuum 
pressure during DNA 
binding 
Adjust vacuum pressure according 
to the manufacturer’s suggestions 
15 No visible hexamer 
band (~700 bp) 
Not adding equimolar 
amounts of monomers 
Gel normalize monomer 
concentration 
  Degraded DTT or 
ATP 
Use fresh stocks of DTT and ATP, 
which degrade easily 
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(Table 3.2, continued) 
 No visible hexamer 
band (~700 bp) but 
smaller bands 
present 
Wrong monomer(s) 
added during pipetting 
Re-select monomers 
  Monomer 
concentration is too 
low 
Increase the number of Golden Gate 
digestion-ligation cycles and/or 
increase the concentration of 
monomers to >20 ng/ul; there is no 
detrimental effect to using more 
monomers in an equimolar ratio 
20 No visible hexamer 
band (~700 bp) 
Unsuccessful Golden 
Gate digestion-ligation 
Verify on a gel that the Golden Gate 
digestion-ligation product from Step 
15 is visible; increase monomer 
concentration 
24 Low concentration 
for purified 
hexamers 
Unsuccessful gel 
extraction 
Ensure that there is no residual 
ethanol during elution or increase 
PCR reaction volume 
28 No visible 18mer 
band (~1.8 kbp) 
Unsuccessful Golden 
Gate digestion-ligation 
Increase hexamer concentration in 
Golden Gate digestion-ligation in 
Step 26 or proceed directly to 
transformation in Step 29 
    
 77 
(Table 3.2, continued) 
30 More than a few 
colonies on 
negative control 
plate 
Compromised TALE 
backbone 
Perform a restriction digest of the 
backbone to verify integrity 
35 Colony PCR bands 
are smeared 
Too much template Dilute colony suspension 10x-100x 
38 Monomers 
assembled in 
incorrect order 
Misligation Misligation occurs at a very low 
frequency; analyze two additional 
clones 
45 Low transfection 
efficiency 
Low DNA quality Prepare DNA using high quality 
plasmid preparation 
  Suboptimal DNA to 
Lipofectamine2000 
ratio 
Titrate DNA to Lipofectamine2000 
ratio to determine optimal 
transfection condition 
46Av Multiple amplicons Nonspecific primers Design new primers and verify 
specificity using PrimerBLAST; use 
touchdown PCR 
 No amplification Suboptimal PCR 
condition 
Optimize annealing temperature and 
Mg2+ and DMSO concentrations 
46Axiii No cleavage bands 
visible 
TALEN unable to 
cleave target site 
Design new TALEN pairs targeting 
nearby sequences 
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(Table 3.2, continued) 
46Bxii No increase in 
transcription in 
target mRNA 
TALE-TF unable to 
access target site 
Design new TALE-TFs targeting 
nearby sequences 
 
3.5 Anticipated results 
TALE-TFs and TALENs can facilitate site-specific transcriptional modulation(27, 53, 54, 57) 
and genome editing(39, 53, 56, 58, 60-63) (Table 3.1). TALENs can be readily designed to 
introduce double-stranded breaks at specific genomic loci with high efficiency. In our 
experience, a pair of TALENs designed to target the human AAVS1 locus is able to achieve up 
to 3.6% cutting efficiency in 293FT cells as determined by Surveyor nuclease assay (Fig. 3.6a-
b). TALE-TFs can also robustly increase the mRNA levels of endogenous genes. For example, a 
TALE-TF designed to target the proximal promoter region of SOX2 in human cells is able to 
elevate the level of endogenous SOX2 gene expression by up to 5 fold(27) (Fig. 3.6c). The 
ability for TALE-TFs and TALENs to act at endogenous genomic loci is dependent on the 
chromatin state as well as yet-to-be-determined mechanisms regulating TALE DNA 
binding(102, 103). For these reasons we typically build several TALE-TFs or TALEN pairs for 
each genomic locus we aim to target. These TALE-TFs and TALENs are designed to bind 
neighboring regions around a specific target site since some binding sites might be more 
accessible than others. The reason why some TALEs exhibit significantly lower levels of activity 
remains unknown, though it is likely due to position- or cell state-specific epigenetic 
modifications preventing access to the binding site. Due to differences in epigenetic states 
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between different cells, it is possible that TALEs that fail to work in a particular cell type might 
work in a different cell type. 
 Table 3.3 Primer sequences for TALE construction 
Name Sequence Purpose 
Ex-F1 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcCTGACCCCAGAGCAGGTCGTG monomer amplification 
Ex-F2 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGACTTACACCCGAACAAGTCGTGGCAATTGCGAGC  
Ex-F3 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGCGGCCTCACCCCAGAGCAGGTCG  
Ex-F4 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGTGGGCTCACCCCAGAGCAGGTCG  
Ex-R1 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTAAGTCCGTGCGCTTGGCAC  
Ex-R2 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcAGCCGTGCGCTTGGCACAG  
Ex-R3 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTCCCATGGGCCTGACATAACACAGGCAGCAACCTCTG  
Ex-R4 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTTAGACCGTGCGCTTGGCACAG  
In-F2 CTTGTTATGGACGAGTTGCCcgtctcGTACGCCAGAGCAGGTCGTGGC  
In-F3 CCAAAGATTCAACCGTCCTGcgtctcGAACCCCAGAGCAGGTCGTG  
In-F4 TATTCATGCTTGGACGGACTcgtctcGGTTGACCCCAGAGCAGGTCGTG  
In-F5 GTCCTAGTGAGGAATACCGGcgtctcGCCTGACCCCAGAGCAGGTCGTG  
In-F6 TTCCTTGATACCGTAGCTCGcgtctcGGACACCAGAGCAGGTCGTGGC  
In-R1 TCTTATCGGTGCTTCGTTCTcgtctcCCGTAAGTCCGTGCGCTTGGCAC  
In-R2 CGTTTCTTTCCGGTCGTTAGcgtctcTGGTTAGTCCGTGCGCTTGGCAC  
In-R3 TGAGCCTTATGATTTCCCGTcgtctcTCAACCCGTGCGCTTGGCACAG  
In-R4 AGTCTGTCTTTCCCCTTTCCcgtctcTCAGGCCGTGCGCTTGGCACAG  
In-R5 CCGAAGAATCGCAGATCCTAcgtctcTTGTCAGTCCGTGCGCTTGGCAC  
Hex-F CTTAAACCGGCCAACATACC hexamer amplification 
Hex-R AGTCTGTCTTTCCCCTTTCC  
TALE-Seq-F1 
(aka colony 
PCR forward) 
CCAGTTGCTGAAGATCGCGAAGC 
sequencing forward primer used to check 
monomers 1-6. 
TALE-Seq-F2 ACTTACACCCGAACAAGTCG 
sequencing forward primer used to check 
monomers 7-12 
TALE-Seq-R1 
(aka colony 
PCR reverse) 
TGCCACTCGATGTGATGTCCTC 
sequencing primer used to check monomers 
13-18 for TALEs with less than 18 full 
monomer repeats, and used to check 
monomers 19-24 for TALEs with more than 
18 monomers. 
TALE-Seq-R2 CCCATGGGCCTGACATAA 
sequencing reverse primer used to check 
monomers 13-18 in TALEs with more than 
18 full monomer repeats 
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4. Comprehensive Interrogation of Natural TALE DNA Binding Modules and 
Transcriptional Repressor Domains 
The majority of the work presented here is done by Le Cong, with help from Dr. Ruhong 
Zhou on the computational work, Yu-chi Kuo, and Margaret Cunniff on the molecular 
biology work. The contents in this chapter has been pubished as Cong L, et al. Nature 
Communications. 2012 (29). 
 
4.1 Introduction 
Transcription activator-like effectors (TALEs) are bacterial effector proteins found in 
Xanthamonas sp. and Ralstonia sp. Each TALE contains a DNA binding domain 
consisting of 34 amino acid tandem repeat modules, where the 12th and 13th residues of 
each module, referred to as repeat variable diresidues (RVDs), specify the target DNA 
base(23, 25). Four of the most abundant RVDs from naturally occurring TALEs have 
established a simple code for DNA recognition (e.g. NI for adenine, HD for cytosine, NG 
for thymine, and NN for guanine or adenine)(23, 25). Using this simple code, TALEs 
have been developed into a versatile platform for achieving precise genomic and 
transcriptomic perturbations across a diverse range of biological systems(27, 28, 53, 54, 
57, 104). However, two limitations remain: first, there lacks a RVD capable of robustly 
and specifically recognizing the DNA base guanine, a highly prevalent base in 
mammalian genomes(105); and second, a viable TALE transcriptional repressor for 
mammalian applications has remained elusive, which is highly desirable for a variety of 
synthetic biology and disease-modeling applications(105). To address these two 
limitations, we conducted a series of screens and found that: first, of all naturally 
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occurring TALE RVDs, the previously unidentified RVD Asn-His (NH) can be used to 
achieve guanine-specific recognition; and second, the mSin Interaction Domain 
(SID)(106) can be fused to TALEs to facilitate targeted transcriptional repression of 
endogenous mammalian gene expression. These advances further improve the power and 
precision of TALE-based genome engineering technologies, enabling efficient bimodal 
control of mammalian transcriptional processes. 
 
4.2 Results 
4.2.1 Screening of novel TALE RVDs  
Previously, the RVD NK was reported to have more specificity for guanine than NN(54). 
However, recent studies have show that substitution of NK with NN leads to substantially 
lower levels of activity(87). To identify a more specific guanine-binding RVD with 
higher biological activity, we identified and evaluated a total of 23 naturally occurring 
RVDs (Fig. 4.1) from the set of known Xanthomonas TALE sequences in Genbank. In 
order to directly compare the DNA binding specificity and activity of all RVDs in an 
unbiased manner, we designed a set of 2312.5-repeat TALEs where we systematically 
substituted RVDs 5 and 6 with the 23 naturally occurring RVDs (RVD-TALEs; Fig. 
4.1a). This design allowed us to maintain a consistent RVD context surrounding the two 
varied RVD positions. Additionally, we fused a Gaussian luciferase gene (Gluc) with a 
2A peptide linker to the RVD-TALEs to control for the differences in TALE protein 
expression levels (Fig. 4.1a). We used each RVD-TALE (e.g. NI-TALE, HD-TALE, etc.) 
to assess the base-preference and activity strength of its corresponding RVD – this is 
measured by comparing each RVD-TALE’s ability to activate transcription from each of 
   
84 
the four base-specific Cypridina luciferase reporter (Cluc) plasmids with A, G, T, and C 
substituted in the 6th and 7th positions of the TALE binding site (A-, G-, T-, or C-
reporters; Fig. 4.1a). 
 
 
Figure 4.1 Identification of an optimal guanine-specific repeat variable diresidue 
(RVD). a, Design of the TALE RVD screening system. Each RVD screening TALE 
(RVD-TALE) contains 12.5 repeats with RVDs 5 and 6 substituted with the 23 naturally 
occurring RVDs, and is fused to a Gaussia luciferase gene via a 2A peptide linker. The 
truncations used for the TALE is marked at the N- and C- termini with numbers of amino 
acids retained (top). Four different base-specific reporters with A, T, G, and C substituted 
in the 6th and 7th nucleotides of the binding site are used to determine the base-
specificity of each RVD (middle). Each reporter is constructed by placing the TALE 
binding site upstream of a minimal CMV promoter driving Cypridina luciferase (bottom). 
b, Base-preference of each natural RVD (top) is determined by measuring the levels of 
relative luminescence unit (RLU) for each base-specific reporter after background 
subtraction and normalization based on TALE protein expression level (top). We 
clustered RVDs according to their base-preference after performing one-way analysis of 
variance (ANOVA) tests on each RVD. For RVDs with a single statistically significant 
reporter activity (p < 0.05, one-way ANOVA), we plotted the reporter activity of the 
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(Figure 4.1, continued) preferred base above the x-axis, whereas the reporter activities for 
the non-preferred bases are shown below the x-axis as negative. We clustered and ranked 
the RVDs without a single preferred base according to their total activity level. The 
abundance of each RVD in natural TALE sequences, as determined using all available 
Xanthomonas TALE sequences in GenBank, is plotted on a log scale (bottom). All bases 
in the TALE binding site are color-coded (green for A, red for T, orange for G, and blue 
for C). NLS, nuclear localization signal; VP64, VP64 viral activation domain; 2A, 2A 
peptide linker; Gluc, Gaussia luciferase; minCMV, minimal CMV promoter; Cluc, 
Cypridina luciferase; polyA signal, poly-adenylation signal. All results are collected from 
three independent experiments in HEK 293FT cells. Error bars indicate s.e.m.; n = 3. 
 
The 23 RVD-TALEs exhibited a wide range of DNA base preferences and biological 
activities in our reporter assay (Fig. 4.1b). In particular, NH- and HN-TALEs activated 
the guanine-reporter preferentially and at similar levels as the NN-TALE. Interestingly, 
the NH-TALE also exhibited significantly higher specificity for the G-reporter than the 
NN-TALE (ratio of G- to A-reporter activations: 16.9 for NH-TALE and 2.7for NN-
TALE; Fig. 4.1b), suggesting that NH might be a more optimal RVD for targeting 
guanines. Our computational analysis of TALE-RVD specificity using a recently 
published crystal structure of TALE-dsDNA complex(107, 108) also suggests that NH 
has a significantly higher affinity for guanine than NN (Fig. 4.2). We found that 
substitution of NN with NH in one repeat within the TALE DNA binding domain 
resulted in a gain of 0.86 ± 0.67 kcal/mol in free energy (ΔΔG) in the DNA bound state 
(Fig. 4.2). This result could be explained by the observation that the imidazole ring on the 
histidine residue (NH RVD) has a more compact base-stacking interaction with the target 
guanine base (Fig. 4.2b), indicating that NH would be able to bind guanine more tightly 
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than NN and thus suggesting a possible mechanism for the increased specificity of NH 
for guanine. Additionally, the RVD NA exhibited similar levels of reporter activation for 
all four bases and may be a promising candidate for high efficiency targeting of 
degenerate DNA sequences in scenarios where non-specific binding is desired(103). 
 
 
Figure 4.2 Computational analysis of TALE RVD Specificity. We performed 
extensive free energy perturbation (FEP) calculations for the relative binding affinities 
between the TALE and its bound DNA. Images show the three-dimensional configuration 
and results of the free energy calculation for NN:G (a) and NH:G (b) interactions from 
one repeat in the TALE-DNA complex. The second amino acid of the guanine-
recognizing RVD (i.e., asparagine for RVD NN and histidine for RVD NH) and the 
guanine base of the bound double-stranded DNA are presented in space filling model and 
labeled. The free energy calculation results are listed below their corresponding structures. 
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4.2.2 Relative activity and specificity of guanine-binding RVDs 
To determine whether NH and HN are suitable replacements for NN as the G-specific 
RVD, we directly compared the specificity and activity strength of NN, NK, NH, and 
HN. We chose two 18bp targets within the CACNA1C locus in the human genome and 
constructed four TALEs for each target, using NN, NK, NH, or HN as the G-targeting 
RVD (Fig. 4.3a). Since the screening result (Fig. 4.1b) suggested that HN might be less 
discriminatory than NH when the targeted base is A instead of G, we first designed a 
luciferase assay to further characterize the G-specificity of each RVD. For each 
CACNA1C target site, we constructed four luciferase reporters: wild type genomic target, 
and wild type target with 2, 4, or all guanines mutated into adenines (Fig. 4.3a, G-to-A 
reporters), and compared the activity of each TALE using these reporters (Fig. 4.3a). For 
both CACNA1Ctarget sites, we found that the TALE with NH as the G-targeting RVD 
exhibited significantly higher specificity for guanine over adenine than the corresponding 
NK-, HN-, and NN-containing TALEs. For target site 1, introduction of 2 G to A 
mutations led to 35.4% (TALE1-NN), 40.3% (TALE1-NK), 71.4% (TALE1-NH), and 
30.8% (TALE1-HN) of reduction in luciferase activity. For target site 2, two G-to-A 
mutations led to 21.8% (TALE2-NN), 36.3% (TALE2-NK), 66.1% (TALE2-NH), and 
13.9% (TALE2-HN) reduction in reporter activity. Additional G-to-A mutations resulted 
in further reduction of reporter activity, with NH exhibiting the highest level of 
discrimination (4a). Additionally, NH TALEs exhibited significantly higher levels of 
reporter induction than NK TALEs (1.9 times for site 1 and 2.7 times for site 2), and 
comparable to NN and NH TALEs (Fig. 4.3a). Thus, we decided to focus on the RVDs 
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NN, NK, and NH in subsequent experiments to assess their usefulness in modulating 
transcription at endogenous human genome targets.  
 
 
Figure 4.3 Characterization of guanine-specific repeat-variable diresidues (RVDs). a, 
specificity and activity of different Guanine-targeting RVDs. Schematic showing the 
selection of two TALE binding sites within the CACNA1C locus of the human genome. 
The TALE RVDs are shown above the binding site sequences and yellow rectangles 
indicate positions of G-targeting RVDs (left). Four different TALEs using NN, NK, NH, 
and HN as the putative G-targeting RVD were synthesized for each target site. The 
specificity for each putative G-targeting RVD is assessed using luciferase reporter assay, 
by measuring the levels of reporter activation of the wild-type TALE binding site and 
mutant binding sites, with either 2, 4, or all guanines substituted by adenine. The mutated 
guanines and adenines are highlighted with orange and green respectively. b, 
Endogenous transcriptional modulation using TALEs containing putative G-specific 
RVDs. TALEs using NN, NK, NH, and HN as the G-targeting RVD were synthesized to 
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(Figure 4.3, continued) target two distinct 18bp target sites in the human CACNA1C 
locus. Changes in mRNA are measured using qRT-PCR as described previously(27). 
VP64, VP64 transcription activation domain. All results are collected from three 
independent experiments in HEK 293FT cells. Error bars indicate s.e.m.; n = 3. 
 
4.2.3 Evaluation of guanine-binding RVDs at endogenous genome loci 
Using qRT-PCR, we further compared the performance of NN, NK, NH, and HN for 
targeting endogenous genomic sequences. We tested the ability of NN-, NK-, NH-, and 
HN- TALEs to activate CACNA1C transcription by targeting the two endogenous target 
sites (Fig. 4.3b). To control for differences in TALE expression levels, all TALE were 
fused to 2A-GFP and exhibited similar levels of GFP fluorescence(27). Using qRT-PCR, 
we found that the endogenous activity of each TALE corresponded to the reporter assay. 
Both TALE1-NH and TALE2-NH were able to achieve similar levels of transcriptional 
activation as TALE1-NN and TALE2-NN (~5 and ~3 folds of activation for targets 1 and 
2 respectively) and twice more than TALE1-NK and TALE2-NK (Fig. 4.3b). Although 
TALE1-HN and TALE2-HN exhibited comparable activity with TALEs bearing RVDs 
NN and NH, the lack of specificity in distinguishing guanine and adenosine bases as 
shown in previous test (Fig. 4.3a) does not warrant the superiority of HN over existing 
guanine-binding RVDs. On the other hand, based on all the results from specificity and 
endogenous activity tests, the RVD NH seems to be a more suitable substitute for NN 
than NK when higher targeting specificity is desired, as it also provides higher levels of 
biological activity. Further testing using additional endogenous genomic targets will help 
validate the broad utility of NH as a highly specific G-targeting RVD. 
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4.2.4 Development of mammalian TALE transcriptional repressors 
Having identified NH as a more specific G-recognizing RVD, we sought to develop a 
mammalian TALE repressor architecture to enable researchers to suppress transcription 
of endogenous genes. TALE repressors have the potential to suppress the expression of 
genes as well as non-coding transcripts such as microRNAs, rendering it a highly 
desirable tool for testing the causal role of specific genetic elements. In order to identify a 
suitable repression domain for use with TALEs in mammalian cells, we used a TALE 
targeting the promoter of the human SOX2 gene to evaluate the transcriptional repression 
activity of a collection of candidate repression domains (Fig. 4.4a). We selected 
repression domains across a range of eukaryotic host species to increase the change of 
finding a potent synthetic repressor, including the PIE-1repression domain (PIE-1)(109) 
from Caenorhabditis elegans, the QA domain within the Ubx gene (Ubx-QA)(110) from 
Drosophila melanogaster, the IAA28 repression domain (IAA28-RD)(111) from 
Arabidopsis thaliana, the mSin interaction domain (SID)(106), Tbx3 repression domain 
(Tbx3-RD), and the Krüppel associated box (KRAB)(112) repression domain from Homo 
Sapiens (Fig. 4.4b). Since different truncations of KRAB have been known to exhibit 
varying levels of transcriptional repression(112), we tested three different truncations of 
KRAB (Fig. 4.4c). We expressed these candidate TALE repressors in HEK 293FTcells 
and found that TALEs carrying two widely used mammalian transcriptional repression 
domains, the SID(106) and KRAB(112) domains, were able to repress endogenous SOX2 
expression, while the other domains had little effect on transcriptional activity (Fig. 4.4c). 
To control for potential perturbation of SOX2 transcription due to TALE binding, 
expression of the SOX2-targeting TALE DNA binding domain alone without any 
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effector domain had no effect (similar to mock or expression of GFP) on the 
transcriptional activity of SOX2 (Fig. 4.4c, Null condition). Since the SID domain was 
able to achieve 26% more transcriptional repression of the endogenous SOX2 locus than 
the KRAB domain (Fig. 4.4c), we decided to use the SID domain for our subsequent 
studies. 
 
To further test the effectiveness of the SID repressor domain for down regulating 
endogenous transcription, we combined SID with CACNA1C-target TALEs from the 
previous experiment (Fig. 4.3, Fig. 4.4d). Using qRT-PCR, we found that replacement of 
the VP64 domain on CACNA1C-targeting TALEs with SID was able to repress 
CACNA1C transcription. Additionally, similar to the transcriptional activation study 
(Fig. 4.3b, left), NH-containing TALE repressor was able to achieve a similar level of 
transcriptional repression as the NN-containing TALE (~4 fold repression), while the 
TALE repressor using NK was significantly less active (~2 fold repression) (Fig. 4.4d). 
These data demonstrate that SID is indeed a suitable repression domain, while also 
further supporting NH as a more suitable G-targeting RVD than NK. 
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Figure 4.4 Development of aTALE transcriptional repressor architecture. a, Design of 
SOX2 TALE for TALE repressor screening. A TALE targeting a 14bp sequence within 
the SOX2 locus of the human genome was synthesized as described previously(27). b, 
List of all repressors screened and their host origin (left). Eight different candidate 
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(Figure 4.4, continued) repressor domains were fused to the C-term of the SOX2 TALE. 
c, The fold decrease of endogenous SOX2 mRNA is measured using qRT-PCR by 
dividing the SOX2 mRNA levels in mock transfected cells by SOX2 mRNA levels in cells 
transfected with each candidate TALE repressor. d, Transcriptional repression of 
endogenous CACNA1C. TALEs using NN, NK, and NH as the G-targeting RVD were 
constructed to target a 18bp target site within the human CACNA1C locus (site 1 in 
Figure 4.2). Each TALE is fused to the SID repression domain. NLS, nuclear localization 
signal; KRAB, Krüppel-associated box; SID, mSin interaction domain. All results are 
collected from three independent experiments in HEK 293FT cells. Error bars indicate 
s.e.m.; n = 3. * p < 0.05, Student’s t test. 
 
4.3 Discussion 
TALEs can be easily customized to recognize specific sequences on the endogenous 
genome. Here, we conducted a series of screens to address two important limitations of 
the TALE toolbox. Together, the identification of a more stringent G-specific RVD with 
uncompromised activity strength as well as a robust TALE repressor architecture further 
expands the utility of TALEs for probing mammalian transcription and genome function. 
 
4.4 Methods 
4.4.1 Construction of TALE activators, repressors and reporters 
All TALE activators or repressors were constructed as previously described using a 
hierarchical ligation strategy(27). The sequences for all constructs used in this study can 
be found in Supplementary Table 1. To control for differences in the expression of each 
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TALE, all TALEs are in-frame fused with the Gaussia luciferase (Gluc) gene via a 2A 
linker. The Gluc gene will be translated in an equimolar amount as TALEs. Truncation 
variants of the Krüppel-associated box (KRAB) domain, the PIE-1 repression domain 
(PIE-1), the QA domain within the Ubx gene (Ubx-QA), the IAA28 repression domain 
(IAA28-RD), Tbx3 repression domain (Tbx3-RD), and the mSin interaction domain 
(SID) were codon optimized for mammalian expression and synthesized with flanking 
NheI and XbaI restriction sites (Genscript). All repressor domains were cloned into the 
TALE backbone by replacing the VP64 activation domain using NheI and XbaI 
restriction sites. To control for any effect on transcription resulting from TALE binding, 
we constructed expression vectors carrying the TALE DNA binding domain alone using 
PCR cloning. The coding regions of all constructs were completely verified using Sanger 
sequencing. 
 
All luciferase reporter plasmids were designed and synthesized by inserting the TALE 
binding site upstream of the minimal CMV promoter driving the expression of a 
Cypridina luciferase (Cluc) gene (Fig. 4.1), similar to minCMV-mCherry reporter used in 
previous studies(27). 
 
4.4.2 Cell culture and luciferase reporter activation assay 
Maintenance of human embryonic kidney cell line HEK 293FT (Invitrogen) were carried 
out with Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum (HyClone), 2mM GlutaMAX (Invitrogen), 100U/mL Penicillin, and 
100µg/mL Streptomycin, under 37ºC, 5% CO2 incubation condition. 
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Luciferase reporter assays were performed by co-transfecting HEK 293FT cells with 
TALE-2A-luciferaseexpression and luciferase reporter plasmids. In the case of the 
reporter-only control, cells were co-transfected with a control Gaussia luciferase plasmid 
(pCMV-Gluc, New England BioLabs). HEK 293FT cells were seeded into 24-well plates 
the day prior to transfection at densities of 2x105 cells/well. Approximately 24h after 
initial seeding, cells were transfected using Lipofectamine2000 (Invitrogen) following the 
manufacturer’s protocol. For each well of the 24-well plates 700ng of dTALE and 50ng 
of each reporter plasmids were used to transfect HEK 293FT cells. 
 
Dual luciferase reporter assays were carried out with the BioLux Gaussia luciferase flex 
assay kit and BioLux Cypridina luciferase assay kit (New England Biolabs) following the 
manufacturer’s recommended protocol. Briefly, media from each well of transfected cells 
were collected 48 hours after transfection. For each sample, 20uL of the media were 
added into a 96-well assay plate, mixed with each one of the dual luciferase assay mixes. 
After briefly incubation, as indicated in the manufacturer’s protocol, luminescence levels 
of each sample were measured using the Varioskan flash multimode reader (Thermo 
Scientific). 
 
The activity of each TALE is determined by measuring the level of luciferase reporter 
induction, calculated as the level of Cluc induction in the presence of TALE activator 
minus the level of Cluc induction without TALE activator. The activity of each TALE is 
normalized to the level of TALE expression as determined by the Gluc activity level 
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(each TALE is in frame fused to 2A-Gluc), to control for differences in cell number, 
sample preparation, transfection efficiency, and protein expression level. The 
concentration of all DNA used in transfection experiments were determined using gel 
analysis. 
 
We determined the base preference of each RVD according to the induction of each base-
specific reporters by the corresponding RVD screening TALE (RVD-TALE, Figure 4.1a). 
Statistical analysis were performed using one-way analysis of variance (ANOVA) tests. 
Each RVD was tested by taking the reporter with the highest luciferase activity as the 
putative preferred base and comparing it with the remaining three bases as a group. For a 
given RVD, if the putative preferred base gave statistically significant test results (p < 
0.05, one-way ANOVA), we classified that RVD as having a single preferred base, 
otherwise that RVD is tagged as not having a single preferred base. 
 
4.4.3 Endogenous gene transcriptional activation assay 
For the endogenous gene transcriptional level assay to test the biological activities of 
TALE activators and TALE repressors, HEK 293FT cells were seeded into 24-well 
plates. 1ug of TALE plasmid was transfected using Lipofectamine2000 (Invitrogen) 
according to manufacturer’s protocol. Transfected cells were cultured at 37°C for 72 
hours before RNA extraction. At least 100,000 cells were harvested and subsequently 
processed for total RNA extraction using the RNAeasyPlus Mini Kit (Qiagen). cDNA 
was generated using the High Capacity RNA-to-cDNA Master Mix (Applied Biosystems) 
according to the manufacturer's recommended protocol. After cDNA synthesis, cDNA 
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from each samples were added to the qRT-PCR assay with the Taqman Advanced PCR 
Master Mix (Applied Biosystems) using a StepOne Plus qRT-PCR machine. The fold 
activation in the transcriptional levels of SOX2 and CACNA1C mRNA were detected 
using standard TaqMan Gene Expression Assays with probes having the best coverage 
(Applied Biosystems; SOX2, Hs01053049_s1; CACNA1C, Hs00167681_m1). 
 
4.4.4 Computational analysis of RVD specificity 
To assess the guanine-specificity of NH, we performed extensive computational 
simulations to compare the relative binding affinities between guanine and NN or NH 
using free energy perturbation (FEP)(113, 114), a widely used approach for calculating 
binding affinities for a variety of biological interactions, such as ligand-receptor binding, 
protein–protein interaction, and protein-nucleic acid binding(115, 116). Molecular 
dynamics simulations were carried out as previously described(115, 116). We based our 
calculations on the recently released crystal structure of the TALE PthXo1 bound to 
DNA (PDB ID: 3UGM)(107). We used a fragment of the crystal structure containing 
repeats 11-18 of PthXo1 (RVD sequence: HD[11]-NG[12]-NI[13]-HD[14]-NG[15]-
NN[16]-NG[17]-NI[18], repeat number specified in square brackets) and the 
corresponding double-stranded DNA molecule containing the TALE binding sequence 
(5’-CTACTGTA-3’) to compare the binding affinities of RVDs NN, NK, and NH for 
guanine. Since the 16th repeat in the structure is NN, we computationally mutated NN 
into NH or NK and calculated the binding affinity of each configuration (NN:G, NH:G). 
The affinity was calculated as the gain of free energy (ΔΔG) in the DNA bound state 
taking NN:G as reference (ΔΔG = 0).  
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5. Multiplex Genome Engineering Using CRISPR/Cas Systems 
The work described in this chapter is done with Fei Ann Ran as equal contributors, and 
has been published as Cong L*, Ran FA*, et al. Science. 2013 (33). 
 
5.1 Introduction 
Precise and efficient genome targeting technologies are needed to enable systematic 
reverse engineering of causal genetic variations by allowing selective perturbation of 
individual genetic elements. Although genome-editing technologies such as designer zinc 
fingers (ZFs) (15, 27, 60, 117), transcription activator-like effectors (TALEs) (23, 25, 27, 
39, 53, 60, 118), and homing meganucleases (119) have begun to enable targeted genome 
modifications, there remains a need for new technologies that are scalable, affordable, 
and easy to engineer. Here, we report the development of a new class of precision 
genome engineering tools based on the RNA-guided Cas9 nuclease (30, 120, 121) from 
the type II prokaryotic CRISPR adaptive immune system (31, 32, 122, 123). 
 
The Streptococcus pyogenes SF370 type II CRISPR locus consists of four genes, 
including the Cas9 nuclease, as well as two non-coding RNAs: tracrRNA and a pre-
crRNA array containing nuclease guide sequences (spacers) interspaced by identical 
direct repeats (DRs) (Fig. S1) (124). We sought to harness this prokaryotic RNA-
programmable nuclease system to introduce targeted double stranded breaks (DSBs) in 
mammalian chromosomes through heterologous expression of the key components. It has 
been previously shown that expression of tracrRNA, pre-crRNA, host factor RNase III, 
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and Cas9 nuclease are necessary and sufficient for cleavage of DNA in vitro (120, 121) 
and in prokaryotic cells (125, 126). We codon optimized the S. pyogenes Cas9 (SpCas9) 
and RNase III (SpRNase III) and attached nuclear localization signals (NLS) to ensure 
nuclear compartmentalization in mammalian cells. Expression of these constructs in 
human 293FT cells revealed that two NLSs are most efficient at targeting SpCas9 to the 
nucleus (Fig. 5.1A). To reconstitute the non-coding RNA components of CRISPR, we 
expressed an 89-nucleotide (nt) tracrRNA (Fig. S2) under the RNA polymerase III U6 
promoter (Fig. 5.1B). Similarly, we used the U6 promoter to drive the expression of a 
pre-crRNA array comprising a single guide spacer flanked by DRs (Fig. 5.1B). We 
designed our initial spacer to target a 30-basepair (bp) site (protospacer) in the human 
EMX1 locus that precedes an NGG, the requisite protospacer adjacent motif (PAM) (Fig. 
5.1C and fig. S1) (127, 128). 
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Figure 5.1 The Type II CRISPR locus from Streptococcus pyogenes SF370 can be 
reconstituted in mammalian cells to facilitate targeted DSBs of DNA. (A) Engineering of 
SpCas9 and SpRNase III with NLSs enables import into the mammalian nucleus. (B) 
Mammalian expression of SpCas9 and SpRNase III are driven by the EF1a promoter, 
whereas tracrRNA and pre-crRNA array (DR-Spacer-DR) are driven by the U6 promoter. 
A protospacer (blue highlight) from the human EMX1 locus with PAM is used as 
template for the spacer in the pre-crRNA array. (C) Schematic representation of base 
pairing between target locus and EMX1-targeting crRNA. Red arrow indicates putative 
cleavage site. (D) SURVEYOR assay for SpCas9-mediated indels. (E) An example 
chromatogram showing a micro-deletion, as well as representative sequences of mutated 
alleles identified from 187 clonal amplicons. Red dashes, deleted bases; red bases, 
insertions or mutations. Scale bar = 10µm. 
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5.2 Reconstitution of the CRISPR/Cas system in mammalian cells 
To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, 
tracrRNA, and pre-crRNA) can achieve targeted cleavage of mammalian chromosomes, 
we transfected 293FT cells with different combinations of CRISPR components. Since 
DSBs in mammalian DNA are partially repaired by the indel-forming non-homologous 
end joining (NHEJ) pathway, we used the SURVEYOR assay (Fig. S3) to detect 
endogenous target cleavage (Fig. 5.1D and fig. S2B). Co-transfection of all four required 
CRISPR components resulted in efficient cleavage of the protospacer (Fig. 5.1D and fig. 
S2B), which is subsequently verified by Sanger sequencing (Fig. 5.1E). Interestingly, 
SpRNase III was not necessary for cleavage of the protospacer (Fig. 5.1D), and the 89-nt 
tracrRNA is processed in its absence (Fig. S2C). Similarly, maturation of pre-crRNA 
does not require RNase III (Fig. 5.1D and fig. S4), suggesting that there may be 
endogenous mammalian RNases that assist in pre-crRNA maturation (129-131). 
Removing any of the remaining RNA or Cas9 components abolished the genome 
cleavage activity of the CRISPR system (Fig. 5.1D). These results define a minimal 
three-component system for efficient CRISPR-mediated genome modification in 
mammalian cells. 
 
5.3 Endogenous genome cleavage by CRISPR/Cas system 
Next, we explored the generalizability of CRISPR-mediated cleavage in eukaryotic cells 
by targeting additional protospacers within the EMX1 locus (Fig. 5.2A). To improve co-
delivery, we designed an expression vector to drive both pre-crRNA and SpCas9 (Fig. 
S5). In parallel, we  adapted a chimeric crRNA-tracrRNA hybrid (Fig. 5.2B, top) design 
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recently validated in vitro (120), where a mature crRNA is fused to a partial tracrRNA 
via a synthetic stem-loop to mimic the natural crRNA:tracrRNA duplex (Fig. 5.2B, 
bottom). We observed cleavage of all protospacer targets when SpCas9 is co-expressed 
with pre-crRNA (DR-spacer-DR) and tracrRNA. However, not all chimeric RNA designs 
could facilitate cleavage of their genomic targets (Fig. 5.2C, Table S1). We then tested 
targeting of additional genomic loci in both human and mouse cells by designing pre-
crRNAs and chimeric RNAs targeting the human PVALB and the mouse Th loci (Fig. 
S6). We achieved efficient modification at all three mouse Th and one PVALB targets 
using the crRNA:tracrRNA design, thus demonstrating the broad applicability of the 
CRISPR system in modifying different loci across multiple organisms (Table S1). For the 
same protospacer targets, cleavage efficiencies of chimeric RNAs were either lower than 
those of crRNA:tracrRNA duplexes or undetectable. This may be due to differences in 
the expression and stability of RNAs, degradation by endogenous RNAi machinery, or 
secondary structures leading to inefficient Cas9 loading or target recognition. 
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Figure 5.2 SpCas9 can be reprogrammed to target multiple genomic loci in 
mammalian cells. (A) Schematic of the human EMX1 locus showing the location of five 
protospacers, indicated by blue lines with corresponding PAM in magenta. (B) Schematic 
of the pre-crRNA:tracrRNA complex (top) showing hybridization between the direct 
repeat (gray) region of the pre-crRNA and tracrRNA. Schematic of a chimeric RNA 
design (120) (bottom). tracrRNA sequence is shown in red and the 20bp spacer sequence 
in blue. (C) SURVEYOR assay comparing the efficacy of Cas9-mediated cleavage at 
five protospacers in the human EMX1 locus. Each protospacer is targeted using either 
processed pre-crRNA:tracrRNA complex (crRNA) or chimeric RNA (chiRNA). 
 
5.4 Target cleavage specificity of the CRISPR/Cas system in mammalian cells 
Effective genome editing requires that nucleases target specific genomic loci with both 
high precision and efficiency. To investigate the specificity of CRISPR-mediated 
cleavage, we analyzed single-nucleotide mismatches between the spacer and its 
mammalian protospacer target (Fig. 5.3A). We observed that single-base mismatch up to 
12-bp 5’ of the PAM completely abolished genomic cleavage by SpCas9, whereas 
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spacers with mutations farther upstream retained activity against the protospacer target 
(Fig. 5.3B). This is consistent with previous bacterial and in vitro studies of Cas9 
specificity (120, 125). Furthermore, CRISPR is able to mediate genomic cleavage as 
efficiently as a pair of TALE nucleases (TALEN) targeting the same EMX1 protospacer 
(Fig. 5.3, C and D). 
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Figure 5.3 Evaluation of the SpCas9 specificity and comparison of efficiency with 
TALENs. (A) EMX1-targeting chimeric crRNAs with single point mutations were 
generated to evaluate the effects of spacer-protospacer mismatches. (B) SURVEYOR 
assay comparing the cleavage efficiency of different mutant chimeric RNAs. (C) 
Schematic showing the design of TALENs targeting EMX1. (D) SURVEYOR gel 
comparing the efficiency of TALEN and SpCas9 (N = 3). 
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5.5 Development of a Cas9 nickase and its application in inducing homology-
directed repair 
Targeted modification of genomes ideally avoids mutations arising from the error-prone 
NHEJ mechanism. The wild-type SpCas9 is able to mediate site-specific DSBs, which 
can be repaired through either NHEJ or homology-directed repair (HDR). We engineered 
an aspartate-to-alanine substitution (D10A) in the RuvC I domain of SpCas9 to convert 
the nuclease into a DNA nickase (SpCas9n, Fig. 5.4A) (120, 121, 125), because nicked 
genomic DNA is typically repaired either seamlessly or through high-fidelity HDR. 
SURVEYOR (Fig. 5.4B) and sequencing of 327 amplicons did not detect any indels 
induced by SpCas9n. However, it is worth noting that nicked DNA can in rare cases be 
processed via a DSB intermediate and result in a NHEJ event (132). We then tested Cas9-
mediated HDR at the same EMX1 locus with a homology repair template to introduce a 
pair of restriction sites near the protospacer (Fig. 5.4C). SpCas9 and SpCas9n catalyzed 
integration of the repair template into EMX1 locus at similar levels (Fig. 5.4D), which we 
further verified via Sanger sequencing (Fig. 5.4E). These results demonstrate the utility 
of CRISPR for facilitating targeted genomic insertions. Given the 14-bp (12-bp from the 
seed sequence and 2-bp from PAM) target specificity (Fig. 5.3B) of the wild type 
SpCas9, the use of a nickase may reduce off-target mutations.  
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Figure 5.4 Applications of Cas9 for homologous recombination and multiplex 
genome engineering. (A) Mutation of the RuvC I domain converts Cas9 into a nicking 
enzyme (SpCas9n) (B) Co-expression of EMX1-targeting chimeric RNA with SpCas9 
leads to indels, whereas SpCas9n does not (N = 3). (C) Schematic representation of the 
recombination strategy. A repair template is designed to insert restriction sites into EMX1 
locus. Primers used to amplify the modified region are shown as red arrows. (D)    
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(Figure 5.4, continued) Restriction fragments length polymorphism gel analysis. Arrows 
indicate fragments generated by HindIII digestion. (E) Example chromatogram showing 
successful recombination. (F) SpCas9 can facilitate multiplex genome modification using 
a crRNA array containing two spacers targeting EMX1 and PVALB. Schematic showing 
the design of the crRNA array (top). Both spacers mediate efficient protospacer cleavage 
(bottom). (G) SpCas9 can be used to achieve precise genomic deletion. Two spacers 
targeting EMX1 (top) mediated a 118bp genomic deletion (bottom).  
 
5.6 Multiplexed mammalian genome engineering with CRISPR/Cas system 
Finally, the natural architecture of CRISPR loci with arrayed spacers (Fig. S1) suggests 
the possibility of multiplexed genome engineering. Using a single CRISPR array 
encoding a pair of EMX1- and PVALB-targeting spacers, we detected efficient cleavage at 
both loci (Fig. 5.4F). We further tested targeted deletion of larger genomic regions 
through concurrent DSBs using spacers against two targets within EMX1 spaced by 119-
bp, and observed a 1.6% deletion efficacy (3 out of 182 amplicons; Fig. 5.4G), thus 
demonstrating the CRISPR system can mediate multiplexed editing within a single 
genome. 
 
5.7 Potential of CRISPR/Cas systems for genome engineering 
The ability to use RNA to program sequence-specific DNA cleavage defines a new class 
of genome engineering tools. Here, we have shown that the S. pyogenes CRISPR system 
can be heterologously reconstituted in mammalian cells to facilitate efficient genome 
editing; an accompanying study has independently confirmed high efficiency CRISPR-
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mediated genome targeting in several human cell lines (133). However, several aspects of 
the CRISPR system can be further improved to increase its efficiency and versatility. The 
requirement for an NGG PAM restricts the S. pyogenes CRISPR target space to every 8-
bp on average in the human genome (Fig. S7), not accounting for potential constraints 
posed by crRNA secondary structure or genomic accessibility due to chromatin and DNA 
methylation states. Some of these restrictions may be overcome by exploiting the family 
of Cas9 enzymes and its differing PAM requirements (127, 128) across the microbial 
diversity (122). Indeed, other CRISPR loci are likely to be transplantable into mammalian 
cells; for example, the Streptococcus thermophilus LMD-9 CRISPR1 can also mediate 
mammalian genome cleavage (Fig. S8). Finally, the ability to carry out multiplex genome 
editing in mammalian cells enables powerful applications across basic science, 
biotechnology, and medicine (134). 
 
5.8 Materials and methods 
5.8.1 Cell culture and transfection 
Human embryonic kidney (HEK) cell line 293FT (Life Technologies) was maintained in 
Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (HyClone), 2mM GlutaMAX (Life Technologies), 100U/mL penicillin, and 
100µg/mL streptomycin at 37ºC with 5% CO2 incubation. Mouse neuro2A (N2A) cell 
line (ATCC) was maintained with DMEM supplemented with 5% fetal bovine serum 
(HyClone), 2mM GlutaMAX (Life Technologies), 100U/mL penicillin, and 100µg/mL 
streptomycin at 37ºC with 5% CO2. 
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293FT or N2A cells were seeded into 24-well plates (Corning) one day prior to 
transfection at a density of 200,000 cells per well. Cells were transfected using 
Lipofectamine 2000 (Life Technologies) following the manufacturer’s recommended 
protocol. For each well of a 24-well plate a total of 800ng plasmids was used. 
 
5.8.2 Surveryor assay and sequencing analysis for genome modification 
293FT or N2A cells were transfected with plasmid DNA as described above. Cells were 
incubated at 37ºC for 72 hours post transfection before genomic DNA extraction. 
Genomic DNA was extracted using the QuickExtract DNA extraction kit (Epicentre) 
following the manufacturer’s protocol. Briefly, cells were resuspended in QuickExtract 
solution and incubated at 65ºC for 15 minutes and 98ºC for 10 minutes. 
 
Genomic region surrounding the CRISPR target site for each gene was PCR amplified, 
and products were purified using QiaQuick Spin Column (Qiagen) following 
manufacturer’s protocol. A total of 400ng of the purified PCR products were mixed with 
2µl 10X Taq polymerase PCR buffer (Enzymatics) and ultrapure water to a final volume 
of 20µl, and subjected to a re-annealing process to enable heteroduplex formation: 95ºC 
for 10min, 95ºC to 85ºC ramping at – 2ºC/s, 85ºC to 25ºC at – 0.25ºC/s, and 25ºC hold 
for 1 minute. After re-annealing, products were treated with SURVEYOR nuclease and 
SURVEYOR enhancer S (Transgenomics) following the manufacturer’s recommended 
protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). 
Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and 
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imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on 
relative band intensities.  
 
5.8.3 Restriction fragment length polymorphism assay for detection of homologous 
recombination 
HEK 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C 
for 72 hours before genomic DNA extraction as described above. The target genomic 
region was PCR amplified using primers outside the homology arms of the homologous 
recombination (HR) template. PCR products were separated on a 1% agarose gel and 
extracted with MinElute GelExtraction Kit (Qiagen). Purified products were digested 
with HindIII (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life 
Technologies). 
 
5.8.4 RNA extraction and purification 
HEK 293FT cells were maintained and transfected as stated previously. Cells were 
harvested by trypsinization followed by washing in phosphate buffered saline (PBS). 
Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer’s 
protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and 
normalized to same concentration. 
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5.8.5 Northern blot analysis of small RNA expression in mammalian cells 
RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95ºC for 
5 min, chilled on ice for 1 min and then loaded onto 8% denaturing polyacrylamide gels 
(SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The 
samples were electrophoresed for 1.5 hours at 40W limit. Afterwards, the RNA was 
transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi-dry transfer 
apparatus (Bio-rad) at room temperature for 1.5 hours. The RNA was crosslinked to the 
membrane using autocrosslink button on Stratagene UV Crosslinker the Stratalinker 
(Stratagene). The membrane was pre-hybridized in ULTRAhyb-Oligo Hybridization 
Buffer (Ambion) for 30 min with rotation at 42ºC and then probes were added and 
hybridized overnight. Probes were ordered from IDT and labeled with [gamma-32P] ATP 
(Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane 
was washed once with pre-warmed (42ºC) 2xSSC, 0.5% SDS for 1 min followed by two 
30 minute washes at 42ºC. The membrane was exposed to phosphor screen for one hour 
or overnight at room temperature and then scanned with phosphorimager (Typhoon). 
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6. Conclusion And Future Directions 
6.1 Broad implication of the development of genome engineering technologies 
The development of novel technologies have always been a driving force for biological 
and biomedical research, to name just a few of them, the advances of microscopy that 
transformed classic biology through breaking our observational barriers, the invention of 
polymerase chain reaction (PCR) that laid the defining pedestals for the modern 
molecular biology, and the realization of massive parallel sequencing that revolutionized 
the way we collect, analyze, and apply biological data. In a word, the pursuit of better 
tools for answering basic questions shapes the way we are discovering and practicing 
essential principles. 
 
Resounding to this theme, in recent years, the fascinating evolvement of biotechnology, 
especially in the genome engineering field that enables exact, efficient control of 
biological systems, has been moving forward beyond our anticipations. It shows no signs 
of slowing down, continuing to demonstrate its influence at an even accelerated speed. 
This emerging trend is both driven by the fundamental need of a versatile technological 
platform to address the age of ‘big data’ in biology and medicine, and, at the same time, 
made possible in large part by the bioengineering capacity built upon the realization of 
genome sequencing and genome-wide data acquisition and analysis. Hence, a key 
conclusion from this process is that this relationship between the two major technological 
wave fronts are reciprocal. 
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The path of my thesis research has been revolving around this point and in fact serves as 
repeated demonstration of this interplay between observational and interventional 
technologies. The paradigm-changing surge in our capacity to sequence metagenomic 
space, largely from the implementation of human genome project and associated 
initiatives, in joint force with the improved ability to study the function of genes and 
genome structures, led to the discoveries of TALEs and CRISPR/Cas systems from plant 
bacteria and various strains of bacteria/archaea, respectively; the engineering of designer 
TALEs and customizable CRISPR/Cas technologies in return has the potential of 
transforming our way to address the challenge of making sense of the data generated by 
genomic sequencing and other investigations, again not alone, but through combining 
them with mighty read-out methodologies. 
 
This inspires another encouraging development, the rising impact of synthetic biology. 
Specifically, the integration of all the biology and technologies mentioned above in 
innovative ways would bring together a cornucopia of synthetic tools that utilizes our 
biological understandings to re-invent the discipline itself and create incredibly enduring 
effects upon human health. Therefore I would like to propose a few integrative ideas that 
might lead to such synthetic biotechnologies and their applications. 
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6.2 The application of inducible domains to modulate protein activity for 
temporally and spatially precise control of genome engineering tools 
The fulfillment of high-efficiency genome engineering have long been confounded by the 
issue of accuracy, i.e., off-target effects. To develop reliable disease models or 
therapeutics with these technologies, the ability to have fine control of these tools is 
necessary and critical for its applications in the study of human disorders. 
 
Among the various control methodology available for protein activity, the best 
mechanism that currently allow for fine temporal resolution, low toxicity, and high 
sensitivity, is light or small molecule-mediated chemical activation and inactivation of 
protein function (135-144). Both directions will be a key component in the promise of 
developing models and therapeutic interventions for human diseases through application 
of genome engineering technology.  
 
It is desirable, for example, when creating a complex hierarchical structure of a synthetic 
circuit, one could control the activity of each circuit parts via optical or chemical stimuli 
serving as inputs or triggers. In another case, during the production of bio-material 
through metabolic engineering, the inducibility of genome engineering tools could enable 
the system to tightly monitor and regulate each component of the relevant metabolic 
pathways throughout the manufacturing cycle (145-149).   
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6.3 Other future directions for improving the functional versatility of genome 
engineering technologies 
In addition to precision restriction of activity, there is also huge space for future 
development of genome engineering technologies with regard to the engineering activity 
itself. Because both technological platforms developed in my research work, TALE and 
CRISPR/Cas systems, are capable of serving as a general approach for targeting specific 
loci within the mammalian genomes, there is a large number of possibilities for using 
these genome-targeting tools for controlling other aspects of the sophisticated genome 
organization in addition to the alternation of DNA sequence or modulating the expression 
level of particular genes. This relies on the fact that the TALE DNA binding domain, 
which contains the N-terminus and the repetitive region, is sufficient for binding to target 
genomic sites, whereas recent work on CRISPR-Cas system revealed that the nuclease-
activity-compromised version of the Cas9 enzyme, i.e., with mutations in either of its two 
catalytic RuvC and HNH nuclease domains, is still bound to the target DNA substrate 
when directed by the guide RNA (29, 121, 150). Hence, the fusion protein strategies 
delineated in the introduction part of this report could be applied to both technologies for 
expanding their power for genome engineering (1, 2, 5). 
 
Indeed, while most current efforts focus on increasing the efficiency for the introduction 
of genetic variants into the genome with either improved nuclease domains or 
cooperative activities of auxiliary factors or delivery methodologies, a growing number 
of researchers have started to pay attention to other potential capacities of these systems 
within a broader definition of genome engineering, e.g. the modulation of transcriptional 
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activity within mammalian cells, the regulation of a variety of epigenetic markers and in 
larger scale the chromatin states of the mammalian genomes, and the implementation of a 
designer integrase/recombinase that allows scarless, higher-order engineering at the 
whole genome scale with minimal off-target effects (1, 3, 13, 14, 23, 25, 29, 48, 51, 53, 
73, 84, 103, 117, 135, 151-153). 
 
6.4 Application of genome engineering in disease modeling and the development 
of human gene therapy for currently untreatable diseases 
One of our preeminent and long-term goal for developing efficient and accurate genome 
engineering technologies is the application of these tools in molecular and cellular 
medicine.  Here I would focus the discussion on two major efforts in this field, creating 
models for complex disorders and developing gene therapies for various human diseases. 
 
The underlying genetic causes of a variety of human diseases are being investigated 
through large-scale sequencing or genome-wide association studies with an urgent need 
for validation of putative causes of disease and determination of effective targets for drug 
development. Taking the example of neuro-psychiatric diseases, they together forms one 
of the most devastating and prevalent categories of human disorders in the modern times 
as measured by the physical and mental burdens inflicted by these diseases at personal, 
family, and society levels (154-158). A major consensus now for the patho-physiology of 
neuro-psychiatric diseases is that they arise from complex interactions of multiple genetic 
and epigenetic factors. Significant heritability of several neuro-psychiatric diseases like 
schizophrenia, major depressive diseases (MDDs), and autism spectrum disorders 
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(ASDs) indicates the importance of creating disease models based on such information 
(159-161). Notwithstanding years of investigation and the maturity of numerous powerful 
read-out technologies, we are still at the beginning of exploring this area due to 
technological limits in the creation of disease models. Now with this new generation of 
genome engineering tools based on TALEs and CRISPR-Cas systems, it is feasible to 
quickly build thousands of target-specific nucleases or epigenetic modulators to generate 
potentially all the exact genomic or epigenomic variants in a model systems so that the 
biochemical, physiological, and behavior implications of these variants could be 
thoroughly studied in appropriate contexts and experimental set-ups (53, 60, 89, 118, 
151, 162-165). Hence, the process of using these technologies to generate large library of 
model organisms could significantly improve the cost-effectiveness, duration, and 
precision for disease modeling, and thereby speed up the progress of verifying bona fide 
disease causes, drug targets and screening these targets for new therapeutics (1, 14, 17, 
36, 60).  
 
More recently, the emerging application of stem cell technology in disease modeling is 
bringing a new wave of interactions among biotechnolgies for tackling human diseases. 
We now have the ability to reprogram somatic cells and re-differentiate them into diverse 
cell types (166-168). Given initial evidence that induced pluripotent stem cells (iPSCs) 
exhibit the hallmarks of disease phenotype at cellular level and the fact that the molecular 
basis of many neuro-psychiatric diseases are developmental, iPSCs might hold the 
promise of serving as an ideal existing technology to combine with these genome 
engineering technology (168-172). The iPSCs will enable a fast and universal platform of 
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testing the effects of disease-relevant variants or confirming their involvement through 
phenotypic rescue experiments. They ultimately could be combined with aforementioned 
whole-animal in vivo studies to fully realize its potential in therapeutic development.  
 
On the other hand, the more direct way of applying genome engineering technologies for 
medicine is gene therapy. There have been many concerns over the effectiveness and 
safety of gene therapy in the past decades, particularly given the issue with viral vector 
integration and off-target effects (173-175). Nonetheless, new progress in the delivery 
methods, gene editing tools, and above all the elucidation of underlying genetic causes of 
a great variety of human diseases, led to perhaps one of the most promising and 
encouraging time for the development and clinical implementation of gene therapy (172, 
176-185). After many years of stagnation, we started to see the revive of gene therapy 
studies and clinical trials around the world. One prominent example for using gene 
therapy in human disorders is the ongoing phase II/III clinical trial on using zinc finger 
nucleases to target the human CCR5 gene for treatment and prevention of HIV/AIDS, 
developed and implemented by Sangamo Biosciences (SGM), which have demonstrated 
promising results in pre-clinical studies and benefited from relatively clear biological 
rationale for the design of the therapeutic strategy (172). The same approach is being 
utilized in a few other cases for the development of targeted gene therapy (85, 172). Most 
of the efforts from Sangamo are based on the technology zinc finger nucleases (ZFNs) 
which has similar basic functional manifestation to the more recent TALE and 
CRISPR/Cas systems, thus representing a general strategy by which genome engineering 
tools could be used as clinical treatment or the only cure for many of the most difficult-
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to-conquer human hereditary disorders that have hardly any effective existing therapies 
(151, 176-178). 
 
6.5 Integration of genome engineering technology and its future potential 
Overall, the integration of technologies based on my work from all three parts, along with 
other existing genome engineering tools and a variety of readout methods, could form a 
truly transforming technology platform that can improve our understanding of biology 
and human diseases. Future endeavor built upon these genome-scale high-throughput 
tools will enable more powerful applications. The impact of these integrations range from 
the detailed knowledge of fine structures and regulations of the human genome, to the 
building of reliable disease models, to groundbreaking therapeutics of human disorders, 
to ultimately improve the quality of life for every member of our society. 
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Appendix A. Supplementary Information for Chapter 2 
Additional methods 
Endogenous gene activation assay in mouse cell line 
Endogenous gene activation assay: neuro-2a cells were seeded in 24 well plates. 1ug of 
dTALE plasmid was transfected using Lipofectamine 2000 (Life Technologies). 
Transfected cells were cultured at 37°C for 48 hours. Cells were harvested and 
subsequently processed for total RNA extraction using the RNAeasy Plus Mini Kit 
(Qiagen). cDNA was generated using the qScript cDNA supermix (Quanta Bio) 
according to the manufacturer's recommended protocol. Oct4 and cMyc mRNA were 
detected using TaqMan Gene Expression Assays (Life Technologies: Oct4 - 
Mm03053917_g1, cMyc - Mm00487804_m1) following the manufacturer’s protocol 
using Taqman Advanced MasterMix (Life Technologies). 
 
Design and synthesis strategy for designer TALEs: 
Designer TALEs with customized DNA binding domains were constructed using 
hierarchical ligation as described below. 
 
Step 1: Optimization of DNA sequence for each repeat monomer to minimize 
repetitiveness of the final product. 
 
Repetitive DNA sequences are difficult to manipulate for a number of reasons, including 
susceptibility to recombination and difficulty for PCR amplification. To reduce the 
repetitiveness of designer TALEs, we first optimized the DNA sequence of the four 
monomers (NI, HD, NN, NG) to minimize homology while preserving the amino acid 
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sequence. We used the 34aa repeat monomer from the Xanthomonas sp. hax3 gene and 
generated 4 monomers (Supplementary Table 1). The new monomers were synthesized 
(DNA2.0, Menlo Park, CA) and cloned into individual plasmids to be used as 
amplification templates. 
 
Step 2: Design of a ligation strategy that utilizes orthogonal sticky ends to specify the 
position of each monomer in the ligated tandem repeat. 
 
In order to assemble the individual monomers in a specific order, we altered the DNA 
sequence at the junction between each pair of monomers, similar to the Golden Gate 
cloning method(43, 44). The junction is Gly-Leu and has a total of 24 possible codon 
pairs (4 codons for Gly and 6 codons for Leu) with 4 variable bases. We initially chose 
12 ligation linkers and found that the ability to ligate 12 pieces together into the specified 
order was very inefficient. Therefore, we tested multi-piece ligation reactions containing 
2 to 12 pieces and found that 4-piece ligation was most efficient. This led us to revise our 
assembly strategy using hierarchical ligation where three 4-mer tandem repeats were 
assembled first, and the pre-assembled 4-mer tandem repeats were subsequently ligated 
to form the final 12-mer tandem repeats. To minimize the formation of incorrectly ligated 
products, we tested a series of ligases and found that T7 ligase gave the highest efficiency 
for multi-piece ligation. For specifying the order of the 4 monomers, we used the 
following linkers to construct each 4-mer tandem repeat: 
 
AA :                  G   L          G   L          G   L           
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DNA:   5’ ............GGA CTC........GGC CTC........GGA TTA............ 
3’ 
       3’ ............CCT GAG........CCG GAG........CCT AAT............ 
5’ 
          |---repeat 1---|---repeat 2---|---repeat 3---|---repeat 4---| 
 
The 4-mers were used as assembly blocks for constructing the full 12-mer repeat. The 
completely assembled 12-mer was cloned into the appropriate destination plasmid 
containing the N- and C-termini of hax3 as well as one 0.5 repeat. The ligated tandem 
repeat along with the N- and C-termini form a fully functional designer TALE. The 
sequences for the destination plasmids are listed in Supplementary Sequences. 
 
Step 3: Construction of designer TALEs 
 
We used PCR amplification to generate a set of monomers (HD, NI, NN, NG) for each 
position. We designed a set of 24 primers (Supplementary Table 2) to attach the right 
ligation junction onto each monomer. Using type IIs enzymes (e.g. BsmBI and BsaI) we 
can process the ends of each repeat monomer to expose the sticky-end ligation junctions. 
An example is: 
 
AA:               L  T  P  E  Q  V  V  .....  C  Q  A  H  G  L 
DNA:  5’ cgtctcGACTCACCCCAGAGCAGGTCGTG.......TGCCAAGCGCACGGCCTCAgagacc 
      3’ gcagagCTGAGTGGGGTCTCGTCCAGCAC.......ACGGTTCGCGTGCCGGAGTctctgg 
          BsmBI Site                                        BsaI Site 
 
      | 
      |   Digest with BsaI 
V 
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AA:                 L  T  P  E  Q  V  V  .....  C  Q  A  H  G  L  
DNA:           5’ ACTCACCCCAGAGCAGGTCGTG.......TGCCAAGCGCACGG 
               3’     TGGGGTCTCGTCCAGCAC.......ACGGTTCGCGTGCCGGAG 
 
Step 4: Ligate monomers into specific tandem repeats (Fig. 1b). We constructed 12mer 
tandem repeats in two steps. 4mer tandem repeats were first assembled in 10ul ligation 
reactions consisting of 25ng for each monomer. We specifically chose the T7 DNA ligase 
based on its 1000x higher activity on sticky ends than blunt ends. The correct size 
ligation product (~440bp) for each 4mer tandem repeat is then purified and PCR 
amplified. The 4mer PCR products were then processed with the appropriate type IIs 
enzyme and then ligated again to form 12mer tandem repeats. The correctly ligated 
12mer product is then PCR amplified again and processed with Type IIs enzyme for 
ligation into the backbone plasmid. The final assembled dTALE is verified by 
sequencing. 
 
Material and procools for building designer TALEs 
 
The original set of primers (Supplementary Table 2) was designed for optimizing the 
dTALE assembly procedure. Each monomer had two different restriction sites flanking 
the 5’ and 3’ ends. We tested a number of ligation conditions by varying the number of 
pieces being ligated simultaneously and found that 4-piece ligation works most 
efficiently. To avoid the need for double digests using two different restriction enzymes 
at different temperatures, we revised the original dTALE construction protocol as well as 
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primer design (Supplementary Table 3) to streamline the assembly process. A step-by-
step protocol for the simplified dTALE construction method is presented below: 
 
1. A library consisting of 48 monomers (4 monomers for each position in the final 
assembled 12-mer tandem repeat) is generated using PCR. Plasmids containing 
each type of monomer repeat (monomer sequence listed in Supplementary Table 
1) are used as the template for amplification. PCR reactions are set up for each 
monomer, according to the following table of template and primer pairing 
(primers shown in Supplementary Table 3). 
 
Primer:  
Template: 
F1/R1 
NI 
F2/R2 
NI 
F3/R3 
NI 
F4/R4 
NI 
F5/R5 
NI 
F6/R6 
NI 
F7/R7 
NI 
F8/R8 
NI 
F9/R9 
NI 
F10/R10 
NI 
F11/R11 
NI 
F12/R12 
NI 
 F1/R1 
HD 
F2/R2 
HD 
F3/R3 
HD 
F4/R4 
HD 
F5/R5 
HD 
F6/R6 
HD 
F7/R7 
HD 
F8/R8 
HD 
F9/R9 
HD 
F10/R10 
HD 
F11/R11 
HD 
F12/R12 
HD 
 F1/R1 
NG 
F2/R2 
NG 
F3/R3 
NG 
F4/R4 
NG 
F5/R5 
NG 
F6/R6 
NG 
F7/R7 
NG 
F8/R8 
NG 
F9/R9 
NG 
F10/R10 
NG 
F11/R11 
NG 
F12/R12 
NG 
 F1/R1 
NN 
F2/R2 
NN 
F3/R3 
NN 
F4/R4 
NG 
F5/R5 
NN 
F6/R6 
NN 
F7/R7 
NN 
F8/R8 
NN 
F9/R9 
NN 
F10/R10 
NN 
F11/R11 
NN 
F12/R12 
NN 
 
2. For monomer PCR, high-fidelity polymerase (e.g. Herculase II) (Stratagene) is 
used to minimize mutation and achieve the highest product yield. Monomers are 
amplified in 100ml PCR reactions following appropriate protocols of polymerase 
manufacturers. 
 
3. After completion of the PCR reaction, each monomer is purified using the 96 
QIAquick PCR Purification Kit (Qiagen) and the product eluted in 70ml of 
ddH2O. 
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4. Each monomer is digested using BsaI (New England BioLabs) at 37oC for 1 hour 
in a 100ml reactions as follows: 
 
70ml purified PCR Product 
5ml BsaI (50 units) 
5ml 10X Buffer #4 
1ml 100X BSA 
19ml ddH2O 
  
5. After digestion, digested monomers are purified using the 96 QIAquick PCR 
Purification Kit (Qiagen) and eluted in 70ml of ddH2O. 
 
6. The concentration of each monomer is adjusted to 25ng/ml for monomers 1, 4, 5, 
8, 9, 12; and 20ng/ml for monomers 2,3,6,7,10,11. 
 
7. For each dTALE to be assembled, individual 4-mer tandem repeats are first 
constructed by simultaneously ligating four repeat monomers together at equal 
molar ratio (25ng for monomers 1 and 4, 20ng for monomers 2 and 3 in 10ul total 
ligation mix, using 300units of T7 ligase from Enzymatics and 10X ligation 
buffer). The ligation is incubated at room temperature for 30 minutes. 
 
8. 5ml of the 4-mer ligation reactions are run on a 2% E-Gel EX (Invitrogen) and the 
correct size products are amplified by gel-stab PCR(186). Specifically, a 10 µL 
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pipette tip is used to puncture the gel at the location of the desired product. The 
stab is mixed up and down in 10 µL of water, and the water is heated to 65 °C for 
2 min. 2.5 µL of the gel-isolated product diluted in water is then amplified in a 50 
µL PCR reaction using Herculase II polymerase (Stratagene). 
 
9. The amplified 4-mer tandem repeats are purified using the QIAquick PCR 
Purification kit and eluted in 40ml of ddH2O. 
 
10. Purified 4-mer tandem repeats as well as the appropriate dTALE backbone are 
digested using BsmBI at 55oC for 1 hour. 
 
40ul  purified PCR product   500ng dTALE backbone vector 
5ul 10X Buffer #3                      and 5ul 10X Buffer #3 
5ul BsmBI (50 units)   5ul BsmBI (50 units) 
      (bring volume to 50ul with 
ddH2O) 
 
11. Purify digested 4-mer tandem repeats using QIAquick PCR Purification Kit 
(Qiagen). Gel purify the digested backbone. 
 
12. Fully assembled dTALEs are generated by simultaneously ligating the three 4-
mer tandem repeats with the backbone vector at equal molar ratio (1ng for each 4-
mer tandem repeat and 28ng for backbone vector; in a 10ul ligation reaction using 
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1500U T7 ligase from Enzymatics). A negative control reaction should be set up 
with 28ng of the backbone vector alone. All ligation reactions are incubated in a 
thermal cycler using the following parameters: 37oC for 1 min followed by 25oC 
for 5min, for 30 cycles. 
 
13. 2ul of each dTALE ligation reaction is transformed into XL-10 Gold chemically 
competent cells (Stratagene). 
 
14. Plasmid DNA for assembled dTALE are prepared from ligation transformants and 
analyzed via restriction digest and DNA sequencing. Transformation of the 
negative control ligation should not yield any transformants. 
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Supplementary Table 1 | List of repeat monomer sequences. Forward and reverse priming 
sites are highlighted in blue and red respectively. 
NI  L  T  P  E  Q  V  V  A  I  A  S  N  I  G  G  K  Q  A  L 
CTGACCCCAGAGCAGGTCGTGGCAATCGCCTCCAACATTGGCGGGAAACAGGCACTC 
 E  T  V  Q  R  L  L  P  V  L  C  Q  A  H  G 
GAGACTGTCCAGCGCCTGCTTCCCGTGCTGTGCCAAGCGCACGGA 
 
HD  L  T  P  E  Q  V  V  A  I  A  S  H  D  G  G  K  Q  A  L 
TTGACCCCAGAGCAGGTCGTGGCGATCGCAAGCCACGACGGAGGAAAGCAAGCCTTG 
 E  T  V  Q  R  L  L  P  V  L  C  Q  A  H  G 
GAAACAGTACAGAGGCTGTTGCCTGTGCTGTGCCAAGCGCACGGG 
 
NN  L  T  P  E  Q  V  V  A  I  A  S  N  N  G  G  K  Q  A  L 
CTTACCCCAGAGCAGGTCGTGGCAATCGCGAGCAATAACGGCGGAAAACAGGCTTTG 
 E  T  V  Q  R  L  L  P  V  L  C  Q  A  H  G 
GAAACGGTGCAGAGGCTCCTTCCAGTGCTGTGCCAAGCGCACGGG 
 
NG  L  T  P  E  Q  V  V  A  I  A  S  N  G  G  G  K  Q  A  L 
CTGACCCCAGAGCAGGTCGTGGCCATTGCCTCGAATGGAGGGGGCAAACAGGCGTTG 
 E  T  V  Q  R  L  L  P  V  L  C  Q  A  H  G 
GAAACCGTACAACGATTGCTGCCGGTGCTGTGCCAAGCGCACGGC 
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Supplementary Table 2 | Primers used for the amplification and assembly of artificial 
TALEs reported in this manuscript. Unique linkers used to specify the ligation ordering 
are highlighted in blue; sequences written from 5’ to 3’. BsmBI sites are highlighted in 
yellow and BsaI sites are highlighted in gray. 
 
F1 AGATGCCGTCCTAGCGcgtctcCTGACCCCAGAGCAGGTCGTGG 
F2 AGATGCCGTCCTAGCGcgtctcGACTCACCCCAGAGCAGGTCGTG 
F3 AGATGCCGTCCTAGCGcgtctcGCCTCACCCCAGAGCAGGTCGTG 
F4 AGATGCCGTCCTAGCGcgtctcGATTAACCCCAGAGCAGGTCGTG 
 
F5 AGATGCCGTCCTAGCGcgtctcGCTTAACCCCAGAGCAGGTCGTG 
F6 AGATGCCGTCCTAGCGcgtctcGACTTACCCCAGAGCAGGTCGTG 
F7 AGATGCCGTCCTAGCGcgtctcGCCTTACCCCAGAGCAGGTCGTG 
F8 AGATGCCGTCCTAGCGcgtctcGACTAACCCCAGAGCAGGTCGTG 
 
F9 AGATGCCGTCCTAGCGcgtctcGGCTCACCCCAGAGCAGGTCGTG 
F10 AGATGCCGTCCTAGCGcgtctcGGCTAACCCCAGAGCAGGTCGTG 
F11 AGATGCCGTCCTAGCGcgtctcGCCTAACCCCAGAGCAGGTCGTG 
F12 AGATGCCGTCCTAGCGcgtctcGGTTAACCCCAGAGCAGGTCGTG 
 
R1 GTATCTTTCCTGTGCCCAggtctcTGAGTCCGTGCGCTTGGCAC 
R2 GTATCTTTCCTGTGCCCAggtctcTGAGGCCGTGCGCTTGGCAC 
R3 GTATCTTTCCTGTGCCCAggtctcTTAATCCGTGCGCTTGGCAC 
R4 GTATCTTTCCTGTGCCCAggtctcTTAAGCCGTGCGCTTGGCAC 
 
R5 GTATCTTTCCTGTGCCCAggtctcTAAGTCCGTGCGCTTGGCAC 
R6 GTATCTTTCCTGTGCCCAggtctcTAAGGCCGTGCGCTTGGCAC 
R7 GTATCTTTCCTGTGCCCAggtctcTTAGTCCGTGCGCTTGGCAC 
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(Supplementary Table 2, continued) 
R8 GTATCTTTCCTGTGCCCAggtctcTGAGCCCGTGCGCTTGGCAC 
 
R9 GTATCTTTCCTGTGCCCAggtctcTTAGCCCGTGCGCTTGGCAC 
R10 GTATCTTTCCTGTGCCCAggtctcTTAGGCCGTGCGCTTGGCAC 
R11 GTATCTTTCCTGTGCCCAggtctcTTAACCCGTGCGCTTGGCAC 
R12 GTATCTTTCCTGTGCCCAggtctcTTAAACCGTGCGCTTGGCAC 
 
F-assem ATATAGATGCCGTCCTAGCGC 
R-assem AAGTATCTTTCCTGTGCCCAG 
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Supplementary Table 3 | Primers used in the simplified step-by-step dTALE construction 
method. Unique linkers used to specify the ligation ordering are highlighted in blue; 
sequences written from 5’ to 3’. BsmBI sites are highlighted in yellow and BsaI sites are 
highlighted in gray. 
 
F1 ATATAGATGCCGTCCTAGCGcgtctcCTGACCCCAGAGCAGGTCGTGG 
F2 TGCTCTTTATTCGTTGCGTCggtctcGACTCACCCCAGAGCAGGTCGTG 
F3 TGCTCTTTATTCGTTGCGTCggtctcGCCTCACCCCAGAGCAGGTCGTG 
F4 TGCTCTTTATTCGTTGCGTCggtctcGATTAACCCCAGAGCAGGTCGTG 
 
F5 ATATAGATGCCGTCCTAGCGcgtctcGCTTAACCCCAGAGCAGGTCGTG 
F6 TGCTCTTTATTCGTTGCGTCggtctcGACTCACCCCAGAGCAGGTCGTG 
F7 TGCTCTTTATTCGTTGCGTCggtctcGCCTCACCCCAGAGCAGGTCGTG 
F8 TGCTCTTTATTCGTTGCGTCggtctcGATTAACCCCAGAGCAGGTCGTG 
 
F9 ATATAGATGCCGTCCTAGCGcgtctcGGCTCACCCCAGAGCAGGTCGTG 
F10 TGCTCTTTATTCGTTGCGTCggtctcGACTCACCCCAGAGCAGGTCGTG 
F11 TGCTCTTTATTCGTTGCGTCggtctcGCCTCACCCCAGAGCAGGTCGTG 
F12 TGCTCTTTATTCGTTGCGTCggtctcGATTAACCCCAGAGCAGGTCGTG 
 
R1 TCTTATCGGTGCTTCGTTCTggtctcTGAGTCCGTGCGCTTGGCAC 
R2 TCTTATCGGTGCTTCGTTCTggtctcTGAGGCCGTGCGCTTGGCAC 
R3 TCTTATCGGTGCTTCGTTCTggtctcTTAATCCGTGCGCTTGGCAC 
R4 AAGTATCTTTCCTGTGCCCAcgtctcTTAAGCCGTGCGCTTGGCAC 
 
R5 TCTTATCGGTGCTTCGTTCTggtctcTGAGTCCGTGCGCTTGGCAC 
R6 TCTTATCGGTGCTTCGTTCTggtctcTGAGGCCGTGCGCTTGGCAC 
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(Supplementary Table 3, continued) 
R7 TCTTATCGGTGCTTCGTTCTggtctcTTAATCCGTGCGCTTGGCAC 
R8 AAGTATCTTTCCTGTGCCCAcgtctcTGAGCCCGTGCGCTTGGCAC 
 
R9 TCTTATCGGTGCTTCGTTCTggtctcTGAGTCCGTGCGCTTGGCAC 
R10 TCTTATCGGTGCTTCGTTCTggtctcTGAGGCCGTGCGCTTGGCAC 
R11 TCTTATCGGTGCTTCGTTCTggtctcTTAATCCGTGCGCTTGGCAC 
R12 AAGTATCTTTCCTGTGCCCAcgtctcTGAGTCCGTGCGCTTGGCAC 
 
F-assem ATATAGATGCCGTCCTAGCG 
R-assem AAGTATCTTTCCTGTGCCCA 
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Supplementary Figure 1 | Design of mCherry reporter plasmid. Target binding site of a 
dTALE was cloned into the mCherry reporter plasmid between the XbaI and BamHI 
restriction sites. Hence, the dTALE binding site is placed -96bp upstream of the 
transcription start site of a full-length mCherry gene, with a minimal CMV promoter in 
the middle. 
  
...TCTAGA                                                GGATCCACGTATGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGGTACCGCCACCATGGTG...
XbaI BamHI
binding site
minCMV Promoter mCherry
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Supplementary Figure 2 | Test of the DNA binding specificity of dTALE using reporters 
with varying numbers of mismatches. a, Each diresidue in dTALE1 was tested against its 
non-preferred DNA bases to determine the binding specificity for each diresidue. b, 
Single base pair mismatches were used to test the binding specificity of dTALE1. The 
relative activity of dTALE1 for each mutant reporter compared to the intended reporter is 
shown on the right. All error bars indicate s.e.m, n=3. The fold induction was determined 
via flow cytometry analysis of mCherry expression in transfected 293FT cells, and 
calculated as the ratio of the total mCherry fluorescence intensity of cells transfected with 
and without the specified dTALE. 
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Supplementary Figure 3 | Tests of the DNA binding specificity of dTALE to mismatched 
sequences. DNA binding specificity of dTALE was tested using dTALE13 and a series of 
reporters bearing systematically designed mutations in the binding site for dTALE13. The 
design of the reporter series is shown on the left, with three different groups: A, C, and G. 
Within each group, the base T at one or two positions of the dTALE-binding site 
(designated by numbers to the left of each target sequence) were altered to A, C, or G 
(the mutated bases are highlighted). The relative activity of dTALE13 for each mutant 
reporter compared to the original reporter is shown on the right. All error bars indicate 
s.e.m, n=3. The fold induction was determined via flow cytometry analysis of mCherry 
expression in transfected 293FT cells, and calculated as the ratio of the total mCherry 
fluorescence intensity of cells transfected with and without the specified dTALE. 
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Supplementary Figure 4 | Activation of endogenous pluripotency factors from the mouse 
genome by designer TALEs. a, b, mRNA levels of cMyc and Oct4 in mouse neuro-2a 
cells transfected with mock, cMyc-dTALE and Oct4-dTALE. Bars represent the levels of 
cMyc and Oct4 mRNA in the transfected cell as determined via quantitative RT-PCR. 
Mock consists of cells receiving the transfection vehicle. All error bars indicate s.e.m.; 
n=3. * p < 0.5, ** p < 0.05, un-paired student’s t test. 
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Supplementary sequences 
Type IIs sites are colored in blue. NLS is colored in red. 2A-GFP is colored in green. The 
variable diresidue is highlighted yellow. 
 
>dTALE-Backbone(NI in 0.5 repeat)-NLS-VP64-2A-EGFP 
 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTA
GGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCG
GCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCC
GTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCC
CGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGA
CAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCC
TGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATC
GTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGT
GCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCgagacgGTACATGAAACGCATGGCACGGcgtct
cAACTCACGCCTGAGCAGGTAGTGGCTATTGCATCCAATATCGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCC
AGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACG
ACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCC
GAGAGGACATCACATCGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACC
CCGCACAAGCGTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTC
GGTGTCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTTCGCAG
ACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAgctagccccaagaa
gaagagaaaggtggaggccagcggttccGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCT
CGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCC
TTGATGATTTCGACCTGGACATGCTGATTAACtctagaggcagtggagagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctg
gcccaGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACC
CCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGT
GCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCT
GAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCC
GCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
 
>dTALE-Backbone(NG in 0.5 repeat)-NLS-VP64-2A-EGFP 
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ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTA
GGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCG
GCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCC
GTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCC
CGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGA
CAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCC
TGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATC
GTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGT
GCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCgagacgGTACATGAAACGCATGGCACGGcgtct
cAACTCACGCCTGAGCAGGTAGTGGCTATTGCATCCAATGGCGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCC
AGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACG
ACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCC
GAGAGGACATCACATCGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACC
CCGCACAAGCGTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTC
GGTGTCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTTCGCAG
ACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAgctagccccaagaa
gaagagaaaggtggaggccagcggttccGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCT
CGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCC
TTGATGATTTCGACCTGGACATGCTGATTAACtctagaggcagtggagagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctg
gcccaGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACC
CCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGT
GCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCT
GAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCC
GCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
>dTALE-Backbone(HD in 0.5 repeat)-NLS-VP64-2A-EGFP 
 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTA
GGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCG
GCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCC
GTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCC
CGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGA
CAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCC
TGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATC
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GTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGT
GCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCgagacgGTACATGAAACGCATGGCACGGcgtct
cAACTCACGCCTGAGCAGGTAGTGGCTATTGCATCCCATGACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCC
AGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACG
ACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCC
GAGAGGACATCACATCGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACC
CCGCACAAGCGTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTC
GGTGTCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTTCGCAG
ACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAgctagccccaagaa
gaagagaaaggtggaggccagcggttccGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCT
CGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCC
TTGATGATTTCGACCTGGACATGCTGATTAACtctagaggcagtggagagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctg
gcccaGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACC
CCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGT
GCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCT
GAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCC
GCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
 
>dTALE-Backbone(NN in 0.5 repeat)-NLS-VP64-2A-EGFP 
 
ATGTCGCGGACCCGGCTCCCTTCCCCACCCGCACCCAGCCCAGCGTTTTCGGCCGACTCGTTCTCAGACCTGCTTA
GGCAGTTCGACCCCTCACTGTTTAACACATCGTTGTTCGACTCCCTTCCTCCGTTTGGGGCGCACCATACGGAGGCG
GCCACCGGGGAGTGGGATGAGGTGCAGTCGGGATTGAGAGCTGCGGATGCACCACCCCCAACCATGCGGGTGGCC
GTCACCGCTGCCCGACCGCCGAGGGCGAAGCCCGCACCAAGGCGGAGGGCAGCGCAACCGTCCGACGCAAGCCC
CGCAGCGCAAGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAAGTGAGGTCGA
CAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGCCCACATCGTAGCCTTGTCGCAGCACCC
TGCAGCCCTTGGCACGGTCGCCGTCAAGTACCAGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATC
GTCGGTGTGGGGAAACAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCACGGCGGTCGAGGCGGT
GCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTGACCgagacgGTACATGAAACGCATGGCACGGcgtct
cAACTCACGCCTGAGCAGGTAGTGGCTATTGCATCCAATAACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCC
AGCTTTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCTGCCTCGGCGGACG
ACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCATTGATTAAGCGGACCAACAGAAGGATTCCC
GAGAGGACATCACATCGAGTGGCAGATCACGCGCAAGTGGTCCGCGTGCTCGGATTCTTCCAGTGTCACTCCCACC
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CCGCACAAGCGTTCGATGACGCCATGACTCAATTTGGTATGTCGAGACACGGACTGCTGCAGCTCTTTCGTAGAGTC
GGTGTCACAGAACTCGAGGCCCGCTCGGGCACACTGCCTCCCGCCTCCCAGCGGTGGGACAGGATTCTCCAAGCG
AGCGGTATGAAACGCGCGAAGCCTTCACCTACGTCAACTCAGACACCTGACCAGGCGAGCCTTCATGCGTTCGCAG
ACTCGCTGGAGAGGGATTTGGACGCGCCCTCGCCCATGCATGAAGGGGACCAAACTCGCGCGTCAgctagccccaagaa
gaagagaaaggtggaggccagcggttccGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCT
CGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCC
TTGATGATTTCGACCTGGACATGCTGATTAACtctagaggcagtggagagggcagaggaagtctgctaacatgcggtgacgtcgaggagaatcctg
gcccaGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACC
CCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGT
GCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCT
GAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCC
GCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA 
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Appendix B. Supplementary Information for Chapter 5 
 
Fig. S1. Schematic of the type II CRISPR-mediated DNA double-strand break. The type 
II CRISPR locus from Streptococcus pyogenes SF370 contains a cluster of four genes, 
Cas9, Cas1, Cas2, and Csn1, as well as two non-coding RNA elements, tracrRNA and a 
characteristic array of repetitive sequences (direct repeats) interspaced by short stretches 
of non-repetitive sequences (spacers, 30bp each) (31, 32, 122, 123, 187, 188). Each 
spacer is typically derived from foreign genetic material (protospacer), and directs the 
specificity of CRISPR-mediated nucleic acid cleavage. In the target nucleic acid, each 
protospacer is associated with a protospacer adjacent motif (PAM) whose recognition is 
specific to individual CRISPR systems (127, 128). The Type II CRISPR system carries 
out targeted DNA double-strand break (DSB) in sequential steps (30, 120, 121, 125, 126). 
First, the pre-crRNA array and tracrRNA are transcribed from the CRISPR locus. 
Second, tracrRNA hybridizes to the direct repeats of pre-crRNA and associates with Cas9 
as a duplex, which mediates the processing of the pre-crRNA into mature crRNAs 
containing individual, truncated spacer sequences. Third, the mature crRNA:tracrRNA 
duplex directs Cas9 to the DNA target consisting of the protospacer and the requisite 
PAM via heteroduplex formation between the spacer region of the crRNA and the      
pre-crRNA
Cas9 Cas1
2. maturation by RNase III & unknown nuclease(s)
Cas2 Csn2
tracrRNA
3. target 
recognition
4. Cas9-
mediated 
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Cas9
processed 
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(Fig. S1, continued) protospacer DNA. Finally, Cas9 mediates cleavage of target DNA 
upstream of PAM to create a DSB within the protospacer. 
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Fig S2. Comparison of different tracrRNA transcripts for Cas9-mediated gene targeting. 
(A) Schematic showing the design and sequences of two tracrRNA transcripts tested 
(short and long). Each transcript is driven by a U6 promoter. Transcription start site is 
marked as +1 and transcription terminator is as indicated. Blue line indicates the region 
whose reverse-complement sequence is used to generate northern blot probes for 
tracrRNA detection. (B) SURVEYOR assay comparing the efficiency of SpCas9-
mediated cleavage of the EMX1 locus. Two biological replicas are shown for each 
tracrRNA transcript. (C) Northern blot analysis of total RNA extracted from 293FT cells 
transfected with U6 expression constructs carrying long or short tracrRNA, as well as 
SpCas9 and DR-EMX1(1)-DR. Left and right panels are from 293FT cells transfected 
without or with SpRNase III respectively. U6 indicate loading control blotted with a  
probe targeting human U6 snRNA. Transfection of the short tracrRNA expression     
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(Fig. S2, continued) construct led to abundant levels of the processed form of tracrRNA 
(~75bp) (124). Very low amounts of long tracrRNA are detected on the northern blot. As 
a result of these experiments, we chose to use short tracrRNA for application in 
mammalian cells. 
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Fig. S3. SURVEYOR assay for detection of double strand break-induced micro insertions 
and deletions (93). Schematic of the SURVEYOR assay used to determine Cas9-
mediated cleavage efficiency. First, genomic PCR (gPCR) is used to amplify the Cas9 
target region from a heterogeneous population of modified and unmodified cells, and the 
gPCR products are reannealed slowly to generate heteroduplexes. The reannealed 
heteroduplexes are cleaved by SURVEYOR nuclease, whereas homoduplexes are left 
intact. Cas9-mediated cleavage efficiency (% indel) is calculated based on the fraction of 
cleaved DNA. 
rehybridize
surveyor nuclease
gel quantification
a b
c
% indel = 1 - (a + b)/(a + b + c)   *1001-(             )
indel
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Fig. S4. Northern blot analysis of crRNA processing in mammalian cells. (A) Schematic 
showing the expression vector for a single spacer flanked by two direct repeats (DR-
EMX1(1)-DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (Table 
S1) is shown in blue and direct repeats are in shown in gray. Orange line indicates the 
region whose reverse-complement sequence is used to generate northern blot probes for 
EMX1(1) crRNA detection. (B) Northern blot analysis of total RNA extracted from    
293FT cells transfected with U6 expression constructs carrying DR-EMX1(1)-DR. Left 
and right panels are from 293FT cells transfected without or with SpRNase III            
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(Fig. S4, continued) respectively. DR-EMX1(1)-DR was processed into mature crRNAs 
only in the presence of SpCas9 and short tracrRNA, and was not dependent on the 
presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA 
is ~33bp and is shorter than the 39-42bp mature crRNA from S. pyogenes (124), 
suggesting that the processed mature crRNA in human 293FT cells is likely different 
from the bacterial mature crRNA in S. pyogenes. 
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Fig. S5. Bicistronic expression vectors for pre-crRNA array or chimeric crRNA with 
Cas9. (A) Schematic showing the design of an expression vector for the pre-crRNA 
array. Spacers can be inserted between two BbsI sites using annealed oligonucleotides. 
Sequence design for the oligonucleotides are shown below with the appropriate ligation 
adapters indicated. (B) Schematic of the expression vector for chimeric crRNA. The 
guide sequence can be inserted between two BbsI sites using annealed oligonucleotides. 
The vector already contains the partial direct repeat (gray) and partial tracrRNA (red) 
sequences. WPRE, Woodchuck hepatitis virus post-transcriptional regulatory element. 
B
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Fig. S6. Selection of protospacers in the human PVALB and mouse Th loci. Schematic of 
the human PVALB (A) and mouse Th (B) loci and the location of the three protospacers 
within the last exon of the PVALB and Th genes, respectively. The 30bp protospacers are 
indicated by black lines and the adjacent PAM sequences are indicated by the magenta 
bar. Protospacers on the sense and anti-sense strands are indicated above and below the 
DNA sequences respectively. 
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Fig. S7. Occurrences of PAM sequences in the human genome. Histograms of distances 
between adjacent Streptococcus pyogenes SF370 type II CRISPR PAM (NGG) (A) and 
Streptococcus thermophiles LMD-9 CRISPR1 PAM (NNAGAAW) (B) in the human 
genome. (C) Distances for each PAM by chromosome. Chr, chromosome. Putative 
targets were identified using both the plus and minus strands of human chromosomal 
sequences. Given that there may be chromatin, DNA methylation-, RNA structure, and 
other factors that may limit the cleavage activity at some protospacer targets, it is 
important to note that the actual targeting ability might be less than the result of this 
computational analysis.  
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Fig S8. Type II CRISPR from Streptococcus thermophilus LMD-9 can also function in 
eukaryotic cells. (A) Schematic of CRISPR locus 2 from Streptococcus thermophilus 
LMD-9. (B) Design of the expression system for the S. thermphilus CRISPR system. 
Human codon-optimized StCas9 is expressed using a constitutive EF1a promoter. Mature 
versions of tracrRNA and crRNA are expressed using the U6 promoter to ensure precise 
transcription initiation. Sequences for the mature crRNA and tracrRNA are shown. A 
single based indicated by the lower case “a” in the crRNA sequence was used to remove 
the polyU sequence, which serves as a RNA Pol III transcriptional terminator. Sp, spacer. 
A
C
StCas9 Cas1 Cas2 Csn2
direct repeats
spacerSt-tracrRNA
Streptococcus thermophilus LMD-9 CRISPR1
B
D StCas9
St-tracrRNA
crRNA guide 16
crRNA guide 15
–   +   +   +  
–   +   +   +  
–   –   +   –  
–   –   –   +  
651bp
200
300
400
500
650
850
indel (%) 14 6.4
619bp
225bp
193bp
844bp
U6
St-tracrRNA
EF1_ hStCas9 U6
Sp DR
5’– NNNNNNNNNNNNNNNNNNNGUUaUUGUACUCU-CAAGAUUUAUUUUU -3’
________________
GAAACAUCGAAGACGUUCUAAAUUCAUUG -5’A U
AAGGCUUCAUGCCGAAAUCAACACCCUGUCAU             U
U
U3’- AAUUUAUUGCUUU---UGUGGGACGGUA
___________________
crRNA
St-tracrRNA
human
EMX1
locus
2kb
· ·
5’-..TTTTCTAGTGCTGAGTTTCTGTGACTCCTCTACATTCTACTTCTCTGTGTTTCTGTATACTACCTCCTCC..-3’
     ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3’-..AAAAGATCACGACTCAAAGACACTGAGGAGATGTAAGATGAAGAGACACAAAGACATATGATGGAGGAGG..-5’
protospacer (16) protospacer (15)PAM PAM
   
154 
(Fig. S8, continued) (C) Schematic showing protospacer and corresponding PAM 
sequences targets in the human EMX1 locus. Two protospacer sequences are highlighted 
and their corresponding PAM sequences satisfying the NNAGAAW motif are indicated 
by magenta lines. Both protospacers are targeting the anti-sense strand. (D) SURVEYOR 
assay showing StCas9-mediated cleavage in the target locus. RNA guide spacers 1 and 2 
induced 14% and 6.4% respectively. Statistical analysis of cleavage activity across 
biological replica at these two protospacer sites can be found in Table S1. 
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Table S1. Protospacer sequences and modification efficiencies of mammalian genomic 
targets. Protospacer targets designed based on Streptococcus pyogenes type II CRISPR 
and Streptococcus thermophilus CRISPR1 loci with their requisite PAMs against three 
different genes in human and mouse genomes. Cells were transfected with Cas9 and 
either pre-crRNA/tracrRNA or chimeric RNA. Cells were analyzed 72 hours after 
transfection. Percent indels are calculated based on SURVEYOR assay results from 
indicated cell lines, N = 3 for all protospacer targets, errors are S.E.M. N.D., not 
detectable using the SURVEYOR assay; N.T., not tested in this study. 
 
  
target
species gene protospacer sequence (5' to 3') PAM strand
cell line
tested
% indel
(pre-crRNA + tracrRNA)
EMX1
GGACATCGATGTCACCTCCAATGACTAGGG TGG
+ 293FT
EMX1 CATTGGAGGTGACATCGATGTCCTCCCCAT TGG – 293FT
EMX1
GGG
+ 293FT
20 ± 1.8
2.1 ± 0.31
14 ± 1.1
PVALB
GGTGGCGAGAGGGGCCGAGATTGGGTGTTC
AGG + 293FT
PVALB ATGCAGGAGGGTGGCGAGAGGGGCCGAGAT TGG + 293FT
Th CAAGCACTGAGTGCCATTAGCTAAATGCAT AGG – Neuro2A
Th AATGCATAGGGTACCACCCACAGGTGCCAG GGG – Neuro2A
Th ACACACATGGGAAAGCCTCTGGGCCAGGAA AGG + Neuro2A
27 ± 4.3
4.8 ± 1.2
11.3 ± 1.3
Homo
sapiens 
Mus
musculus
CTAGAAA
GTAGAAT
AGAATGTAGAGGAGTCACAGAAACTCAGCA
GGAGGAGGTAGTATACAGAAACACAGAGAA
PVALB
AGGGGCCGAGATTGGGTGTTCAGGGCAGAG
AGG + 293FT
293FT
293FT
EMX1
EMX1
–
–
Cas9
S. pyogenes
SF370 type II
CRISPR
S. thermophilus
LMD-9 CRISPR1
GGAAGGGCCTGAGTCCGAGCAGAAGAAGAA
21 ± 2.6
N.D.
N.D.
CATCGATGTCCTCCCCATTGGCCTGCTTCG TGGEMX1 – 293FT 11 ± 1.7
TTCGTGGCAATGCGCCACCGGTTGATGTGA TGGEMX1 – 293FT 4.3 ± 0.46
TCGTGGCAATGCGCCACCGGTTGATGTGAT GGGEMX1 – 293FT 4.0 ± 0.66
GGAGGGAGGGGCACAGATGAGAAACTCAGG AGGEMX1 – 293FT 7.8 ± 0.83
% indel
(chimeric RNA)
6.7 ± 0.62
N.D.
N.D.
4.1 ± 2.2
N.D.
N.D.
14 ± 0.88
7.8 ± 0.77
6.5 ± 0.32
N.D.
N.D.
N.D.
2.1 ± 0.51
0.41 ± 0.25
2.3 ± 1.2
TCCAGCTTCTGCCGTTTGTACTTTGTCCTC CGGEMX1 – 293FT 1.5 ± 0.12 N.D.
Homo
sapiens 
Homo
sapiens 
N.T.
N.T.
protospacer
ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
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Table S2. Sequences for primers and probes used for SURVEYOR assay, RFLP assay, 
genomic sequencing, and Northern blot. 
Primer name Assay 
Genomic 
Target 
Primer sequence 
Sp-EMX1-F 
SURVEYOR. 
sequencing 
EMX1 AAAACCACCCTTCTCTCTGGC 
Sp-EMX1-R 
SURVEYOR. 
sequencing 
EMX1 GGAGATTGGAGACACGGAGAG 
Sp-PVALB-F 
SURVEYOR. 
sequencing 
PVALB CTGGAAAGCCAATGCCTGAC 
Sp-PVALB-R 
SURVEYOR. 
sequencing 
PVALB GGCAGCAAACTCCTTGTCCT 
Sp-Th-F 
SURVEYOR. 
sequencing 
Th GTGCTTTGCAGAGGCCTACC 
Sp-Th-R 
SURVEYOR. 
sequencing 
Th CCTGGAGCGCATGCAGTAGT 
St-EMX1-F 
SURVEYOR. 
sequencing 
EMX1 ACCTTCTGTGTTTCCACCATTC 
St-EMX1-R 
SURVEYOR. 
sequencing 
EMX1 TTGGGGAGTGCACAGACTTC 
Sp-EMX1-
RFLP-F 
RFLP, 
sequencing 
EMX1 GGCTCCCTGGGTTCAAAGTA 
Sp-EMX1-
RFLP-R 
RFLP, 
sequencing 
EMX1 AGAGGGGTCTGGATGTCGTAA 
Pb_EMX1_sp
1 
Northern Blot 
Probe 
Not 
applicable 
TAGCTCTAAAACTTCTTCTTCTGCTCG
GAC 
Pb_tracrRNA 
Northern Blot 
Probe 
Not 
applicable 
CTAGCCTTATTTTAACTTGCTATGCTG
TTT 
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Supplementary sequences 
> U6-short tracrRNA (Streptococcus pyogenes SF370) 
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTA
GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTAT
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA
AGGACGAAACACCGGAACCATTCAAAACAGCATAGCAAGTTAAAATAAGGCTAGTCCGT
TATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT 
 
> U6-long tracrRNA (Streptococcus pyogenes SF370) 
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTA
GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTAT
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA
AGGACGAAACACCGGTAGTATTAAGTATTGTTTTATGGCTGATAAATTTCTTTGAATTT
CTCCTTGATTATTTGTTATAAAAGTTATAAAATAATCTTGTTGGAACCATTCAAAACAG
CATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGG
TGCTTTTTTT 
 
> U6-DR-BbsI backbone-DR (Streptococcus pyogenes SF370) 
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTA
GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTAT
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA
AGGACGAAACACCGGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACGGGTCTTC
GAGAAGACGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAC 
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> U6-chimeric RNA-BbsI backbone (Streptococcus pyogenes 
SF370) 
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTA
GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTAT
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA
AGGACGAAACACCGGGTCTTCGAGAAGACCTGTTTTAGAGCTAGAAATAGCAAGTTAAA
ATAAGGCTAGTCCG 
 
> 3xFLAG-NLS-SpCas9-NLS 
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGA
TGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG
CCGACAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTG
ATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCG
GCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCG
AGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATC
TGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCA
CAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCT
TCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTG
AGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCT
GGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACA
ACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAG
GAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAG
CAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCC
TGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTC
GACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGA
CAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACC
TGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCC
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CCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCT
GAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGA
GCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAG
TTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAA
CAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGA
TCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTG
AAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGG
CCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCA
TCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATC
GAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAG
CCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCG
AGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTG
CTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAA
AATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCC
TGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAG
GAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGA
GATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGC
AGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGC
ATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC
CAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCC
AGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCC
GGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGT
GAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACC
AGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGC
ATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCA
GAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGG
AACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTT
CTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAA
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GAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGC
TGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGA
GGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCG
GCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACG
AGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCC
GATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGC
CCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGC
TGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCC
AAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCAT
GAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGA
TCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACC
GTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGAC
AGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCA
GAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTAT
TCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAA
AGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACT
TTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAG
TACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACT
GCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCA
GCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTG
GAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAG
AGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGG
ATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTG
GGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAG
CACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGA
CACGGATCGACCTGTCTCAGCTGGGAGGCGACAAGCGTCCTGCTGCTACTAAGAAAGCT
GGTCAAGCTAAGAAAAAGAAA 
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> SpRNase3-mCherry-NLS 
ATGAAGCAGCTGGAGGAGTTACTTTCTACCTCTTTCGACATCCAGTTTAATGACCTGAC
CCTGCTGGAAACCGCCTTCACTCACACCTCCTACGCGAATGAGCACCGCCTACTGAATG
TGAGCCACAACGAGCGCCTGGAGTTTCTGGGGGATGCTGTCTTACAGCTGATCATCTCT
GAATATCTGTTTGCCAAATACCCTAAGAAAACCGAAGGGGACATGTCAAAGCTGCGCTC
CATGATAGTCAGGGAAGAGAGCCTGGCGGGCTTTAGTCGTTTTTGCTCATTCGACGCTT
ATATCAAGCTGGGAAAAGGCGAAGAGAAGTCCGGCGGCAGGAGGCGCGATACAATTCTG
GGCGATCTCTTTGAAGCGTTTCTGGGCGCACTTCTACTGGACAAAGGGATCGACGCAGT
CCGCCGCTTTCTGAAACAAGTGATGATCCCTCAGGTCGAAAAGGGAAACTTCGAGAGAG
TGAAGGACTATAAAACATGTTTGCAGGAATTTCTCCAGACCAAGGGAGATGTAGCAATA
GATTATCAGGTAATAAGTGAGAAAGGACCAGCTCACGCCAAACAATTCGAAGTTAGCAT
CGTTGTTAATGGCGCAGTGTTGTCGAAGGGCTTGGGTAAATCAAAAAAACTGGCCGAGC
AGGACGCTGCTAAAAACGCCCTCGCTCAGCTCAGCGAGGTAGGATCCGTGAGCAAGGGC
GAGGAGGATAACATGGCCATCATCAAGGAGTTCATGCGCTTCAAGGTGCACATGGAGGG
CTCCGTGAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGG
GCACCCAGACCGCCAAGCTGAAGGTGACCAAGGGTGGCCCCCTGCCCTTCGCCTGGGAC
ATCCTGTCCCCTCAGTTCATGTACGGCTCCAAGGCCTACGTGAAGCACCCCGCCGACAT
CCCCGACTACTTGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGATGAACT
TCGAGGACGGCGGCGTGGTGACCGTGACCCAGGACTCCTCCCTGCAGGACGGCGAGTTC
ATCTACAAGGTGAAGCTGCGCGGCACCAACTTCCCCTCCGACGGCCCCGTAATGCAGAA
GAAGACCATGGGCTGGGAGGCCTCCTCCGAGCGGATGTACCCCGAGGACGGCGCCCTGA
AGGGCGAGATCAAGCAGAGGCTGAAGCTGAAGGACGGCGGCCACTACGACGCTGAGGTC
AAGACCACCTACAAGGCCAAGAAGCCCGTGCAGCTGCCCGGCGCCTACAACGTCAACAT
CAAGTTGGACATCACCTCCCACAACGAGGACTACACCATCGTGGAACAGTACGAACGCG
CCGAGGGCCGCCACTCCACCGGCGGCATGGACGAGCTGTACAAGAAGCGTCCTGCTGCT
ACTAAGAAAGCTGGTCAAGCTAAGAAAAAGAAA 
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> 3xFLAG-NLS-SpCas9n-NLS (the D10A nickase mutation is 
labeled in red)  
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGA
TGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG
CCGACAAGAAGTACAGCATCGGCCTGGCCATCGGCACCAACTCTGTGGGCTGGGCCGTG
ATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCG
GCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCG
AGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGATC
TGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCTTCCA
CAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCT
TCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTG
AGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGGCCCT
GGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACA
ACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAG
GAAAACCCCATCAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAG
CAAGAGCAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCC
TGTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTC
GACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGA
CAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACC
TGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGCC
CCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCT
GAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGA
GCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAG
TTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAA
CAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGA
TCCACCTGGGAGAGCTGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTG
AAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGG
CCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCA
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TCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATC
GAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAG
CCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCG
AGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTG
CTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAA
AATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCC
TGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGACAATGAG
GAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGTTTGAGGACAGAGA
GATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGC
AGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGC
ATCCGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGC
CAACAGAAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCC
AGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCC
GGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGT
GAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAACC
AGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGC
ATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCAGCTGCA
GAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGG
AACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATCGTGCCTCAGAGCTTT
CTGAAGGACGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAA
GAGCGACAACGTGCCCTCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGC
TGCTGAACGCCAAGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGA
GGCGGCCTGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCG
GCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACG
AGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCC
GATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACGC
CCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGC
TGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCC
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AAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCAT
GAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGA
TCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGGATAAGGGCCGGGATTTTGCCACC
GTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGAC
AGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCA
GAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTAT
TCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAA
AGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACT
TTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAG
TACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACT
GCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTACCTGGCCA
GCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGTG
GAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGTTCTCCAAGAG
AGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACAAGCACCGGG
ATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCTG
GGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAG
CACCAAAGAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGA
CACGGATCGACCTGTCTCAGCTGGGAGGCGACAAGCGTCCTGCTGCTACTAAGAAAGCT
GGTCAAGCTAAGAAAAAGAAA 
 
> hEMX1-HRTemplate-HindIII-NheI 
GAATGCTGCCCTCAGACCCGCTTCCTCCCTGTCCTTGTCTGTCCAAGGAGAATGAGGTC
TCACTGGTGGATTTCGGACTACCCTGAGGAGCTGGCACCTGAGGGACAAGGCCCCCCAC
CTGCCCAGCTCCAGCCTCTGATGAGGGGTGGGAGAGAGCTACATGAGGTTGCTAAGAAA
GCCTCCCCTGAAGGAGACCACACAGTGTGTGAGGTTGGAGTCTCTAGCAGCGGGTTCTG
TGCCCCCAGGGATAGTCTGGCTGTCCAGGCACTGCTCTTGATATAAACACCACCTCCTA
GTTATGAAACCATGCCCATTCTGCCTCTCTGTATGGAAAAGAGCATGGGGCTGGCCCGT
GGGGTGGTGTCCACTTTAGGCCCTGTGGGAGATCATGGGAACCCACGCAGTGGGTCATA
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GGCTCTCTCATTTACTACTCACATCCACTCTGTGAAGAAGCGATTATGATCTCTCCTCT
AGAAACTCGTAGAGTCCCATGTCTGCCGGCTTCCAGAGCCTGCACTCCTCCACCTTGGC
TTGGCTTTGCTGGGGCTAGAGGAGCTAGGATGCACAGCAGCTCTGTGACCCTTTGTTTG
AGAGGAACAGGAAAACCACCCTTCTCTCTGGCCCACTGTGTCCTCTTCCTGCCCTGCCA
TCCCCTTCTGTGAATGTTAGACCCATGGGAGCAGCTGGTCAGAGGGGACCCCGGCCTGG
GGCCCCTAACCCTATGTAGCCTCAGTCTTCCCATCAGGCTCTCAGCTCAGCCTGAGTGT
TGAGGCCCCAGTGGCTGCTCTGGGGGCCTCCTGAGTTTCTCATCTGTGCCCCTCCCTCC
CTGGCCCAGGTGAAGGTGTGGTTCCAGAACCGGAGGACAAAGTACAAACGGCAGAAGCT
GGAGGAGGAAGGGCCTGAGTCCGAGCAGAAGAAGAAGGGCTCCCATCACATCAACCGGT
GGCGCATTGCCACGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTCCAATGACaag
cttgctagcGGTGGGCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCA
GGCCCCTGCGTGGGCCCAAGCTGGACTCTGGCCACTCCCTGGCCAGGCTTTGGGGAGGC
CTGGAGTCATGGCCCCACAGGGCTTGAAGCCCGGGGCCGCCATTGACAGAGGGACAAGC
AATGGGCTGGCTGAGGCCTGGGACCACTTGGCCTTCTCCTCGGAGAGCCTGCCTGCCTG
GGCGGGCCCGCCCGCCACCGCAGCCTCCCAGCTGCTCTCCGTGTCTCCAATCTCCCTTT
TGTTTTGATGCATTTCTGTTTTAATTTATTTTCCAGGCACCACTGTAGTTTAGTGATCC
CCAGTGTCCCCCTTCCCTATGGGAATAATAAAAGTCTCTCTCTTAATGACACGGGCATC
CAGCTCCAGCCCCAGAGCCTGGGGTGGTAGATTCCGGCTCTGAGGGCCAGTGGGGGCTG
GTAGAGCAAACGCGTTCAGGGCCTGGGAGCCTGGGGTGGGGTACTGGTGGAGGGGGTCA
AGGGTAATTCATTAACTCCTCTCTTTTGTTGGGGGACCCTGGTCTCTACCTCCAGCTCC
ACAGCAGGAGAAACAGGCTAGACATAGGGAAGGGCCATCCTGTATCTTGAGGGAGGACA
GGCCCAGGTCTTTCTTAACGTATTGAGAGGTGGGAATCAGGCCCAGGTAGTTCAATGGG
AGAGGGAGAGTGCTTCCCTCTGCCTAGAGACTCTGGTGGCTTCTCCAGTTGAGGAGAAA
CCAGAGGAAAGGGGAGGATTGGGGTCTGGGGGAGGGAACACCATTCACAAAGGCTGACG
GTTCCAGTCCGAAGTCGTGGGCCCACCAGGATGCTCACCTGTCCTTGGAGAACCGCTGG
GCAGGTTGAGACTGCAGAGACAGGGCTTAAGGCTGAGCCTGCAACCAGTCCCCAGTGAC
TCAGGGCCTCCTCAGCCCAAGAAAGAGCAACGTGCCAGGGCCCGCTGAGCTCTTGTGTT
CACCTG 
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> NLS-StCsn1-NLS 
ATGAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGTCCGACCT
GGTACTTGGACTGGATATTGGTATCGGTTCGGTGGGAGTCGGAATCCTCAACAAGGTCA
CGGGGGAGATCATTCACAAGAACTCGCGGATCTTCCCCGCAGCTCAGGCTGAGAACAAC
TTGGTGCGGAGAACGAATAGGCAGGGCAGGCGACTGGCGAGGAGGAAGAAACACAGGAG
AGTCCGATTGAACCGGCTGTTCGAGGAGTCCGGTTTGATCACCGACTTTACGAAAATCT
CGATTAACCTTAATCCCTATCAGCTTCGGGTGAAAGGCCTGACAGACGAACTTTCGAAT
GAGGAACTTTTCATCGCGCTGAAAAACATGGTCAAGCACAGAGGGATTTCCTACCTCGA
TGACGCCTCGGATGACGGAAATTCCTCAGTAGGAGATTATGCACAGATCGTGAAAGAGA
ACTCAAAGCAACTGGAAACAAAGACACCGGGGCAGATCCAACTTGAAAGATACCAGACA
TACGGACAGCTCAGAGGAGATTTTACGGTGGAGAAGGACGGTAAAAAGCACAGACTCAT
TAACGTATTTCCCACGTCGGCGTACAGATCCGAAGCGCTCCGCATCCTTCAGACTCAAC
AGGAGTTCAACCCGCAAATTACTGATGAGTTCATCAACCGCTATTTGGAAATCTTGACC
GGAAAGCGCAAGTATTATCATGGGCCGGGTAATGAGAAATCCAGAACAGATTACGGCCG
ATACAGAACTTCGGGGGAAACCTTGGATAACATCTTTGGTATTTTGATTGGAAAGTGCA
CCTTTTACCCGGACGAGTTTCGAGCGGCCAAGGCGTCATACACAGCACAAGAGTTTAAT
CTCTTGAATGATTTGAACAACTTGACGGTCCCCACGGAGACAAAGAAGCTCTCCAAAGA
GCAAAAGAACCAAATCATCAACTACGTCAAGAACGAGAAGGCTATGGGGCCAGCGAAGC
TGTTCAAGTATATCGCTAAACTTCTCAGCTGTGATGTGGCGGACATCAAAGGGTACCGA
ATCGACAAGTCGGGAAAAGCGGAAATTCACACGTTTGAAGCATATCGAAAGATGAAAAC
GTTGGAAACACTGGACATTGAGCAGATGGACCGGGAAACGCTCGACAAACTGGCATACG
TGCTCACGTTGAATACTGAACGAGAGGGAATCCAAGAGGCCCTTGAACATGAGTTCGCC
GATGGATCGTTCAGCCAGAAGCAGGTCGACGAACTTGTGCAATTCCGCAAGGCGAATAG
CTCCATCTTCGGGAAGGGATGGCACAACTTTTCGGTCAAACTCATGATGGAGTTGATCC
CAGAACTTTATGAGACTTCGGAGGAGCAAATGACGATCTTGACGCGCTTGGGGAAACAG
AAAACGACAAGCTCATCGAACAAAACTAAGTACATTGATGAGAAATTGCTGACGGAAGA
AATCTATAATCCGGTAGTAGCGAAATCGGTAAGACAAGCGATCAAAATCGTGAACGCGG
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CGATCAAGGAATATGGTGACTTTGATAACATCGTAATTGAAATGGCTAGAGAGACGAAC
GAAGATGACGAGAAAAAGGCAATCCAGAAGATCCAGAAGGCCAACAAGGATGAAAAAGA
TGCAGCGATGCTTAAAGCGGCCAACCAATACAATGGAAAGGCGGAGCTGCCCCATTCAG
TGTTTCACGGTCATAAACAGTTGGCGACCAAGATCCGACTCTGGCATCAGCAGGGTGAG
CGGTGTCTCTACACCGGAAAGACTATCTCCATCCATGACTTGATTAACAATTCGAACCA
GTTTGAAGTGGATCATATTCTGCCCCTGTCAATCACCTTTGACGACTCGCTTGCGAACA
AGGTGCTCGTGTACGCAACGGCAAATCAGGAGAAAGGCCAGCGGACTCCGTATCAGGCG
CTCGACTCAATGGACGATGCGTGGTCATTCCGGGAGCTGAAGGCGTTCGTACGCGAGAG
CAAGACACTGAGCAACAAAAAGAAAGAGTATCTGCTGACAGAGGAGGACATCTCGAAAT
TCGATGTCAGGAAGAAGTTCATCGAGCGGAATCTTGTCGACACTCGCTACGCTTCCAGA
GTAGTACTGAACGCGCTCCAGGAACACTTTAGAGCGCACAAAATTGACACGAAGGTGTC
AGTGGTGAGAGGGCAGTTCACATCCCAACTCCGCCGACATTGGGGCATCGAAAAGACGC
GGGACACATATCACCATCATGCGGTGGACGCGCTGATTATTGCCGCTTCGTCCCAGTTG
AATCTCTGGAAAAAGCAGAAGAACACGCTGGTGTCGTATTCGGAGGATCAGCTTTTGGA
CATCGAAACCGGGGAGCTGATTTCCGACGATGAATACAAAGAATCGGTGTTTAAGGCAC
CATATCAGCATTTCGTGGACACGCTGAAGAGCAAAGAGTTTGAGGACAGCATCCTCTTT
TCGTACCAAGTGGACTCGAAGTTTAATCGCAAGATTTCAGACGCCACAATCTACGCGAC
GAGGCAGGCGAAGGTGGGCAAAGATAAAGCAGATGAAACCTACGTCCTTGGTAAAATCA
AGGACATCTACACTCAGGACGGGTACGATGCGTTCATGAAAATCTACAAGAAGGATAAG
TCGAAGTTTCTCATGTACCGCCACGATCCACAGACTTTCGAAAAAGTCATTGAGCCTAT
TTTGGAGAACTACCCTAACAAGCAAATCAACGAGAAAGGGAAAGAAGTCCCGTGCAACC
CCTTTCTGAAGTACAAGGAAGAGCACGGTTATATCCGCAAATACTCGAAGAAAGGAAAT
GGGCCTGAGATTAAGTCGCTTAAGTATTACGACTCAAAGTTGGGTAACCACATCGACAT
TACCCCGAAAGACTCCAACAACAAAGTCGTGTTGCAGTCCGTCTCGCCCTGGCGAGCAG
ATGTGTATTTTAATAAGACGACCGGCAAATATGAGATCCTTGGACTCAAATACGCAGAC
CTTCAATTCGAAAAGGGGACGGGCACTTATAAGATTTCACAAGAGAAGTACAACGACAT
CAAGAAAAAGGAAGGGGTCGATTCAGATTCGGAGTTCAAATTCACCCTCTACAAAAACG
ACCTCCTGCTTGTGAAGGACACAGAAACGAAGGAGCAGCAGCTCTTTCGGTTCCTCTCA
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CGCACGATGCCCAAACAAAAACATTACGTCGAACTTAAACCTTACGATAAGCAAAAGTT
TGAAGGGGGAGAGGCACTGATCAAAGTATTGGGTAACGTAGCCAATAGCGGACAGTGTA
AGAAAGGGCTGGGAAAGTCCAATATCTCGATCTATAAAGTACGAACAGATGTATTGGGA
AACCAGCATATCATCAAAAATGAGGGGGATAAACCCAAACTCGATTTCAAGCGTCCTGC
TGCTACTAAGAAAGCTGGTCAAGCTAAGAAAAAGAAATAA 
 
> U6-St_tracrRNA(7-97) 
GAGGGCCTATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGA
GATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGTGACGTA
GAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAATGGACTAT
CATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAA
AGGACGAAACACCGTTACTTAAATCTTGCAGAAGCTACAAAGATAAGGCTTCATGCCGA
AATCAACACCCTGTCATTTTATGGCAGGGTGTTTTCGTTATTTAA 
 
>EMX1_TALEN_Left 
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGA
TGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG
CCGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAA
GTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGC
CCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCGCCGTCAAGTACC
AGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGTGGGGAAA
CAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCA
CGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTG
ACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAAC
CGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCG
TGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTG
CCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAA
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CATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAG
CGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAG
GCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCC
AGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCC
AGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCA
ATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGT
GCTGTGCCAAGCGCACGGACTTACACCCGAACAAGTCGTGGCAATTGCGAGCAACCACG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCAC
GGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACT
CGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGC
AGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGG
TTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGC
GAGCAACATCGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGT
GCCAAGCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGA
AAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACT
GACACCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAA
CCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTA
GTGGCTATTGCATCCAACAACGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCT
TTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCT
GCCTCGGCGGACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCA
TTGATTAAGCGGACCAACAGAAGGATTCCCGAGAGGACATCACATCGAGTGGCAGGTTC
CCAACTCGTGAAGAGTGAACTTGAGGAGAAAAAGTCGGAGCTGCGGCACAAATTGAAAT
ACGTACCGCATGAATACATCGAACTTATCGAAATTGCTAGGAACTCGACTCAAGACAGA
ATCCTTGAGATGAAGGTAATGGAGTTCTTTATGAAGGTTTATGGATACCGAGGGAAGCA
TCTCGGTGGATCACGAAAACCCGACGGAGCAATCTATACGGTGGGGAGCCCGATTGATT
ACGGAGTGATCGTCGACACGAAAGCCTACAGCGGTGGGTACAATCTTCCCATCGGGCAG
GCAGATGAGATGCAACGTTATGTCGAAGAAAATCAGACCAGGAACAAACACATCAATCC
AAATGAGTGGTGGAAAGTGTATCCTTCATCAGTGACCGAGTTTAAGTTTTTGTTTGTCT
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CTGGGCATTTCAAAGGCAACTATAAGGCCCAGCTCACACGGTTGAATCACATTACGAAC
TGCAATGGTGCGGTTTTGTCCGTAGAGGAACTGCTCATTGGTGGAGAAATGATCAAAGC
GGGAACTCTGACACTGGAAGAAGTCAGACGCAAGTTTAACAATGGCGAGATCAATTTCC
GCTCA 
 
>EMX1_TALEN_Right 
ATGGACTATAAGGACCACGACGGAGACTACAAGGATCATGATATTGATTACAAAGACGA
TGACGATAAGATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAG
CCGTAGATTTGAGAACTTTGGGATATTCACAGCAGCAGCAGGAAAAGATCAAGCCCAAA
GTGAGGTCGACAGTCGCGCAGCATCACGAAGCGCTGGTGGGTCATGGGTTTACACATGC
CCACATCGTAGCCTTGTCGCAGCACCCTGCAGCCCTTGGCACGGTCGCCGTCAAGTACC
AGGACATGATTGCGGCGTTGCCGGAAGCCACACATGAGGCGATCGTCGGTGTGGGGAAA
CAGTGGAGCGGAGCCCGAGCGCTTGAGGCCCTGTTGACGGTCGCGGGAGAGCTGAGAGG
GCCTCCCCTTCAGCTGGACACGGGCCAGTTGCTGAAGATCGCGAAGCGGGGAGGAGTCA
CGGCGGTCGAGGCGGTGCACGCGTGGCGCAATGCGCTCACGGGAGCACCCCTCAACCTG
ACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAAC
CGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTTACGCCAGAGCAGGTCG
TGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTG
CCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGCAGGTCGTGGCAATTGCGAGCAA
CCACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAG
CGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCAACATCGGGGGAAAGCAG
GCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGCCTGACCCC
AGAGCAGGTCGTGGCAATTGCGAGCAACCACGGGGGAAAGCAGGCACTCGAAACCGTCC
AGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTGACACCAGAGCAGGTCGTGGCA
ATTGCGAGCCATGACGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGT
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GCTGTGCCAAGCGCACGGACTTACACCCGAACAAGTCGTGGCAATTGCGAGCCATGACG
GGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCAC
GGACTTACGCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGAAAGCAGGCACT
CGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTAACCCCAGAGC
AGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGG
TTGCTGCCTGTGCTGTGCCAAGCGCACGGGTTGACCCCAGAGCAGGTCGTGGCAATTGC
GAGCAACGGAGGGGGAAAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGT
GCCAAGCGCACGGCCTGACCCCAGAGCAGGTCGTGGCAATTGCGAGCCATGACGGGGGA
AAGCAGGCACTCGAAACCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACT
GACACCAGAGCAGGTCGTGGCAATTGCGAGCAACGGAGGGGGAAAGCAGGCACTCGAAA
CCGTCCAGAGGTTGCTGCCTGTGCTGTGCCAAGCGCACGGACTCACGCCTGAGCAGGTA
GTGGCTATTGCATCCAACGGAGGGGGCAGACCCGCACTGGAGTCAATCGTGGCCCAGCT
TTCGAGGCCGGACCCCGCGCTGGCCGCACTCACTAATGATCATCTTGTAGCGCTGGCCT
GCCTCGGCGGACGACCCGCCTTGGATGCGGTGAAGAAGGGGCTCCCGCACGCGCCTGCA
TTGATTAAGCGGACCAACAGAAGGATTCCCGAGAGGACATCACATCGAGTGGCAGGTTC
CCAACTCGTGAAGAGTGAACTTGAGGAGAAAAAGTCGGAGCTGCGGCACAAATTGAAAT
ACGTACCGCATGAATACATCGAACTTATCGAAATTGCTAGGAACTCGACTCAAGACAGA
ATCCTTGAGATGAAGGTAATGGAGTTCTTTATGAAGGTTTATGGATACCGAGGGAAGCA
TCTCGGTGGATCACGAAAACCCGACGGAGCAATCTATACGGTGGGGAGCCCGATTGATT
ACGGAGTGATCGTCGACACGAAAGCCTACAGCGGTGGGTACAATCTTCCCATCGGGCAG
GCAGATGAGATGCAACGTTATGTCGAAGAAAATCAGACCAGGAACAAACACATCAATCC
AAATGAGTGGTGGAAAGTGTATCCTTCATCAGTGACCGAGTTTAAGTTTTTGTTTGTCT
CTGGGCATTTCAAAGGCAACTATAAGGCCCAGCTCACACGGTTGAATCACATTACGAAC
TGCAATGGTGCGGTTTTGTCCGTAGAGGAACTGCTCATTGGTGGAGAAATGATCAAAGC
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GGGAACTCTGACACTGGAAGAAGTCAGACGCAAGTTTAACAATGGCGAGATCAATTTCC
GCTCA 
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